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FOREWORD 
 
The School of Pharmacy and Pharmaceutical Sciences, Cardiff University, is the only school 
of pharmacy in Wales and is one of the top schools of pharmacy in the UK. Our students 
graduate well-prepared and satisfied, as seen by the consistently high pass rate in the 
pharmacist registration examination and high ranking in the National Student Survey 
respectively. 
 
In addition to supporting individual pharmacists in their initial and ongoing education and 
development, the School is active in research that has been independently judged to be 
predominantly of international standing, more than half of which is recognised as world-
leading or internationally excellent and with many interdisciplinary and external 
collaborators. Research at the School encompasses medicinal chemistry, drug delivery and 
microbiology, pharmacology and physiology, and pharmacy practice and clinical pharmacy, 
and it impacts on healthcare and pharmaceutical sciences throughout the UK and the world. 
Further information on the School’s research activities and degree programmes, along with 
contact details for academic staff can be found at http://www.cardiff.ac.uk/phrmy. 
 
At the Cardiff School of Pharmacy and Pharmaceutical Sciences, the combination of these 
strengths allows us to successfully deliver research-led learning and teaching. All of our 
MPharm students undertake a significant, independent Masters level research project in the 
final year of the four-year degree, and present and defend their research. The high numbers 
of well-qualified UK, EU and international students that we attract to our postgraduate 
diplomas and degrees also contribute significantly to our research output. 
 
This is the 16th year in which we have published the abstracts of our students’ research. 
Within this publication the student is the first named author, and collaborators and 
supervisors follow. An alphabetical list of authors appears in the index. 
 
Many thanks to our colleagues for their assistance in collating this book. 
 
Rebecca Price-Davies & Justine Jenkins 
June 2016 
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Numerical approach to investigate adhesion between orthopaedic biomaterials and 
staphylococcus bacteria 
Ayah Aboukoura and P Prokopovich 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Biomaterial-associated infections (BAIs) are the third most common cause of revised orthopaedic surgery.1 
Bacteria naturally favour the inert environment of biomaterials where they attach and adhere to the surface 
through non-specific and specific interactions. This encourages formation of a highly resistant structure known 
as a biofilm. Treating such infections is very difficult and often leads to implant failure resolved only by surgical 
removal. Consequently bacterial adhesion is recognised as a critical stage responsible for the pathogenesis 
of BAIs.2,3  
This study examines the adhesion of S. aureus and S. epidermidis on metallic and polymeric biomaterials 
pertinent to orthopaedics. The predefined elastic modulus and surface energy parameters of the biomaterial 
and bacteria were correlated with microbial adhesion through Johnson, Kendall and Roberts (JKR) 
multiasperity adhesion model. This approach, proposed by Prokopovich and her research group, quantifies 
the adhesive forces between the assumed biomaterial’s rough, elastic surface and bacteria’s smooth, rigid 
surface within a liquid medium.4 
 
The results suggest an inverse relationship between surface energy and elastic modulus on bacterial adhesion, 
the latter showing overriding effects. S. aureus displayed the greatest adhesive ability to the most rigid metallic 
and polymeric biomaterials Co-Cr alloy and UHMWPE respectively. Surface energy seemed to potentiate the 
adhesive force strength and relied on the bacteria rather than biomaterial surface tension. This is explained by 
the ability of low surface energy bacteria to spontaneously coat and stick to higher surface energy materials 
resulting in stronger attractive forces. S. epidermidis and Ti alloy exhibited strongest adhesive forces though 
their surface energies are comparable. In light of this discrepancy, other surface and material factors are 
discussed including hydrophobicity and surface charge. 
In general respects, biomaterial physical properties appear to dominate over surface parameters, placing 
greater importance on elastic modulus for future studies. The adhesiveness of bacteria confirms to be strain 
specific especially for S. epidermidis. 
 The National Joint Registry (NJR) Editorial Board. 2015 12th Annual Report, National Joint Registry for England, Wales, Northern 
Ireland and the Isle of Man, Surgical data to 31 December 2014. 2014 [accessed 12 October 2015]. Available from: 
http://www.njrcentre.org.uk/njrcentre/Portals/0/Documents/England/Reports/12th%20annual%20report/NJR%20Online%20Annual%
20Report%202015.pdf 
 Otto M. Staphylococcal Infections: Mechanisms of Biofilm Maturation and Detachment as Critical Determinants of Pathogenicity. 
Annu. Rev. Med. 2013;64:175–88. 
 Busscher HJ, van der Mei HC. How Do Bacteria Know They Are on a Surface and Regulate Their Response to an Adhering State? 
PLoS Pathog. 2012;8(1):e1002440. 
 Prokopovich P, Perni S. Multiasperity Contact Adhesion Model for Universal Asperity Height and Radius of Curvature Distributions. 
Langmuir. 2010;26(22):17028-7036. 
 
 
Alcohol misuse and intervention: the development and evaluation of a computer 
assisted learning package 
Shahd Al-Hassani and RDE Sewell 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
CAL can be described as an effective and interactive method of facilitating learning and self-assessment 
procedures via the use of computers.1 The aim of this study was to assess the potential use of CAL packages 
on the topic of alcohol misuse and its intervention, to be used as a learning aid by MPharm III students. 
 
The CAL package was constructed using Microsoft PowerPoint and included up-to-date information regarding 
the management of alcohol misuse.2 In order to retain student focus, aspects such as appearance, content 
and structure were considered.3 The role of the pharmacist was included, allowing students to relate the 
content to their profession.4 A questionnaire was designed using GoogleDocs for anonymity, employing a five-
point Likert scale and some open questions to evaluate students’ opinions on the appearance, content, and 
overall impression of the package and CAL in general. 
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A total of 30 questionnaires were completed (response rate=25.6%), and the frequency and mode of Likert 
response scores were calculated. All students felt that the package was well presented, while 96% (n=29) 
believed the package had covered the relevant information regarding alcohol misuse. Most students (93%, 
n=28) felt that the role of the pharmacist was now clear to them, with positive feedback also obtained from 
open questions. Fifty per cent (n=15) stated they would prefer to learn from CAL rather than conventional 
methods, however when asked whether they would like a lecture to be given alongside the package, 73% 
(n=22) indicated in the affirmative. 
 
The package overall was well received, as students found that it was effective and relevant. Further interactive 
material, such as audio, video and case studies would enrich the quality of the package, and serve to gratify 
students using CAL. The use of CAL throughout the MPharm course could prove to be very beneficial to 
students, particularly in conjunction with lectures.  
1. Schittek M et al. 'Computer Assisted Learning. A Review'. European Journal of Dental Education 5.3 (2001):93-100. Web. 
2. NICE. Alcohol-use Disorders: Diagnosis, Assessment and Management of Harmful Drinking and Alcohol Dependence. NICE clinical 
guideline 115. 2011. Available at www.nice.org.uk/CG115 [NICE guideline]  
3. Clarke A. Designing computer-based learning materials. Aldershot, Hampshire, England: 2001. Gower. 
4. Chalmers R, Adler D, Haddad A, Hoffman S, Johnson K and Woodward J. The Essential Linkage of Professional Socialization and 
Pharmaceutical Care. American Journal of Pharmaceutical Education. 1995;59:85-90 
 
 
Anti-cancer properties of frankincense extract 
Bisma Ali, A Ali,1 and SE Hiscox 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff CF10 
3NB, and 1School of Biosciences, Cardiff University, Life Sciences Building, Museum Avenue, Cardiff, CF10 3AX  
Natural products represent a significant and important starting point in drug discovery. Boswellia frereana (BF) 
is a frankincense that is only found in Somalia, unlike other frankincense it does not contain boswellic acids. 
However, about 60% of the resin contains epi-lupeol, BF’s active.1 Epi-lupeol is a diastereoisomer of lupeol 
and effects MMP9 levels.2  
 
The aim of this study is to investigate the Boswellia extract, BF4, in a broader, breast cancer specific context 
by assessing its anti-tumour activity in a panel of breast cancer models reflecting the major clinical subtypes. 
The specific project objectives were to determine whether BF4 could inhibit cancer cell growth, using MTT 
assays, and migration, using cell ‘wounding’ assays.  
 
Our results show that the MDA231 cell line were most sensitive to BF4 and they showed a clear dose 
dependent inhibition of cell growth and migration. There are increased levels of MMP9 in breast cancer tissue 
in comparison with normal breast tissue and they are particularly abundant in the aggressive TNBC subtype.[2] 
Literature states that BF4 effects MMP9 levels and this could potentially explain our results.3 
 
To conclude, BF4 dose dependently inhibits the growth of MDA231 cells in contrast to the other cell types, 
where the effect was only observed at the highest concentration of 80ug/ml of BF4. Our data shows that 
Boswellia frereana which contains epi-lupeol may have potent anticancer activities particularly in the TNBC 
subtype where there are no current targeted therapies.  
 
 Compton Group. MMP-9 Anti-inflammatory discovery; 2013 [accessed 26 Nov 2015]. Available from: http://comptongroup.com/our-
activities/investing-in-university-research/mmp-9-anti-inflammatory-discovery/ 
 Yousef EM, Tahir MR, St-Pierre Y, Gaboury LA. MMP-9 expression varies according to molecular subtypes of breast cancer. BMC 
Cancer. 2014 Aug 23;14:609. 
 Blain EJ, Ali AY, Duance VC. Boswellia frereana (frankincense) suppresses cytokine-induced matrix metalloproteinase expression 
and production of pro-inflammatory molecules in articular cartilage. Phytother Res. 2010 Jun;24(6):905-12. 
 
 
Synthesis of oroidin analogues and evaluation of their antimicrobial properties 
Nur Ain Azlam Shah and AW White 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
The marine environment is a rich source of novel bioactive compounds. Marine sponges produce secondary 
metabolites as a part of their natural defence mechanism to deter predators and competition from other sponge 
species. Oroidin, which is a marine sponge metabolite first isolated from the sponge Agelas oroides, has been 
shown to possess antibiofouling1, antiprotozoal2 and antifungal3 properties. With the emergence of antibiotic 
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resistance combined with the decline in the research discovery of novel antibiotics, it has become an urgent 
need to search for novel lead compounds with promising antibacterial properties. The linear structure of oroidin 
and its interesting biological properties, renders it as an ideal candidate for structure manipulation strategies. 
Hence, this study aims to synthesize oroidin analogues in an effort to produce compounds with antimicrobial 
activity. 
The synthesis of the analogues involves a two-step procedure. The oroidin scaffold was prepared by reacting 
2-(trichloroacetyl)pyrrole with bromine to form 4,5-dibromo derivatives. The target compounds were then 
formed by the coupling of the pyrrole compounds – with and without the bromine substitution – with four 
structurally different amines via a nucleophilic displacement reaction. The antimicrobial activities of the 
analogues were assayed using the agar well diffusion method against Staphyloccoccus aureus. 
Of the four analogues prepared, only one displayed antimicrobial activity against S. aureus with a zone of 
inhibition of 12 mm at a concentration of 1.0 mg/mL. The active analogue had the bromopyrrole moiety whilst 
the other three inactive analogues were non-halogenated compounds. 
The contrasting results between the active analogue and its non-brominated counterpart suggest structure 
activity relationships and that the dibromopyrrole group is involved in the antimicrobial activity. With improved 
chemical methods and further chemical optimisation of the dibromo analogue synthesis, the compounds would 
serve as a good foundation for a future class of novel antibiotic drugs. 
 
 Kelly SR, Jensen PR, Henkel TP, Fenical W, Pawlik JR. Effects of Caribbean sponge extracts on bacterial attachment. Aquatic 
Microbial Ecology. 2003;31(2):175-82. 
 Tasdemir D, Topaloglu B, Perozzo R, Brun R, O'Neill R, Carballeira NM, et al. Marine natural products from the Turkish sponge 
Agelas oroides that inhibit the enoyl reductases from Plasmodium falciparum, Mycobacterium tuberculosis and Escherichia coli. 
Bioorganic & Medicinal Chemistry. 2007;15(21):6834-45. 
 da Silva FR, Tessis AC, Ferreira PF, Rangel LP, Garcia-Gomes AS, Pereira FR, et al. Oroidin Inhibits the Activity of the Multidrug 
Resistance Target Pdr5p from Yeast Plasma Membranes. Journal of Natural Products. 2011;74(2):279-82. 
 
 
Drug release across aural implant devices for the treatment of otitis media and otitis 
externa 
Emma Baczkowski, R McLeod,1 H Elhassan1 and JC Birchall 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff CF10 
3NB, and 1University Hospital Wales Main Building, Heath Park, Cardiff CF14 4XN, Wales, UK 
Otitis externa (OE) and otitis media (OM) are two common inflammatory conditions affecting the outer and 
middle ear. 1% of patients experience OE annually and 75% of children under the age of 10 experience OM.1,2 
Severe cases can result in the insertion of an ear wick in OE or grommet in OM.2,3 These interventions result 
in pain, increased clinical visits and significant costs for the NHS. Aural implants may however present an 
opportunity for the delivery of therapeutics.4 This study aims to determine whether candidate drugs can 
permeate through, or elute from biodegradable materials representing a drug eluting stent in OE and drug 
permeable grommet in OM.  
Three biodegradable polymers and a clinically appropriate antibiotic, anaesthetic and anti-inflammatory were 
selected. Drug-loaded discs were submerged in PBS, whilst polymer films were placed in Franz-type diffusion 
cells where drugs were applied via the donor chamber. Aliquots of the sample medium were taken at 
designated time intervals for UV-Visible spectroscopic analysis and results were plotted as cumulative release. 
Release studies found that hydrophilic drugs were released in greater quantities than hydrophobic drugs from 
each polymer, however therapeutic concentrations were not achieved. Permeation studies showed two of the 
polymers were poorly permeable to candidate drugs and the third was too brittle to be used. 
Poor permeability suggests that these polymers may not be suitable for drug permeable grommets, but testing 
further materials and tailoring their parameters as drug eluting stents could be possible. Treating OE and OM 
more effectively could result in reduced clinical visits, controlled drug delivery and improved patient 
compliance, however controlled release is a complex process that relies upon numerous parameters. The 
small number of sample repeats required more samples to be tested in more standardised discs in order to 
make definitive conclusions.  
 Schaefer P, Baugh RF. Acute otitis externa: an update. Am Fam Physician. 2012 Dec 1;86(11):1055-61.  
 Allen S. Outer and middle ear problems. Pharm J. 2006 Jan 21;276:83-6.  
 Bola S, Rashid M, Hickey S. Penetration through otowicks. Int J Surg. 2014 Nov;12(3):41. 
 Gan CW, Chooi WH, Ng HC, Wong YS, Venkatraman SS, Lim LH. Development of a novel biodegradable drug-eluting ventilation 
tube for chronic otitis media with effusion. Laryngoscope. 2013 Jul;123(7):1770-7.  
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Study of inhaler technique of the patients of the Cardiff and Vale University Health 
Board 
John Benson and WR Ford 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Inhalers are the cornerstone of the treatment of respiratory disease.1 Poor inhaler technique is well 
documented, however there is a lack of engagement between patients and healthcare professionals on this 
issue.2 This study looks aims to establish the quality of patients’ technique with different inhalers in the Cardiff 
and Vale area. 
Data for the study was gathered through patient interviews as well as assessing patient inhaler technique 
through use of the AIMs device, an electronic monitor for measuring patient technique, and patients were 
provided with advice on how to improve their technique. Chi-squared analysis was carried out on the data 
collected to identify any statistically significant results. 
The study showed that MDIs as lone devices are far less reliable when compared to DPIs, as well as when 
they are compared to MDIs used with a spacer device (p-value <0.0001). It also identified that current advice 
given to patients on how to use their inhalers has little or no effect on how they use them from day to day. 
Changes in the way patients are being shown how to use their inhalers needs to change. Patient technique 
would benefit from physical demonstrations.2 To improve patient outcomes, prescribers should aim to give ICs 
in the form of DPIs or MDIs with spacers. Prescription of combination IC/IB inhalers should be seriously 
considered as a way of increasing patient adherence to IC maintainence therapy.3,4 
1. Giraud, V., Roche, N., “Misuse of corticosteroid metered-dose inhaler is associated with decreased asthma stability”, European 
Respiratory Journal, 2002, Vol.19(2), pp.246-251. 
2. Price, D., Bosnic-Anticevich, S., et al., “Inhaler competence in asthma: Common errors, barriers to use and recommended 
solutions”, Respiratory Medicine, 2013, Vol.107(1), pp.37-46. 
3. Beasley, R., Weatherall, M et al., “Combination corticosteroid/β-agonist inhaler as reliever therapy: A solution for intermittent and 
mild asthma?” The Journal of Allergy and Clinical Immunology, 2014, Vol.133(1), pp.39-41. 
4. Hagedorn, C., Kässner, F., et al., “Influence of salmeterol/fluticasone via single versus separate inhalers on exacerbations in 
severe/very severe COPD”, Respiratory Medicine, 2013, Vol.107(4), pp.542-549. 
 
 
Investigating the role of ZIP7 phosphorylation in breast cancer 
Jonathan Bettam, S McGahon and KM Taylor 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
A link has been identified between zinc release and the prolonged activation of growth factors in endocrine 
resistant breast cancer, the mechanism responsible is thought to be ZIP7 mediated zinc induced activation of 
the proliferative tyrosine kinase pathways, via inhibition of tyrosine phosphatases.1,2 The aggressive growth of 
Tamoxifen resistant breast cancer cells can be attributed to their increased expression of the ZIP7 transporter1 
which causes increased intracellular zinc. Two consecutive serine residues have been identified as 
phosphorylation sites of ZIP7, located at residues S275 and S276.3 This study considers ZIP7 phosphorylation 
at the S275/S276 sites as well as investigating the importance of each of the S275 and S276 residues 
individually in the phosphorylation process. Potential downstream targets of ZIP7 mediated zinc release known 
to be linked to growth and invasiveness were also examined (CREB and mTOR).  
MCF-7 cells were transfected with a variety of ZIP7 constructs, both wild-type and mutated, to examine the 
role of the S275 and S276 residues. The mutants used were S275A/S276A, S275D/S276A and S275A/S276D. 
Transfected cells were treated with an exogenous zinc stimuli and detected by chemiluminescence, results 
were normalised to beta-actin by densitometry. 
Our findings in the wild-type and phospho-null mutant (S275A/S276A), when probed for pAKT and pZIP7 were 
consistent with previously published DATA [3], confirming that residues S275 and S276 were the principle 
phosphorylation sites of ZIP7. Our examination of the S275 and S276 residues individually was inconclusive, 
with conflicting data suggesting both the residues may be required for ZIP7 mediated zinc release and that the 
S276 residue alone may initiate ZIP7 phosphorylation. Novel data characterising pCREB and pmTOR 
response to exogenous zinc stimulation was also gathered, highlighting possible pathways leading to cancer 
growth and survival. 
MPharm 
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Further research combined with a crystal structure of ZIP7 could lead to the development of much needed 
therapeutic agents to combat anti-endocrine resistant breast cancers and further our understanding of the 
mechanisms behind the development of resistance.  
 Haase, H. and Maret, W. 2005. Protein Tyrosine Phosphatases as Targets of the Combined Insulinomimetic Effects of Zinc and 
Oxidants. Biometals 18(4), pp. 333-338. 
 Taylor, K. et al. 2008. ZIP7-Mediated Intracellular Zinc Transport Contributes to Aberrant Growth Factor Signalling in Antihormone-
Resistant Breast cancer cells. Endocrinology 149(10), pp. 4912-4920. 
 Taylor, K. et al. 2012. Protein Kinase CK2 Triggers Cytosolic Zinc Signalling Pathways by Phosphorylation of Zinc Channel ZIP7. 
Science Signalling 5(210), pp. ra11-ra11. 
 
 
A preliminary investigation into the impact of the WEDINOS Project 
Kate Bevan, D Acreman,1 J Smith1 and AD Westwell 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff CF10 
3NB, and 1Public Health Wales, Temple of Peace and Health, Cathays Park, Cardiff, CF10 3NW, Wales, UK 
New Psychoactive Substances (NPS), also known as ‘legal highs’, can be defined as ‘substances of abuse, 
either in a pure form or a preparation, that are not controlled by the 1961 Single Convention on Narcotic Drugs 
or the 1971 Convention on Psychotropic Substances, but which may pose a public health threat’.1 NPS are 
designed to produce much the same psychoactive effect on the body as illicit drugs like ecstasy and cannabis. 
With reported incidence of NPS on the rise2, so-called ‘legal highs’ should be assumed to be neither safe nor 
legal. WEDINOS provides a robust mechanism for the collection and analysis of NPS and unidentified 
substances, as well as pragmatic harm reduction advice.3 The aim of this study is to gain a preliminary insight 
into the impact of WEDINOS, and begin to investigate knowledge and opinions surrounding NPS use. 
 
The investigation was conducted via one-to-one semi-structured interviews with three participant groups. This 
included two peer participant groups (student peers and community peers) and one criminal justice participant 
group. Non-probability sampling was used to recruit participants. Results were analysed qualitatively through 
content analysis. Further analysis took place quantitatively through the comparison of numerical charts of ‘yes’ 
or ‘no’ answers. Ethical approval was obtained. 
 
Results revealed a profound lack of knowledge of the surrounding issues of NPS use. Many peer participants 
believed the terminology behind so-called ‘legal highs’ equated them to being safe and decidedly legal. All 
criminal justice participants reported NPS misuse as a problem in their area. A sizeable proportion of 
participants were not aware of the WEDINOS project, and all felt more needed to be done to raise awareness 
in their respective communities. Limitations identified were small sample sizes and a lack of probability 
sampling for quantitative analysis.   
 
Further impact studies on a larger scale need to be conducted to gain a conclusive insight into the impact of 
WEDINOS. Public Health Wales intend on conducting such an impact study in the near future.   
 
 UNODC. NPS: New Psychoactive Substances. (n.d.) Available from: https://www.unodc.org/LSS/Page/NPS (Accessed 15 January 
2016).  
 EMCDDA. EMCDDA - Europol 2014 Annual Report on the implementation of Council Decision 2005/387/JHA. 2015. Available from: 
http://www.emcdda.europa.eu/publications/implementation-reports/2014 (Accessed 06 January 2016)  
 WEDINOS. WEDINOS – Welsh Emerging Drugs & Identification of Novel Substances Project. 2015. Available from: 
http://www.wedinos.org/index.html (Accessed 07 January 2016) 
 
 
Evaluating the suppression of DET1 and PRUNE2 genes in endocrine resistant 
breast cancer 
Annabel Bojkowski, RA McClelland, A Noorani, LA Des Clayes and JMW Gee 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Most breast cancers express oestrogen receptor (ER+). These can be subdivided into luminal A (HER2-) and 
luminal B (HER2+) disease. For ER+ patients, endocrine therapy is the main treatment, however resistance is 
a significant problem.1 To discover mechanisms of resistance, an in vitro panel was developed from endocrine 
responsive parental cells. This panel mimics resistance to prolonged endocrine treatment in luminal A 
(MCF7,T47D) and luminal B disease (BT474,MDA361).2 Preliminary Affymetrix results found suppression of 
genes PRUNE2 and DET1 in BT474-derived resistant models. The main aim of this project was to use the 
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model panel and bioinformatics to further explore whether suppression of PRUNE2 or DET1 might contribute 
in driving endocrine resistance. 
PCR was used to verify the Affymetrix profile in BT474-derived cells and determine any PRUNE2 or DET1 
mRNA suppression in the panel and whether it was related to ER profile. Densitometry semi-quantified 
expression. KM plotter examined prognostic value of the genes using publically-available datasets. Gene 
ontology was interrogated using the online resources PubMed and GeneCards to see whether these genes 
were inhibitory in cancer. 
The Affymetrix profile was broadly confirmed and there was suppression of DET1 and PRUNE2 in many 
luminal B derived models. PRUNE2 was suppressed in some MCF7-derived but not T47D-derived models. No 
marked association with ER profile was seen. KM plotter found for both PRUNE2 and DET1, lower expression 
associated with shorter time to tamoxifen relapse. Lower hazard ratios were seen in luminal B cohorts 
supporting the model findings that DET1 and PRUNE2 suppression was probably more involved in luminal B-
derived resistance. Ontology indicated both genes had tumour-suppressive properties.3,4 
The project findings indicate suppression of PRUNE2 and DET1 could be involved in driving luminal B-derived 
endocrine resistance in breast cancer. Further research could potentially result in new therapeutics to combat 
such disease. 
 
 Clarke R, Tyson J, Dixon J. Endocrine resistance in breast cancer – an overview and update. Mol Cell Endocrinol. 2015 Dec 15; 
418 Pt 3: 220-34 
 Gee J, Meng M, McClelland R, Mottram H, Kyme S, Finlay P et al. Abstract P3-05-19. A new cell panel to study oestrogen receptor 
loss in acquired endocrine resistant breast cancer. Cancer Res. 2015 May 1; 75(9 suppl):P3-05-19 
 Salameh A, Lee A, Cardo Vila M, Nunes D, Efstathiou E, Staquicini F, et al. PRUNE2 is a human prostate cancer suppressor 
regulated by the intronic long noncoding RNA PCA3. Proc Natl Acad Sci U S A. 2015 Jul 7; 112(27):8403-8 
 Ouyand M, Wang H, Ma J, Lu W, Li J,Yao C, et al. COP1, the negative regulator of ETV1, influences prognosis in triple-negative 
breast cancer. BMC Cancer. 2015 Mar 15;15:132 
 
 
Evaluation of inhaler technique in patients of the Cardiff and Vale University Health 
Board 
Tanvi Borade and WR Ford  
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
The efficacy of an inhaler is greatly dependent on a patient’s ability to use their device.1 Many patients have 
poor inhaler technique2 and therefore do not receive a sufficient dose of medication. This could lead to their 
respiratory condition becoming un-controlled, and an overall decreased quality of life.3 Training patients 
correctly is therefore of paramount importance.  
 
The aim of this study was to assess patient inhaler technique. This was done using the Vitalograph Aerosol 
Inhalation Monitor (AIM), a device that estimates drug deposition at different levels of the lung. Low deposition 
in the deep lung correlates with inadequate technique. Patients were asked a short questionnaire to gather 
demographic and inhaler usage data. Excel was used to sub-group the data, which was then analysed using 
Chi-Squared to identify whether the differences in results were of statistical significance (P<0.05). 
 
MDI +Spacer users had significantly better technique than DPI users, who in turn were statistically better than 
patients who used a MDI (without spacer). Poor co-ordination, inspiring too slowly/quickly or holding breath for 
less than 5 seconds resulted in a “fail”. Overall, 82% of MDI users failed the test compared to 17% who used 
a DPI and only 9% who used a Spacer with their MDI. Being shown how to use an inhaler had no statistically 
significant impact on assessment result. This study found that over one third of patients had no knowledge of 
how taking corticosteroid inhalers helps their condition. 
 
Overall, patients of the Cardiff and Vale University Health Board have inadequate inhaler technique. 
Improvements in patient education and training provided by healthcare professionals need to be made. 
 
 Health and Social Care Information Centre (2014). Prescriptions dispensed in the Community. England 2003-13. Health and Social 
Care Information Centre, London 
 Hardwell A, Barber V, Hargadon T, McKnight E, Holmes J, Levy ML. Technique training does not improve the ability of most 
patients to use pressurised metered-dose inhalers (pMDIs) Prim Care Respir J. 2011;20:92–96. 
 Levy ML, Hardwell A, McKnight E, Holmes J. Asthma patients' inability to use a pressurised metered-dose inhaler (pMDI) correctly 
correlates with poor asthma control as defined by the global initiative for asthma (GINA) strategy: a retrospective analysis. Prim 
Care Respir J. 2013;22(4):406–411. 
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Investigating what the public know about reporting Adverse Drug Reactions 
Catherine Cassidy and ML Hughes 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
An Adverse Drug Reaction (ADR) is an unwanted or harmful side effect that can occur after the administration 
of any medicine.1 The aim of this research project was to design and pilot a questionnaire for the Yellow Card 
Centre Wales, in order to gather information surrounding the public’s views and experiences reporting ADRs. 
A postal questionnaire was chosen as the most appropriate method of collecting the data.2 ADRs are rare 
medical events, therefore purposive sampling was chosen to target those most at risk of having an ADR. 
Literature showed that those that were elderly, living with a limiting long term illness and with a lower socio 
economic status were most likely to experience an ADR. Census data was then used to determine electoral 
wards in Cardiff with the highest and lowest density of individuals in these three categories. After ethical 
consideration, the questionnaire and a cover letter were sent to 400 members of the public.  
There was a 14% response rate (n=55) with an even distribution of gender and those with / without a limiting 
long term illness. The mean age of respondents was 50 (SD 19.03). Thirty-one respondents had heard of the 
term ‘Adverse Drug Reaction’ and twenty-eight had experienced an ADR themselves. Of the 55 that responded 
to the questionnaire, only nine respondents had heard of the YCS and just two had reported an ADR through 
the YCS. Preferred methods of reporting were online, by post and by smartphone app. The most popular 
methods of learning more about the YCS were online and through social media.   
The results are in line with studies previously carried out that suggest an increase in the awareness of Adverse 
Drug Reactions is needed to improve pharmacovigilance.3 
 NICE. Adverse Drug Reactions. Nice; 2012 [accessed 10th November]. Available from: www.cks.nice.org.uk/adverse-drug-reactions 
 Dillman DA, Smyth JD, Christian LM. Internet, Phone, Mail and Mixed Mode Surveys: The Tailored Design Method. New Jersey: 
John Wiley & Sons; 2014 
 Avery AJ, Anderson C, Bond CM, Fortnum H, Gifford A, Hannaford PC, et al. Evaluation of patient reporting of adverse drug 
reactions to the UK Yellow Card Scheme: literature review, descriptive and qualitative analysis, and questionnaire surveys. Health 
Technology Assessment. 2013 Feb 12;15(20).  
 
 
Molecular modelling studies on methyltransferase enzymes as a novel drug target 
to treat schistosomiasis 
Daniel Caulfield, S Ferla and A Brancale 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Schistosomiasis is an infectious parasitic disease caused by the trematode fluke worm (Genus schistosoma). 
Usually found in fresh water like rivers and lakes, it burrows into exposed skin, the fluke matures and the 
females release eggs, most are excreted with some getting lodged into the hosts tissues giving rise to the 
clinical symptoms associated.1 Schistosomiasis is thought to affect around 243 million people annually mostly 
in tropical and subtropical regions.2,3 
Here we try to target Methyltransferases (O-Methyltransferase and N-Methyltransferase) as novel drug targets 
to treat Schistosomiasis. We aligned the schistosoma fasta sequences to crystal structures of the same 
enzyme of different organisms, doing so we were able to create homology models of both. Using the homology 
models, we used docking programs consensus scoring and visual inspection to screen potential inhibitors in 
the active site(s) we decided to target.  
For the O-Methyltransferase for both the cofactor and peptide active site, using the docking programs and 
consensus scoring we managed to reduce the number of potential inhibitors to 1355 and 1558 compounds 
respectively. Further visual inspection we identified the top 40 potential inhibitors for both. For the N-
Methyltransferase only targeting the ‘arm’ portion of the dimer we reduced the number of inhibitors to 48,821 
using HTVS, and then conducting negative screening we managed to exclude 16,390 compounds  
The 40 inhibitors selected for both O-Methyltransferase active sites show a lot of promise, although selectivity 
may be a potential issue in the future. These will now be purchased and tested further in Aberystwyth University 
in the hope of identifying a lead compound. There needs to be a lot more work conducted on the N-
Methyltransferase but selectivity seems promising with the high results seen from the negative screening and 
the differences between the target area (‘arm’) of the Schistosoma and Human dimer.  
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 World Health Organisation. Schistosomiasis. World Health Organisation Media Centre; May 2015 [accessed 8 Dec 2015]. Available 
from: http://www.who.int/mediacentre/factsheets/fs115/en/  
  National Health Service. Schistosomiasis (Bilharzia). National Health Service Choices; Jan 2016 [accessed 10 Jan 2016]. Available 
from: http://www.nhs.uk/conditions/schistosomiasis/Pages/Introduction.aspx  
 Thétiot‐Laurent SA, Boissier J, Robert A, Meunier B. Schistosomiasis chemotherapy. Angewandte Chemie International Edition. 
2013 Jul 29;52(31):7936-56.  
 
 
Topical delivery of Rho-kinase inhibitor Y-27632 to the cornea via mucoadhesive 
film 
Wendy Chan, A Quantock,1 A Akhbanbetova and CM Heard 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff CF10 
3NB, and 1School of Optometry & Vision Sciences, Cardiff University, Maindy Road, Cardiff, CF24 4HQ Wales, UK. 
Dual cryoprobe/ROCK inhibitor treatment1 was reported to have clinical benefit for Fuch’s Dystrophy, a 
common hereditary corneal disease. However, prior results obtained with ROCK inhibitor Y-27632 eye drops 
were considered sub-optimal due to run off and drainage.2 The aim of this study was therefore to test in vitro 
the plausibility of delivering Y-27632 to the cornea using an alternative delivery system, namely thin polymeric 
films to be applied directly onto the eye surface.  
 
Thin films were prepared incorporating Y-27632 using polymers that provide mucoadhesion3, and diffusional 
release was determined into PBS, followed by HPLC analysis. Topical ocular delivery from the applied film 
was modeled using freshly excised porcine eyeballs, of which half had undergone transcorneal freezing 
treatment using the cryoprobe device4. Eye drops of equivalent concentration to the film were formulated in 
PBS and applied onto the porcine eyeballs along as control. After 24 hours the formulations were removed 
and the corneas extracted, prior to HPLC analysis. 
 
Drug-loaded thin polymeric films, with high clarity and pliability were readily produced. ROCK inhibitor Y-27632 
was weakly retained within the film, with release attaining equilibrium after 1 hour. This in turn, facilitated its 
rapid ocular delivery - approximately three times greater Y-27632 penetration was observed from the thin film 
(p<0.01) compared to equivalent eye drops into cryoprobe-treated corneas. 
 
Findings from this study support the further development of cryoprobe/ROCK inhibitor delivery from thin 
mucoadhesive films as a combination therapy for Fuch’s Dystrophy. The results also generally support the 
potential development of thin mucoadhesive film as an alternative to eye drops application, by incorporating 
drugs targeting other conditions. The approach is however only appropriate for severe conditions that would 
otherwise require invasive surgery. 
 Koizumi N, Okumura N, Ueno M, Nakagawa H, Hamuro J, Kinoshita S. Rho-associated kinase inhibitor eye drop treatment as a 
possible medical treatment for Fuchs corneal dystrophy. Cornea. 2013;32:1167-70. 
 Patel A, Cholkar K, Agrahari V, Mitra AK. Ocular drug delivery systems: an overview. World J Pharmacol. 2013;2:47-64. 
 Llabot JM, Palma SD, Manzo RH, Allemandi DA. Design of novel antifungal mucoadhesive films. Part II. Formulation and in vitro 
biopharmaceutical evaluation. Int J Pharm. 2007;336:263-8. 
 Quantock A. Cryoprobe. [Patent Application Publication US2014/0316399A1]. United States; 2014. 
 
 
Characterising nigral grafts developed in the presence of L-dopa and/or GLP-1 
agonists in Parkinson’s disease 
Bethan Chesterman, O Elabi and EL Lane 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Parkinson’s Disease (PD) is a chronic neurodegenerative disease, leading to reduced dopamine levels in the 
brain as a result of nigro-striatal degeneration. A potential treatment for PD involves transplantation of fetal 
ventral mesencephalon tissue into the brain to increase striatal dopamine levels.1 Studies of this treatment 
have been carried out in both animals and humans, with varied results.2,3 GLP-1 agonists are currently being 
investigated for their neuro-protective effect on dopaminergic neurons. The aim of this study was to establish 
if GLP-1 agonists and/or L-dopa promote a neuro-protective effect on dopaminergic cells transplanted into the 
brain to manage the symptoms of PD.  
A model of PD was simulated in rats via a unilateral 6-OHDA lesion in the nigrostriatal pathway. There were 
seven treatment groups undergoing the transplantation procedure. Relevant groups were treated with GLP-1 
agonist and/or L-dopa, before the brains were sacrificed and analysed using immunohistochemistry 
techniques. Cell populations were collected using the microscope and analysed using two-way ANOVA.  
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There were no significant differences in the percentages of nigral dopaminergic neurons lost due to the lesion, 
serotonin or dopaminergic neurons in the graft, proportion of dopaminergic neurons which are the A9 subtype 
or inflammatory microglia in the graft and in the striatum between treatment groups. There was a significant 
difference in the percentage of dopaminergic neurons lost in the ventral tegmental area (VTA) between saline 
and liraglutide (with L-dopa) (P=0.0361). Rat weight was unaffected by the treatments. 
To conclude, the results have suggested that GLP-1 agonists do not promote a neuro-protective effect or 
influence the survival of grafted dopaminergic neurons. Further work is needed to see if GLP-1 agonists 
promote a neuro-protective effect on other dopaminergic cell sources. However, I believe that cell 
transplantation show promise for the future treatment of PD, if treated early enough.  
 Lindvall, O. 2015. Treatment of Parkinson’s Disease using cell transplantation. Philosophical Transactions of The Royal Society B 
[online]. 370(1680). Available at: http://rstb.royalsocietypublishing.org/content/370/1680/20140370.long [Accessed: 22 October 2015] 
 Freed, C.R. et al. 2001. Transplantation of Embryonic Dopamine Neurons for Severe Parkinson's Disease. The New England Journal 
of Medicine [online]. 344(10) pp. 710-719. Available at: http://www.nejm.org/doi/full/10.1056/NEJM200103083441002 [Accessed: 30 
December 2015] 
 Björklund, A. and Stenevi, U. 1979. Reconstruction of the nigrostriatal dopamine pathway by intracerebral nigral transplants. Brain 
Research [online]. 177(3) pp. 555-560. Available at: http://www.sciencedirect.com/science/article/pii/0006899379904724 [Accessed: 
20 November 2015] 
 
 
Adhesive ability of S. aureus and E. coli to catheter materials: influence of the 
materials and surface properties on surface energy parameters 
Chang Jun Chin, C Chin and P Prokopovich 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK  
The first emergence of urinary catheter was dated back in the year of 1752 invented by a politician named 
Benjamin Franklin. Ever since the introduction of urinary catheter, patients who exposed to the use of it have 
risen to at least 5 million in 2015. Today, urologists still insist on absolute disinfection to prevent 
microorganisms from infecting the urinary tract, as 80% of nosocomial urinary tract infections are related to 
urethral catheterization.1 The bacteria that are responsible for CAUTI are mostly from E. coli and S. aureus.  
 
The first emergence of urinary catheter was dated back in the year of 1752 invented by a politician named 
Benjamin Franklin. Ever since the introduction of urinary catheter, patients who exposed to the use of it have 
risen to at least 5 million in 2015.1 Today, urologists still insist on absolute disinfection to prevent 
microorganisms from infecting the urinary tract, as 80% of nosocomial urinary tract infections are related to 
urethral catheterization.2 The bacteria that are responsible for CAUTI are mostly from E. coli and S. aureus.  
From the results obtained, the hypothesise that surface of silicone has the highest adhesive force (500uN 
and1000uN) towards bacteria S. aureus and E. coli are truthful.  
 
PTFE (Teflon) is the best material available to make catheters with regard to the low adhesive force (55uN) 
produced between surface and bacteria S. aureus and E. coli. 
 
 Maki, D, 2001. Engineering out the risk for infection with urinary catheters. Emerging Infectious Diseases, [Online]. 7(2), 342-347. 
Available at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2631699/ [Accessed 01 January 2016]. 
 Migill, M, 2014. Multistate point-prevalence survey of health care-associated infections. The New England Journal of Medicines, 
[Online]. 13, 1198-1208. Available at:http://www.ncbi.nlm.nih.gov/pubmed/24670166 [Accessed 08 December 2015]. 
 
 
Skin permeation and penetration studies of metals using laser ablation ion coupled 
plasma mass spectrometry (LA-ICP-MS) 
Sze Yin Chong, S Waller and CM Heard 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff CF10 
3NB, and Cardiff School of Chemistry, Cardiff University Main Building, Park Place, Cardiff CF10 3AT, Wales, UK. 
Metal localisation in skin was relatively poorly studied, where previous methods include laser induced-
breakdown spectroscopy (LIBS), electron microscopy combined with energy dispersive x-ray analysis and 
inductively coupled plasma mass spectroscopy (ICP-MS). Laser ablation ion coupled plasma mass 
spectrometry (LA-ICP-MS) is a relatively new technique in biological samples analysis, its main advantages 
including bioimaging and higher sensitivity compared to other techniques.1 The aim of this novel study was to 
quantitate the localisation of manganese and titanium in excised porcine skin following dosing with potassium 
permanganate wash, commercial sunscreen and lipscreen. The importance of LA-ICP-MS in toxicological 
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assessment in humans and animals was highlighted by detecting the levels of manganese (Mn) and titanium 
(Ti) in skin, two common metals used in cosmetics and medical treatment.2,3  
The epidermis samples were heat separated from porcine ears and treated separately with potassium 
permanganate wash and commercial sunscreens. By calibrating samples with modified ballistic gels containing 
known concentrations of metals, the manganese and titanium levels in skin were quantified by doing depth 
profile analysis. The average molarity and average weight of the metals were then determined. 
The results obtained were semi-quantitative due to the set of standards being non-matrix matched, though a 
clear measure of metal concentrations can be used for toxicological and safety studies of cosmetics and topical 
medications. Some variations existed in the results, which represented the skin’s variability and potential 
selective accumulations in pores and follicles. 
This novel study demonstrated LA-ICP-MS as a promising method for depth profile analysis of metals in skin, 
with further studies required using matrix-matched standards. LA-ICP-MS could potentially be used for skin 
permeation and penetration studies involving new topical drugs containing metals or health and safety 
regulatory studies. 
 
 Pozebon, D. et al. 2014. Review of the Applications of Laser Ablation Inductively Coupled Plasma Mass Spectrometry (LA-ICP-MS) 
to the Analysis of Biological Samples. Journal of Analytical Atomic Spectrometry 29(12), pp. 2204-28. 
 Schilling, K. et al. 2010. Human Safety Review of “Nano” Titanium Dioxide and Zinc Oxide. Photochemical & Photobiology Sciences 
9(4), pp. 495-509. 
 Wakefield, G. et al. 2004. The Effects of Manganese Doping on UVA Absorption and Free Radical Generation of Micronised 
Titanium Dioxide and its Consequences for the Photostability of UVA Absorbing Organic Sunscreen Components. Photchemical & 
Photobiological Sciences 3(7), pp. 648-52. 
 
 
Involvement of oestrogen receptor signalling in Alzheimer’s disease in women 
Zoe Coles, M Alsaqati and EJ Kidd 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Alzheimer’s Disease (AD) is a progressive neurodegenerative disease disproportionately affecting women. 
Oestogen is neuroprotective1, it is hypothesised2 post-menopause there will be an increased incidence of AD 
in women due to altered levels of oestrogen or oestrogen receptors (ER). GSK3 is a kinase implicated in AD 
due to its role in the phosphorylation of tau.3 ERs are involved with activation of GSK3 and therefore 
progression of AD.4 The aim of this project was to determine the relationship between expression of ERs and 
disease progression in male and female samples. 
Brain samples from male and female, AD and control donors were analysed by Western blotting to determine 
the amount of protein present. Samples were probed for ER, ER, GSK3, GSK3, APP, phosphorylated 
tau and total tau. Results were compared between gender and disease status. 
Expression of APP was similar amongst gender and disease progression as shown previously. ER expression 
was significantly higher in female AD compared to female control and male AD samples; expression was also 
higher in male control compared to male AD samples. ER expression was significantly higher in female AD 
compared to female control samples. The expression of GSK3 was only significantly different between male 
and female control samples. Higher expression of phosphorylated tau in AD samples compared to none in 
control samples confirmed disease staging. 
This research suggests there is higher expression of ERs in women with AD. GSK3 action has been linked to 
oestrogen but from the results GSK3 and ER expression has been shown to be independent of one another, 
this may be due to the need to measure active GSK3. The progression of AD may trigger an increased 
synthesis of ERs allowing oestrogen to exert its neuroprotective role. The decrease in oestrogen or ERs post-
menopause may predispose women to a higher risk of AD.  
 Alves, S. and McEwen, B. Estrogens Actions in the Central Nervous System. Endocrine Reviews. 2013;20(3). 
 Grimm, A. Lim, Y-A. Mensah-Nyagan, A. G. Gotz, J. and Eckert, A. Alzheimer’s Disease, Oestrogen and Mitochondria: An 
Ambiguous Relationship. Molecular Neurobiology. 2012;46(1):151-160. 
 Takashima, A. GSK-3 is essential in the pathogenesis of Alzheimer’s Disease. Journal of Alzheimer’s Disease. 2006;9:309-317. 
 Cardona-Gomez, P. Perez, M. Avila, J. Garcia-Segura, L. M. Wandosell, F. Estradiol inhibits GSK3 and regulates interaction of 
estrogen receptors, GSK3, and beta-catenin in the hippocampus. Molecular and Cellular Neuroscience. 2004;25(3):363–373. 
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Does targeted e-learning allow community pharmacy to support affected 
populations during a scarlet fever outbreak? 
Ellen Crowley, D Roberts1 and JL Bowen 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff CF10 
3NB, and 1Wales Centre for Pharmacy Professional Education (WCPPE), 8 North Road, Cardiff, CF10 3DY, Wales, UK.  
Pharmacies are now recognised as key healthcare system entry points, as they are ideally located within the 
community1, leading to an expansion in pharmacy professionals’ roles in public health over recent years.2,3 
The WCPPE have been working alongside Public Health Wales to develop e-learning resources, to better 
prepare pharmacy professionals to deal with communicable disease outbreaks within the community. 
Following an outbreak of scarlet fever in March 2015, an email prompt was sent to pharmacy professionals, 
living or working in areas where outbreaks occurred, to complete the related e-learning module.4 This study 
was designed to explore participants’ identified changes in their knowledge and confidence in providing public 
health related messages on this communicable disease during the outbreak, following completion of the e-
learning package. A secondary aim was to investigate whether the use of a prompting system encourages 
participation in e-learning. 
 
A short structured questionnaire was sent to all pharmacy professionals who had completed the WCPPE 
scarlet fever e-learning package, from March 2015 onwards (n: 188). Data from the responses was collated 
and analysed, both thematically and via unpaired t-tests using GraphPad Prism.  
 
A response rate of 55% was achieved (n: 104). On completion of this e-learning module, the majority of 
pharmacy professionals (~91%) perceived that they had sufficient knowledge and confidence to support 
affected populations during the outbreak. With participants (84%) successfully applying this learning in 
practice, for purposes such as patient counselling and education of other healthcare professionals. Data 
collected suggested lack of prompting would lead to non-participation of professionals (73%). Requirement for 
access to additional resources summarising key information to maintain new found knowledge was also 
expressed.  
Results demonstrated that prompting to complete e-learning resources increases course uptake. Completion 
of communicable disease specific e-learning increases these professionals’ ability to support affected 
populations during a scarlet fever outbreak. 
 Smith MI, Wertheimer AI, Fincham JE. Pharmacy and the US Health Care System. Pharmaceutical  
Press. 2013;115-118, 245-247. 
 Agomo CO. The role of community pharmacists in public health: a scoping review of the literature. J Pharm Health Serv Res. 2012 
Mar 1;3(1):25-33. 
 Eades CE, Ferguson JS, O’Carroll RE. Public health in community pharmacy: A systematic review of pharmacist and consumer 
views. BMC Public Health. 2011 Jul 21;11(1):582. 
 Wales Centre for Pharmacy Professional Education. Scarlet Fever Public health update for pharmacists and pharmacy support staff 
e-learning package. 2014 [accessed 1 Oct 2015]. Available from: https://www.wcppe.org.uk/learning/learning-resources/scarlet-
fever. 
 
 
Evaluating VGLL1 in breast cancer 
Lucy A Des Clayes, RA McClelland, L Farrow, P Finlay, S Kyme, L Goddard, C Dutkowski, A Bojkowski, A 
Noorani, A Green1 and JMW Gee 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff CF10 
3NB, and 1Academic Unit of Oncology, Nottingham City Hospital, Hucknall Road Nottingham, NG51PB, UK 
VGLL1 is a co-activator for TEA domain (TEAD) transcription factors that can drive tumour proliferation.1 
Preliminary microarrays suggested VGLL1 mRNA is induced in Luminal A-derived endocrine resistant breast 
cancer cells that have lost oestrogen receptor (ER). This project aimed to further investigate VGLL1 in 
endocrine resistant models and to extend the research to protein studies including in archived clinical sections.  
 
The Luminal A (MCF-7, T47D) and Luminal B-derived models (BT474, MDA361) used comprised an endocrine 
responsive control and resistance to Tamoxifen (TamR), Faslodex (FasR) or oestrogen deprivation (E2DR). 
RT-PCR profiled VGLL1 expression in relation to ER loss. To detect VGLL1 protein, immunocytochemical 
techniques were optimised in paraformaldehyde-fixed cells and long-term stored formalin-fixed, paraffin-
embedded (FFPE) breast cancer sections based on a previous assay.2 The optimised clinical assay was 
applied to stored sections from 13 breast cancers versus ER status.  
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VGLL1 mRNA induction was seen in MCF-7-derived resistant TamR and FasR models and in all endocrine 
resistant T47D-derived models, broadly-associating with ER loss in Luminal A-derived models. VGLL1 was 
not induced in Luminal B-derived models. VGLL1 protein was predominantly nuclear and increases associated 
with ER loss in T47D-derived resistant cells. An assay for detection of VGLL1 in archived FFPE breast cancer 
sections was successfully-developed using pressure cooker antigen-retrieval that was able to detect an inverse 
relationship between nuclear VGLL1 and ER positivity.  
 
The relationship between ER loss and VGLL1 in Luminal A-derived endocrine resistant models suggests 
VGLL1 might play some part in the 20% of endocrine-treated patients who become ER- at relapse.3 This 
finding is important because biomarkers and targets are needed for endocrine resistance. VGLL1’s nuclear 
localisation corresponds with its reported coactivator function in the Hippo pathway.2,4 The assay developed 
is sensitive enough for future VGLL1 study using valuable stored endocrine resistant clinical breast cancer 
samples.  
 
 Mesrouze Y, Hau J, Erdmann D, Zimmermann C, Fontana P, Schmelzle T et al. The surprising features of the TEAD4-Vgll1 protein-
protein interaction. ChemBioChem. 2014;15(4):537-542. 
 Castilla M, Lopez-Garcia M, Atienza M, Rosa-Rosa J, Diaz-Martin J, Pecero M et al. VGLL1 expression is associated with a triple-
negative basal-like phenotype in breast cancer. Endocr Relat Cancer. 2014;21(4):587-599. 
 Drury S, Detre S, Leary A, Salter J, Reis-Filho J, Barbashina V et al. Changes in breast cancer biomarkers in the IGF1R/PI3K 
pathway in recurrent breast cancer after tamoxifen treatment. Endocr Relat Cancer. 2011;18(5):565-577. 
 Pobbati A, Chan S, Lee I, Song H, Hong W. Structural and functional similarity between the Vgll1-TEAD and the YAP-TEAD 
complexes. Structure. 2012;20(7):1135-1140. 
 
 
Investigating pharmacy involvement in preparation of local infiltration analgesia in 
total knee arthroplasty 
Sarah Dooey and AG Cosslett 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Total knee arthroplasty (TKA) is a common orthopaedic procedure which is currently associated with 
excruciating post operative pain1. Local infiltration analgesia (LIA) is a relatively new method designed to 
combat this pain2. This minimally invasive technique is part of the enhanced recovery after surgery (ERAS) 
approach to surgery where patients have more rapid mobilisation resulting in earlier discharge and decreased 
NHS costs3. Currently, there is no gold standard LIA formulation and this is putting patients at risk of serious 
harm from drug/calculation errors, contamination and unknown product stability4. The aim of the study was 
ultimately to determine if a safe and clinically appropriate LIA formulation could be developed for use following 
TKA. 
 
Service evaluation and ethical approval were obtained, allowing a literature search to be carried out to 
investigate current evidence based practice. SurveyMonkey was used to establish the current LIA 
formulations and procedures used in five Welsh Hospitals providing LIA. The survey was accessed online via 
a weblink and comprised seventeen questions of varying format. This method reached the relevant 
professional target audience using quota, purposive and snowballing techniques. 
 
A response rate of 60% was achieved. The survey met our objective in understanding what LIA formulations 
and procedures are used in Wales. These results mirror the literature: there is variance in local practice proving 
that the LIA technique is not standardised. The development of the optimal ‘LIA-cocktail’ requires further 
research to address both content and dosing of constituent parts. 
 
In conclusion, there is an unmet clinical need to standardise best practice and to provide a ready to use 
standardised LIA formulation. This study aimed to address this unmet clinical need. A gold standard LIA 
formulation as part of a standardised analgesic regimen for this patient group would enhance patient safety. 
 
1. NHS Choices. 2015. Knee Replacement [Online]. Available 
at:http://www.nhs.uk/conditions/Kneereplacement/Pages/Kneereplacementexplained.aspx [Accessed: 06/11/2015]. 
2. Kerr D R, Kohan L. 2008. Local infiltration analgesia: A technique for the control of acute postoperative pain following knee and hip 
surgery: A case study of 325 patients. Acta Orthopaedica 79 (2), 174-183. 
3. Kosev, P. et al. 2015. Fast track surgery in total knee arthroplasty - A review. Journal of IMAB - Annual Proceeding (Scientific 
Papers) 21(3), 837-839. 
4. Zhang, S. et al. 2011. Effect of Single- Injection versus Continuous Local Infiltration Analgesia after Total Knee Arthroplasty: A 
Randomized, Double-Blind, Placebo-Controlled Study. Journal of International Medical Research 39(4), 1369-1380. 
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The public’s opinion on community pharmacists having access to hospital 
discharge information 
Emma Dunleavy, KL Hodson, C Way1 and ML Hughes 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK and 1NHS Informatics Services, Cardiff, UK 
The CQC published a report showing that up to 87% of patients discharged from hospital, had discrepancies 
with their medication.1 Community pharmacists can potentially improve the safety of discharge medication by 
offering a timely review with patients. However, currently pharmacists only receive a brief discharge summary 
of medication changes, making it difficult to fully assess a patient and make decisions about medication 
suitability. These review services would be improved if pharmacists could gain the detailed discharge advice 
letters (DALs), given to general practitioners. Therefore the aim of this study was to quantify the opinions of 
the public of Wales on community pharmacists having access to patients’ hospital discharge advice letters 
 
A mailed questionnaire was used to collect such data from the public in Wales. The questionnaire, cover letter 
and information sheet were designed by a previous Cardiff University student.2 A multi-stage sampling process 
was used; sending 446 questionnaire (and prepaid return envelopes) to Merthyr Tydfil and 888 to Swansea. 
Two weeks were allowed for data collection and on return, results were entered into an SPSS database. 
Descriptive frequencies were run and Chi squared tests performed. 
 
Response rates of 13% for Merthyr Tydfil and 5% for Swansea were achieved. Demographic data showed that 
most respondents were aged 50+. Results showed that around 50% of respondents agreed that community 
pharmacists should have access to all types of hospital discharge information. Respondents believed that 
consent is an important aspect of information transfer. However, limited information was drawn on method of 
transfer, although respondents tended towards electronic transfer. It was also found that respondents worried 
about data security within the community pharmacy and that there was a lack of knowledge surrounding the 
role of the pharmacist.  
 
More research is needed before full conclusions can be drawn, owing to low response rates. However, this 
study can give us an indication of the public’s views on the topic. Public awareness of the role of the pharmacist 
and data handling within pharmacy could help address some of the issues found in this study. Also, considering 
the views of the public in regards to consent and information transfer, could help the policy change be viewed 
more positively.  
 
1 Care Quality Commision. NHS must do more to prevent harm to patients from prescribed medicines after leaving hospital, says 
CQC. 2009. [accessed 5th Nov 2015]. Available at: http://www.cqc.org.uk/content/nhs-must-do-more-prevent-harm-patients-
prescribed-medicines-after-leaving-hospital-says-cqc  
2 Wirt, E. Should Patient’s Discharge Advice Letters (DALs) be Sent to Community Pharmacists: The Views of the Public in Wales – 
Development and Piloting of the Questionnaire. Unpublished MPharm research project. Cardiff University, Welsh School of 
Pharmacy; 2014/15. 
 
 
Evaluating patients’ inhaler technique in Cardiff and Vale University Health Board 
Non Edmunds and WR Ford 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Inhaled drugs form the first line administration route in the management of asthma and COPD. Inhalers provide 
advantages over oral administration by delivering drugs directly to the target site and having a quick onset of 
action.1 However, incorrect technique can cause reduced delivery of drugs to the lungs, leading to poor disease 
control. Previous observational studies have shown that inhaler technique is generally poor in the patient 
population.2,3 The aim of this study was to evaluate possible factors affecting inhaler technique in the 
population of Cardiff and Vale University Health Board. 
 
Participants using inhalers for either COPD or asthma were recruited and information was gathered about 
them and their inhalers. Their inhaler technique was then assessed using a Vitalograph Aerosol Inhalation 
Monitor device which quantitatively estimated drug deposition in the lung.4 The data was evaluated using Excel 
software and analysed for any significance in affecting inhaler technique performance by using chi-squared 
tests. P <0.05 was taken as being significant. 
 
The type of device used had a significant effect on inhaler technique (P <0.0001). The best performance was 
seen using metered dose inhalers (MDI) used alongside a spacer with only 9% scoring an overall ‘fail’ 
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compared to MDIs, with 83% scoring an overall ‘fail’. Of the participants using dry powder inhalers (DPI), 50% 
scored in the sub-optimal range. 
 
When prescribers choose an inhaler device for a patient, they should consider whether the inhaler is to be 
used therapeutically or prophylactically and is appropriate for the patient’s inspiratory effort. The patients’ peak 
inhalation flow should be measured before prescribing DPIs as these require sufficient inspiratory effort to 
work. Spacers should be prescribed alongside MDIs intended for prophylactic use and regular assessments 
of inhaler techniques should be performed to ensure a correct inhaler technique is used and maintained. 
 
1. McFadden ER. Improper patient techniques with metered dose inhalers: clinical consequences and solutions to misuse. J Allergy 
Clin Immunol. 1995;96(2):278-83. 
2. Melani AS, Bonavia M, Cilenti V, Cinti C, Lodi M, Martucci P, et al. Inhaler mishandling remains common in real life and is 
associated with reduced disease control. Respir Med. 2011;105(6):930-8. 
3. Chorão P, Pereira AM, Fonseca JA. Inhaler devices in asthma and COPD – An assessment of inhaler technique and patient 
preferences. Respir Med. 2014;108(7):968-75. 
4. Vitalograph Ltd. Vitalograph AIM (Aerosol Inhalation Monitor) user training manual. c2015 [accessed 11th Oct 2015]. Available 
from: https://vitalograph.co.uk/downloads/view/07608. 
 
 
The Isolation of bacteriophages capable of infecting bacillus cereus group 
organisms and Clostridium difficile 
Daniel G Edwardes and L Baillie 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK  
Bacteriophages have been an interesting research target since the early 20th century.1 Their ability to infect 
and kill specific bacteria has been used to treat infections and conditions such as pneumonia, skin ulcers and 
burns.2,3 Bacteriophages may prove useful to combat the threat of antibiotic-resistant pathogens and agents 
of bioterrorism. Bacillus anthracis is the causative agent of Anthrax, while Clostridium difficile associated 
disease can cause colitis and diarrhoea. Both diseases are potentially fatal, so investigating novel treatments 
and decontamination agents is of interest. This study is based on previous observations in the laboratory and 
sought to determine the ability of specific bacteriophages to infect both Bacillus cereus group organisms and 
C. difficile. The activity of these bacteriophages was also investigated across a range of temperatures. 
 
Over the course of 7 weeks, the activity of 5 bacteriophages (RW, AB1, 3B6, ɣ and LC1H911) was investigated 
against isolates of B. thuringiensis CRY, non-pathogenic B. anthracis SdT-12 and C. difficile (strains 12727 & 
R20291). Bacteria were cultured, bacteriophages were propagated and various phage plaque assays were 
conducted. 
 
RW, AB1, ɣ and LC1H911 phages displayed lytic activity against B. anthracis SdT-12 at 37°C while only 
LC1H911 displayed activity at 25°C and 16°C. No lytic activity was seen for any of the phages against B. 
thuringiensis CRY. When tested against C.difficile LC1H911 and ɣ showed no lytic activity. RW and AB1 
phages were not tested due to time constraints. The 3B6 phage displayed no lytic activity against any of the 
the test bacteria, therefore we cannot confirm or refute the earlier observations of activity against C. difficile. 
 
In conclusion, no single bacteriophage displayed lytic activity against all of the test bacteria. The fact that the 
LC1H911 phage was able to lyse B. anthracis SdT-12 at 25° and 16°C suggests that it has potential to be 
developed as an environmental decontaminant against B. anthracis. 
 
 Duckworth D. History and basic properties of bacterial viruses. In: Goyal S, Gerba C, Bitton G, editors. Phage Ecology. John Wiley 
& Sons, New York. 1987; 1–44. 
 Levin B, Bull J. Phage therapy revisited: the population biology of a bacterial infection and its treatment with bacteriophage and 
antibiotics. The American Naturalist. 1996;147(6):881-898. 
 Abedon S, Kuhl S, Blasdel B, Kutter E. Phage treatment of human infections. Bacteriophage. 2011;1(2):66-85. 
 
 
Exploring pharmacists views on the integration and use of eDAL within the 
community pharmacy setting 
Laura Ellis, G Jones, KL Hodson, ML Hughes, RE Deslandes, C Way1 and E Mantzourani 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward Vll Avenue, Cardiff CF10 
3NB, and 1NHS Wales Informatics Service, Brunel House, 12th Floor, 2 Fitzalan Road, Cardiff CF24 0HA, Wales, UK 
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A discharge medicine review (DMR) is a service offered in Wales, to patients recently discharged from 
hospital.1 The service allows community pharmacists (CPs) to check patients’ medicines for discrepancies 
upon discharge.2 A challenging aspect for CPs is to identify patients who have been discharged from hospital 
as a discharge advice letter (DAL) is not received directly from the hospital, and CPs rely on patients to bring 
a copy of their DAL to the pharmacy.1 Electronic DALs (eDALs) sent to CPs and an online DMR form have 
been piloted in community pharmacies in Betsi Cadwaladar, Cardiff and Vale and Cwm Taff Health Boards; 
this should enable pharmacists to complete DMRs in a timely manner.3 CPs can access these through a secure 
online portal, the Choose Pharmacy application.1 The aim of the study was to evaluate pharmacists’ views on 
the feasibility and usefulness of the pilot of the eDAL and the online DMR form. 
 
Semi-structured interviews were conducted to obtain qualitative data. Purposive and convenience sampling 
were used to recruit pharmacists. The interviews were conducted face to face, audio recorded and transcribed 
verbatim. The data was analysed using thematic analysis. Ethics approval was obtained.  
 
The feedback provided by CPs regarding the usefulness of eDAL was positive. CPs felt it improved 
communication between hospital and the pharmacy setting. Many expressed disappointment in poor uptake 
of the eDAL within hospitals. The quality of the eDAL was reported as good and as helpful to pharmacists 
when completing DMRs, due to its easy to read format; handwriting does not need to be interpreted. Several 
aspects of the application proved time saving; automatic input of the information from the eDAL onto the DMR 
form and reimbursement through the application. Some barriers to initial implementation were raised and 
include technical issues. 
 
The use of eDAL within community pharmacy is welcomed and is feasible. Suggestions have been made on 
how to improve issues with the current application. 
 
1. Community Pharmacy Wales (CPW). 2011. Details of the DMR service [Online] Available at: 
http://www.cpwales.org.uk/Contractors-Area/Pharmacy-Contact---Services/Advanced-Services/20111111-Details-of-the-DMR-
service.aspx [Accessed on ] 4th November 2015. 
2.  Laurence James. 2015. HTTF Improving Communications with Community Pharmacies Project, Choose Pharmacy Application: 
eDMR. NHS Wales Informatics Service.  
3. Gareth Malson. 2014. Electronic sharing of hospital discharge information moves closer in Wales. The Pharmaceutical Journal. 
29:20-27. 
 
 
Computer-aided design and synthesis of novel c-FLIP inhibitors 
Bijo Emmanuel, G Giancotti and A Brancale 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK  
Breast cancer stem cells (bCSCs) facilitate relapse of disease and lead to formation of distant metastases, 
which is the primary cause of mortality in breast cancer patients. Due to heterogeneity of bCSCs there are 
resistance to existing treatments.1 Tumour Necrosis Factor-Related Apoptosis Inducing Ligand (TRAIL) is a 
protein belonging to the TNF family of ligands, is able to induce apoptosis in tumour cells; without affecting 
normal cells, thus it represents an attractive anti-cancer agent.2 In breast cancer, however, different cell lines 
are resistant to TRAIL, especially bCSCs.1 Cellular Flice-Like Inhibitory Protein (c-FLIP) plays an important 
role in TRAIL-resistance, because of its ability to interfere with the TRAIL pathway, therefore preventing the 
TRAIL induced apoptosis.2 Small inhibitors for c-FLIP has not been researched due its high similarity to 
caspase-8, which is a crucial protein for DISC formation in apoptotic pathway.3 However, in a previous study, 
the homology model of c-FLIP and caspase-8 has been constructed and using a structure-based virtual 
screening of commercially available compounds, one selective lead c-FLIP inhibitor at micromolar 
concentrations has been identified.4 Building from the structure of this lead compound, we have designed and 
synthesised 13 new derivatives.  
Before synthesis, all the newly designed compounds were analysed with molecular docking studies, with the 
aim to evaluate their predicted binding mode within the pocket of c-FLIP and non-selectivity to caspase-8. All 
13 derivatives were successfully synthesised, however some synthetic pathways require optimisation to 
maximise yields. These synthesised compounds will be tested on breast cancer cell lines in future studies to 
evaluate their activity. 
1. Piggott L, Omidvar N, Pérez S, Eberl M, Clarkson R. Suppression of apoptosis inhibitor c-FLIP selectively eliminates breast cancer 
stem cell activity in response to the anti-cancer agent, TRAIL. Breast Cancer Research. 2011;13(5):R88. 
2. Safa A. C-FLIP, a master anti-apoptotic regulator. Experimental oncology. 2012;34(3):176-184.  
3. Giancotti G. Computer-aided design, synthesis and evaluation of novel c-FLIP inhibitors in order to sensitise Breast Cancer Stem 
Cells to TRAIL. Presentation presented at; 2015; Cardiff University.  
4. Hayward O. Design and Synthesis of Molecular Inhibitors of c-FLIP Activity as a Therapeutic Strategy to Target Breast Cancer Stem 
Cells [PhD Thesis]. Cardiff: Cardiff University; 2014. 
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Styk1 and mTOR pathway interplay in breast cancer 
Dana Esmail, P Finlay, S Kyme, L Goddard, H Mottram, L Farrow, A Green1 and JMW Gee  
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff CF10 
3NB, Wales and 1Academic Unit of Oncology, Nottingham City Hospital, Hucknall Road Nottingham NG5 1PB, UK. 
While endocrine therapy has revolutionised treatment of oestrogen receptor positive (ER+) breast cancer, 
many patients relapse with acquired resistance.1 The mechanisms of resistance are poorly-understood, but 
‘cross-talk’ between ER and the mTOR pathway is implicated.2 Recently an inhibitor of the mTOR pathway, 
Everolimus, has been clinically-evaluated. However, many patients fail to benefit2 so further pathway 
understanding and thereby biomarkers for Everlolimus responsiveness remain needed. Research in Cardiff 
has found that an endocrine resistant cell line (FASR) that is highly-sensitive to Everolimus also has an 
increase in novel kinase, STYK1. STYK1 interplay with mTOR signalling underpins Everolimus-sensitive 
growth in FASR. The research question was whether there is also any evidence for a relationship between 
STYK1 and mTOR signalling in clinical breast cancer.  
 
An immunohistochemical assay was optimised using pH8 pressure cooker-microwave antigen retrieval to 
detect mTOR signalling in breast cancer sections, monitoring phosphorylation of ribosomal protein S6 (P-
RPS6). This was applied to a clinical primary breast cancer series (n=93) pre-stained for STYK1, using H-
scoring to analyse staining. Statistical testing examined relationship between P-RPS6, STYK1 and further 
parameters available for the series. 
 
A significant correlation (P=0.047) was found between STYK1 and cytoplasmic P-RPS6. Further significant 
association in the all patient group, between P-RPS6, ER-beta (P=0.036) and slight association with IGFR 
(P=0.052) were discovered. Such associations were also seen in ER+ tumours (p=0.044, p=0.001, and 
p=0.016 respectively).  
 
These findings support a novel interplay between STYK1 and mTOR signalling activity in breast cancer. ER 
beta, which may regulate STYK1 expression3, and IGFR may also be involved in this cross-talk between 
STYK1 and the mTOR pathway. Further work is needed to explore this mechanism and to examine its 
prevalence in endocrine resistant disease and any relation to Everolimus outcome in further patient sample 
series, which will help clarify biomarker potential. 
 
1. Roop R, Ma C. Endocrine resistance in breast cancer: molecular pathways and rational development of targeted therapies. Future 
Oncology. 2012;8(3):273-292. 
2. Beaver J, Park B. The BOLERO-2 trial: the addition of everolimus to exemestane in the treatment of postmenopausal hormone 
receptor-positive advanced breast cancer. Future Oncology. 2012;8(6):651-657. 
3. Kimbro K, Duschene K, Willard M, Moore J, Freeman S. A novel gene STYK1/NOK is upregulated in estrogen receptor-alpha 
negative estrogen receptor-beta positive breast cancer cells following estrogen treatment. Molecular Biology Reports. 
2007;35(1):23-27. 
 
 
Development of a novel natural product based germinant and biocidal mixture to 
enhance the decontamination of bacterial spores 
David Gareth Evans and L Baillie 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK  
Bacillus anthracis is the pathogen responsible for anthrax and is found in many areas around the world.1 It 
belongs to a group of bacteria which can form chemically resistant spores making them difficult to eliminate 
with traditional biocides. Bacillus thuringiensis is a closely related, non-pathogenic bacteria also capable of 
forming spores, and is often used as a surrogate for B. anthracis. Natural products are capable of a wide 
variety of effects.2 Some like EGCG3 and Xanthohumol4 are of particular interest. Selected natural products 
were screened for there ability to potentiate spore germination. 
The effect on germination of a range of amino acids and natural products was determined using a high-
throughput plate reader screening assay and a low-throughput manual count method. An Infinite Pro® 200 
plate reader was used to measure the change in absorbance of B. thuringiensis spores exposed to natural 
products and germinants. A reduction of optical density in these samples indicate germination of bacterial 
spores. A drop count approach was also employed to determine the effect of various compounds on the viability 
and germination of the B. thuringiensis spores. 
While both approaches generated results, the degree of variation and the limited number of repeats meant 
that it was not always possible to draw firm conclusions. On those occasions when a full data set was obtained, 
the test compounds failed to stimulate spore germination in excess of that seen for the Alanine (500mmol) and 
Inosine (25mmol) positive control. 
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Due to the variation obtained in the results, and the low number of repeats, it was not possible to draw any 
decisive conclusions about the natural products examined in this study. While the failure of the majority of 
compounds to exceed the values of the positive control suggest a lack of relative activity, further studies are 
required to determine if this is indeed the case. 
 Gordon, N.C., Wareham, D.W., 2010. Antimicrobial activity of the green tea polyphenol (-)-epigallocatechin-3-gallate (EGCG) 
against clinical isolates of Stenotrophomonas maltophilia. Int. J. Antimicrob. Agents 36, 129–13 
doi:10.1016/j.ijantimicag.2010.03.025. 
 Schmidt, B., Ribnicky, D.M., Poulev, A., Logendra, S., Cefalu, W.T., Raskin, I., 2008. A natural history of botanical therapeutics. 
Metabolism. 57, S3–9. doi:10.1016/j.metabol.2008.03.001. 
 Stevens, J.F., Page, J.E., 2004. Xanthohumol and related prenylflavonoids from hops and beer: to your good health! 
Phytochemistry 65, 1317–1330. doi:10.1016/j.phytochem.2004.04.025. 
 Little, S. 1999. Molecular pathogenesis of Bacillus anthracis infection. Microbes and Infection. doi:10.1016/S1286-4579(99)80004-5. 
 
 
Design and synthesis of CYP121 inhibitors as potential tuberculosis therapeutics 
Jack Evans and C Simons 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Tuberculosis (TB) is “a leading cause of death worldwide”.1 There are many challenges associated with current 
antibiotic therapy.2 An important and unexpected link has become apparent between Mycobacterium 
tuberculosis (Mtb), cytochrome P450 (CYP) and possible drug targeting. CYP121 is an exclusive haemoprotein 
essential for Mtb viability.3 The only known high-affinity ligands of CYP121 are azole-antifungals and these 
associate with a distal water molecule to bind to the haem of the CYP121.4 This research aims to design and 
synthesise CYP121 inhibitors targeting CYP121 and showing Mtb activity.  
 
Molecular Operating Environment (MOE) software allowed a database of molecules to be docked in the active 
site to visualise binding interactions to see whether compounds had poses that exploited the haem. Triazole 
and imidazole derived products aim to mimic the azole-binding mode and exploit indirect binding with a distal 
water molecule. Amide-coupled pyridine and imidazole products aim to extend nitrogen nearer the haem to 
explore whether direct binding is beneficial. Purity was analysed using TLC, melting point, 1H-NMR and 13C-
NMR where appropriate.  
 
MOE suggested that all novel CYP121 inhibitors exhibited binding poses that exploited the haem. The triazole 
product was synthesised and sent for microanalysis and biological testing. The amide-coupled imidazole 
product was synthesised but not in sufficient quantity for screening. 1H-NMR showed that the synthesis of the 
imidazole product was unsuccessful. The amide-coupled pyridine was not attempted due to time constraints.  
The synthetic pathways for all products are yet to be optimised. Microanalysis confirmed that the triazole 
product was successfully synthesised and biological testing data is pending. Further work is needed to optimise 
the synthetic pathways and screen all four potential CYP121 inhibitors.   
 
 World Health Organisation. Global tuberculosis report 2015. 20th ed. Geneva (CH): World Health Organisation; 2015. 192.  
 Zumla A, Nahid P, Cole S. Advances in the development of new tuberculosis drugs and treatment regimens. Nat Rev Drug Discov. 
2013;12:388-404. 
 McLean K, Dunford A, Neeli R, Driscoll M, Munro A. Structure, function and drug targeting in Mycobacterium tuberculosis 
cytochrome P450 systems. Arch Biochem Biophys. 2007;464:228-40. 
 Hudson S, McLean K, Surade S, Yang Y, Leys D, Ciulli A et al. Application of fragment screening and merging to the discovery of 
inhibitors of the Mycobacterium tuberculosis cytochrome P450 CYP121. Angew Chem Int Ed Engl. 2012;51:9311-16. 
 
 
How can WCPPE best deliver live CPD events for the pharmacy workforce within a 
rural location? 
Joseph Franchi and KL Hodson 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Due to the lack of healthcare professionals in rural areas, pharmacists are required to play a multidisciplinary 
role in the community and this requires appropriate Continuing Professional Development (CPD) training.1,2 
Over the spring and summer of 2014, the lowest number of pharmacy professionals that attended a live CPD 
event in Powys was 3 and the highest was 5.3 The main aim was to find out why attendance of live CPD events 
in Powys is so low. This information will then be used to construct an informed questionnaire which can be 
distributed to a greater pharmacy population across Powys and provide quantitative feedback for review.  
Ethical approval was sought from the Cardiff School of Pharmacy and Pharmaceutical Sciences ethics panel. 
Then two focus groups were undertaken to try to understand the reasoning behind the low attendances at 
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events. Focus group structures were decided based on literature research. The topic guide for the focus groups 
contained three main open questions. Closed questions were also used as prompts. The focus group dialogues 
were captured, transcribed and then analysed for key themes. The key themes from both focus groups were 
compared and were used to construct an informed draft questionnaire. 
 
From the two focus groups eight key themes emerged. They were: location; learning facilitators; 
communication; IT; timings; learning and events information; frequency; use of expert speakers. 
 
Based on the information from the focus groups, comparisons with other professions and different 
organisations in other countries it is clear that Wales Centre for Pharmacy Professional Education (WCPPE) 
needs to make changes to its current programme in order to improve delivery and attendance at live CPD 
events. Once the questionnaire has been sent out, collected and analysed it will give WCPPE a better idea of 
what their members want from events. 
 Welsh Assembly Government. Delivering Rural Health Care Services. 2011; 16-17 
 Welsh Assembly Government. Improving health delivery across Wales. 2009; 3, 34.  
 Alexander C. To investigate the barriers to Continuous Professional Development for pharmacy staff living and/or working in rural 
locations in Wales. 2014; 3-10, 16-21, 27-28. 
 
 
Investigations into the effects of glucose on intravenous lipid emulsion stability 
Sarah Freeburn, S Emery and AG Cosslett 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Intralipid® (INT), a soybean lipid emulsion, has been used for many years due its high safety profile. SMOFlipid® 
(SMOF) is a new product, containing fish oils which are clinically beneficial due to the increased ω-3 and ω-6 
fatty acid composition that can prevent inflammation1 and reported reductions in infectious complications for 
patients.2 As it is relatively new, not a lot is known about the stability of SMOF. There appears to be uncertainty 
as to whether glucose, an essential component of PN required for energy, helps to maintain the stability or 
causes instability of PN lipid emulsions.3 
 
In order to further investigate the stability properties of each lipid emulsion and to determine what 
concentrations of glucose are the safest to use in clinical practice, the aim of this project was to compare 
SMOF and INT emulsions stability when mixed with a variety of glucose concentrations (5%, 20% and 70%) 
over a period of 5 days (testing every 24 hours). All samples were stored at room temperature (RT) but the 
higher glucose concentration mixtures were also made and stored at 37°C to investigate the effects of 
increased temperatures on stability. Laser diffraction, light microscopy, pH testing and visual inspection were 
carried out to measure any changes in globule size which would indicate changes in stability. 
 
Higher concentrations of glucose were found to reduce the overall pH and increase the presence of larger 
globules. This explains why 70% glucose caused the most stability issues, especially when stored at 37°C. 
20% glucose caused little change in stability and produced consistent results with only a slight decrease in pH. 
5% glucose presented with some inconsistent results as some signs of instability were observed by light 
microscopy but not for visual or laser diffraction tests. 
 
The results concluded that glucose 20% is a safe concentration to use in clinical practice whereas 70% was 
associated with stability issues. Storing mixtures at 37°C does have an accelerating effect on instability. SMOF 
was found to be more susceptible to destabilisation than INT. 
 
1. Goulet, O., H. Antébi, C. Wolf, C. Talbotec, L.-G. Alcindor, O. Corriol, M. Lamor, and V. Colomb-Jung, A new intravenous fat emulsion 
containing soybean oil, medium-chain triglycerides, olive oil, and fish oil: a single-center, double-blind randomized study on efficacy 
and safety in pediatric patients receiving home parenteral nutrition: JPEN. Journal of Parenteral and Enteral Nutrition, 2010;34:485. 
2. Gallegos, M. C., M. C. Valencia, M. P. Partal, M. J. Franco, M. O. Maglio, M. M. Abrahamsson, and M. E. Brito-De La Fuente, Droplet-
size distribution and stability of commercial injectable lipid emulsions containing fish oil: American Journal of Health-System 
Pharmacy, 2012;69:1332-1335. 
3. Black CD, Popovich NG. A study of intravenous emulsion compatibility: effects of dextrose, amino acids, and selected electrolytes. 
Drug Intelligence and Clinical Pharmacy. 1981;15(3):184-93. 
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Exploring factors influencing student motivation for the MPharm: a qualitative study 
Emma Gough and DN John 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Motivation is a student’s willingness, desire and compulsion to participate in and be successful in the learning 
process. Self-Determination Theory1 distinguishes between intrinsic motivation, which is motivation which 
originates from an inherent enjoyment or interest, and extrinsic motivation, which is motivation for a separable 
outcome or reward. In relation to education, academic motivation is a student’s willingness, desire, capabilities 
and compulsion to participate and be successful in the learning process.2,3 Previous research into pharmacy 
student motivation the UK is lacking, allowing the opportunity for the aim of this project to explore motivational 
factors which affect students within MPharm IV at Cardiff University School of Pharmacy and Pharmaceutical 
Sciences (CSPPS). 
One-to-one semi-structured interviews using a topic guide devised as a research group of four MPharm IV 
students. Ethical approval was granted prior to data collection. The topic guide discussed student motivation 
with regards to Pharmacy, the MPharm degree and commitments outside of university. The interviews were 
transcribed verbatim and analysed using thematic analysis4 identifying main themes and sub-themes.  
Twenty-four MPharm IV undergraduate students were purposively selected and interviewed. Nine main 
themes influencing student motivation were identified from the dataset including Interests, Perceived 
Relevance, Influence of Others, Previous Experiences, Extra Commitments, Fear, Goals and Timetable.  
The objectives were met as student motivational factors have been identified and explored. The results could 
potentially help other schools of Pharmacy to identify common factors which motivate students in order to 
promote motivation in their Schools of Pharmacy. Future work could consist of identifying how academics 
promote student motivation and then compare their methods with motivational factors which increase student 
motivation. Academics at CSPPS could then develop teaching strategies to increase student motivation and 
encourage student engagement.  
 Deci, E. Ryan, R. M. 1985. Intrinsic Motivation and Self-Determination in Human Behaviour. United States of America: New York. 
 Schunk, D. H. 1991. Self-efficacy and Academic Motivation. Educational Psychologist 26(3-4):207-231. 
 Vallerand, R. J. Pelletier, L. G. Blais, M. R. Briere, N. M. Senecal, C. Vallieres, E. F. 1992. The Academic Motivation Scale: A 
Measure of Intrinsic, Extrinsic, and Amotivation in Education. Educational and Psychological Measurement 52(4):1003-1017. 
 Braun, V. Clarke, V. 2006. Using Thematic Analysis in Psychology. Qualitative Research in Psychology 3(2):77-101 . 
 
 
What are the drawbacks of fluorescent marker pens to measure cleaning efficacy 
and compliance? 
Robert Green and J-Y Maillard 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
UV fluorescent marker pens were proposed by Carling et al.1 as a visual means of assessing the quality of 
terminal cleaning in hospitals. Hospital acquired infections (HAIs; e.g. MRSA and VRE) can survive on surfaces 
for long periods of time.2 Outbreaks of HAIs place a huge financial burden on the NHS due to longer hospital 
stays, increased medical costs, and the control measures that must be implemented to prevent further spread. 
The quality and management of hospital cleanliness in the UK has been criticised heavily [3] due to poorly 
defined guidelines and a lack of microbiological benchmarks.3 
 
The aim of this study was to assess whether or not fluorescent dyes were predisposed to remain on surfaces 
following wiping and which factors affected dye removal or lack of. 
 
Five replicates of 13 materials, representative of high-touch surfaces, were marked with two types of 
fluorescent dye (A and B). Surfaces were incubated at 40% or 60% relative humidity (RH) for 2h or 24h. The 
surfaces were wiped by two types of wipe which were secured to a mechanical wiping device. The amount of 
dye removed was assessed using a subjective visual 4 scale points (zero scale: no dye present; 4 no dye 
removed). 
Dye A was removed more effectively from surfaces than Dye B by the mechanical wiping device. Mean visual 
ratings were 1.97 and 2.37 out of 4, respectively. There was no significant difference in the amount of dye 
removed at 40% and 60% RH. More dye was removed after 2h than 24h; the visual scores were 1.98 and 2.37 
out of 4, respectively. 
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Fluorescent markers are a rapid, simple and cost-effective cleaning intervention1 that should become the 
preliminary auditing and training tool in an integrated approach to environmental cleaning which should 
encompass microbiological standards to judge cleanliness.3,4 
1. Carling P, Briggs JL, Perkins J, Highlander D. Improved Cleaning of Patient Rooms Using a New Targeting Method. Clin Infect Dis. 
2006;42:385-8. 
2. Dancer SJ. Mopping up hospital infection. J Hosp Infect. 1999;43:85-100. 
3. Cooper RA, Griffith CJ, Malik RE, Obee P, Looker N. Monitoring the effectiveness of cleaning in four British hospitals. Am J Infect 
Control. 2007;35:338-41. 
4. Dancer SJ. The role of environmental cleaning in the control of hospital-acquired infection. J Hosp Infect. 2009;73: 378-85. 
 
 
Computer-aided design of a novel generation of BCL-3 inhibitors 
Chelcie Griffiths-Mead, C Bordoni and A Brancale 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
BCL-3 (B-cell lymphoma-3) is a co-transcriptional factor that can bind to two molecules of p50 and forming a 
tertiary complex with DNA. Once activated, it promotes the transcription of genes that enable cell proliferation 
and hence a contributing factor in cancer.1-3 JS6 and CB1 are putative compounds previously identified to have 
activity with the BCL-3/(p50)2 complex, with the aim of this project to design scaffolds in silico to explore this 
BCL-3 binding pocket.  
A series of computer-aided methods were used, including MOE (Molecular Operating Environment), to create 
four database libraries (i.e. family 1, family 2, family 3, family 4) discovered from previous research. Docking 
methods (FlexX, PLANTS and Glide) were used to obtain relative binding positions of these database libraries 
against the binding pocket. Dynamic methods (Maestro) were used to obtain the binding energies and stability 
profiles on the final selected inhibitors from each family designed and also on JS6 and CB1. 
The docking results showed a large variety in binding positions, with analysis including the best visualised 
position, their amino-acid interactions and their respectable bond lengths. The best binding poses from each 
family were analysed by dynamic calculations, in comparison to JS6. Family 3 was the only compound that 
had stabilised binding within the specified binding pocket, with the exception of family 4 that had interactions 
in what could be an additional pocket on the BCL-3 protein. 
To conclude, prior to researching this further, more experimental research is needed on the BCL-3 protein and 
the binding pocket identified as there is little detailed knowledge in the literature. Such research could include 
crystallography and mutation studies. From this, we can aim to have more accurate computer modelling 
results. 
 Ohno H, Takimoto G, McKeithan T. The candidate proto-oncogene BCL-3 is related to genes implicated in cell lineage 
determination and cell cycle control. Cell. 1990;60:991-97 Available at: http://ac.els-
cdn.com.abc.cardiff.ac.uk/009286749090347H/1-s2.0-009286749090347H-main.pdf?_tid=0d50dc84-a4dd-11e5-916c-
00000aacb361&acdnat=1450370682_a951dcbe0facf88a936389f6916461f5 [Accessed 15 Nov 2015].  
 Urban B, Collard T, Eagle C, Southern S, Greenhough A, Hamdollah-Zadeh M et al. BCL-3 expression promotes colorectal 
tumorigenesis through activation of AKT signalling. Gut. 2015:1-14. Available at: http://www.ncbi.nlm.nih.gov/pubmed/26033966 
[Accessed 02 Oct 2015]. 
 Viator P, Merville MP, Bours V, Chariot A. Protein phosphorylation as a key mechanism for the regulation of BCL-3 activity. Cell 
Cycle. 2004;3:1498-99. Available at: http://www.ncbi.nlm.nih.gov/pubmed/15611665 [Accessed 15 Nov 2015]. 
 
 
The adherence of purified Clostridium difficile spores (Ribotype 012 and 027) to a 
stainless steel surface 
Charlotte Hard and L Baillie 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Clostridium difficile is an anaerobic, spore forming bacteria. It is a major cause of nosocomial acquired 
diarrhoea in the UK, and can lead to life threatening complications.1 Hypervirulent strains exist and include 
those from ribotype 027.2 This study examined three main factors; the effect of different production and 
purification methods on bacterial spore yield, the effect of the spore purification method on the ability of spores 
to adhere to stainless steel, a material commonly found in healthcare facilities and the relative adherence of 
virulent spores (027) versus less virulent (012) spores.  
 
Spores were generated then purified using the methods of Lawley et al1 (method 1) and Sorg and Sonenshein3 
(method 2) and enumerated using a drop-count method.4 The strains used were 1801 and R20291 from 
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ribotype 027 and 630 from ribotype 012. Adhesion to stainless steel was determined using a transfer test in 
which spore inoculated stainless-steel discs were lowered onto supplemented BHI agar on 16 consecutive 
occasions and the total spore transfer to the agar surface was calculated.2 
 
Spore yields were affected by the strain and method. From a single experiment, purity level ranged from 97.17-
100% for method 1 and 93.49-99.65% for method 2. Tests revealed no differences in adhesion to stainless 
steel from any of the strains. No difference was found when comparing results obtained in purification method 
1 versus method 2. When comparing spores of 1801, adhesion to stainless steel was found to be significantly 
different (p<0.05) between purified and unpurified spores. 
 
It would thus appear that the degree of purification of the spores affected the degree to which they adhered to 
stainless steel. Future research is required to establish the best method of spore purification and to determine 
whether virulent strains adhere more strongly than there less virulent counterparts. Access to such data will 
improve our understanding of the importance of stainless steel as a vector and determine the feasibility of 
developing surfaces that prevent adhesion. 
 
1. Lawley, T.D. et al (2009). Preomic and genomic characterization of highly infectious Clostridium difficile 630 spores. Journal of 
bacteriology 191(17):53877-5386 
2. Joshi, L.T. et al (2012). Contribution of spores to the ability of Clostridium difficile to adhere to surfaces. Applied and environmental 
microbiology 78(21):7671-7679. 
3. Sorg, J.A. and Sonenshein, A.L. (2010). Inhibiting the initiation of Clostridium difficile spore germination using analogs of 
chenodeoxycholic acid, a bile acid. Journal of Bacteriology 192(19):4983-4990. 
4. Miles, A.A. and Misra, S.S. (1938). The estimation of the bactericidal power of the blood. The Journal of Hygiene 38(6):732-749. 
 
 
Bacterial adhesion between dental biomaterials and relevant gram positive and 
gram negative bacteria: Influence of surface and material characteristics via a 
numerical approach 
Elizabeth M Hewitt and P Prokopovich 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Between 2009 and 2010 a study conducted on 6,469 particpants found that 85% of adults had at least one 
tooth filling.1 With 9% experiencing secondary decay resulting in 26% needing corrective treatment. [1] Raising 
the question: Do current dental biomaterials have the required antimicrobial properties needed in order to 
prevent initial bacterial adhesion? With the overall aim being to determine which dental biomaterial(s) are the 
best at preventing bacterial adhesion and dental plaque formation.  
Data was collected via a numerical approach using an in-house developed numerical procedure. Based on the 
Johnson-Kendall-Roberts (JKR) multi-asperity adhesion model this procedure estimates adhesive forces 
between two interacting surfaces.2,3 initially adhesive fore data was generated for nine dental biomaterials 
(Zirconia, Glass Ionomer Cement, Hydroxyapatite, Composite Resin, Silver (0.5%.1% and 5% Ag 
concentrations), Gold and Cobalt Chromium) in the presence of Staphylococcus aureus bacteria. Materials 
with the greatest and least adhesive force were then identified and adhesive forces were then estimated for 
these materials in the presence of gram positive (Streptococcus salivarius and Streptococcus mutans) and 
gram negative (Veillonella Parvula and Actinobacillus actinomycetemcomitans) bacteria.  
In the presence of S.aureus, antimicrobial coating 2 (1% Ag) and hydroxyapatite were identified as the least 
and most adhesive materials respectively from all biomaterials studied. While in the presence of oral gram 
positive and negative bacteria S.salivarius was identified as the most adhesive bacteria and S. aureus the 
least adhesive bacteria. 
Overall, antimicrobial coating 2 (1% Ag) is the least adhesive biomaterial which agress with its respective 
surface characteristics. Whereby it has the lowest surface energy value overall biomaterials studied. This 
agrees with the literature whereby materials with high surface energy values experience greater adhesive 
forces and vice versa.4 Therefore antimicrobial coating 2 (1% Ag) is the best dental biomaterial to use when 
preventing biofilm formation and secondary decay.  
1. Steele J, O'Sullivan I. Adult Dental Health Survey 2009: Executive Summary - adul-dent-heal-surv-summ-them-exec-2009-rep2.pdf. 
2011 [accessed 12th Nov]. Available from: http://www.hscic.gov.uk/catalogue/PUB01086/adul-dent-heal-surv-summ-them-exec-
2009-rep2.pdf. 
2. Prokopovich P, Perni S. Multiasperity Contact Adhesion Model for Universal Asperity Height and Radius of Curvature Distributions. 
Langmuir. 2010 Oct 6, 2010;26(22):17028-36. 
3. Prokopovich PP, Perni, S. Comparison of JKR- and DMT-based multi-asperity adhesion model: Theory and experiment. 
Colloids Surf A Physicochem Eng Asp. 2011 June 20;383(Issues 1–3):95–101. 
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4. Teughels W, Van Assche N, Sliepen I, Quirynen M. Effect of material characteristics and/or surface topography on biofilm 
development. Clin Oral Implants Res. 2006 Oct;17(S2):68-81. 
 
 
How can WCPPE best deliver live CPD events for the pharmacy workforce within a 
rural location? 
Daniel Hicks, J Franchi and KL Hodson 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Continuing professional development is an important part of maintaining the necessary competence to be a 
registered pharmacy professional. Organisations such as WCPPE provide opportunities for pharmacy 
professionals in Wales to continue their learning by holding live events.1 WCPPE struggles to gain attendances 
at some of these events, especially in rural locations and as these events are funded by the Welsh government, 
it means taxpayers money is being wasted.2 The aims of this study was to investigate the barriers that prevent 
registered pharmacy professionals from attending live CPD events held by WCPPE in Powys. 
Two focus groups were held at a pre-planned WCPPE event. The focus groups were separated into 
pharmacists and pharmacy technicians. One focus group contained 7 pharmacists and the other focus group 
contained 5 pharmacy technicians. The recordings from the focus groups were transcribed and examined, with 
the key themes from each focus group highlighted.  
Eight key themes came out of the focus groups. These key themes were timing of events, location, frequency 
of events, use of IT, use of learning facilitators, learning and event information, use of expert speakers and 
communication from WCPPE. A theme quite prominent in the pharmacy technician group was the timing of 
events with the preference of day time events over evening events and with that the idea of protected learning 
time in pharmacy contracts. In contrast, a theme that was prominent in the pharmacist focus group was to hold 
a Sunday study day and discuss 3-4 topics in one day. 
The key themes from the focus groups have been used to produce a draft questionnaire which is to be piloted 
before being sent out to the pharmacy workforce of Powys to gather more data to be able to produce 
recommendations to improve attendances at WCPPE live events.  
 Wcppe.org.uk. About Us| WCPPE [Internet]. 2016 [cited 5 January 2016]. Available from: http://www.wcppe.org.uk/about-us. 
 Alexander C. To investigate the barriers to Continuous Professional Development for pharmacy staff living and/or working in rural 
locations in Wales. Wales Centre for Pharmacy Professional Education; 2014. 
 
 
The evaluation of the management of hypnotics in care homes 
Nia Higgs and MW Smith 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
In later life many individuals enter care homes to receive care and accommodation; however these settings 
are often associated with medication errors.1,2 Hypnotics are now being deemed ‘problem drugs’ in this 
setting.2-4 The aim of the study is to identify and document the extent of prescribing of hypnotics, as well as 
the nature and quantity of both prescribing and administration errors in this setting.  
 
A retrospective study was undertaken over 3 months (Jul-Sept) on 12 care homes situated in South Wales. A 
group consensus on error categories enabled analysis and documentation of medication errors. Two sources 
of error of ‘prescriber’ and ‘care home administration’ were agreed. Within these, areas of: dose, duration, 
frequency and drug choice were established, each containing further subcategories. Errors were documented 
and data analysed via SPSS to identify correlations.  
 
Within the 12 care homes and agreed time period 15.02% of residents received a hypnotic. The 44 residents 
were located in 9 care homes and involved 2768 administrations. ‘Duration errors’ (58.93%) were the largest 
contributor to prescribing errors i.e. patients prescribed a hypnotic for more than four weeks. For the care home 
administration process, on average every three administrations of hypnotics have the possibility of containing 
an error. ‘Frequency attendant errors’ (47.33%) i.e. patient administered hypnotic over two hours earlier/later 
than scheduled, and ‘omission’ (46.73%) i.e. dose not given, were the largest contributors to care home 
administration errors. No significant correlation was seen between the total number of administrations a care 
home conducts and the number of care home administration errors for hypnotics. 
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Results support views that improvement in both the extent of prescribing as well as the administration of 
hypnotics in care homes is in need of review. The study enabled an understanding of the pharmaceutical care 
received by care home residents.  
 
1. Alldred DP, Barber ND, Buckle P, Carpenter J, Dickinson R, Franklin B et al. Care homes’ use of medicines study: prevalence 
causes and potential harm of medication errors in care homes for older people. Qual Saf Health Care. 2009;18:341-346. 
2. Centre for policy on ageing. Managing and administering medication in care homes for older people A report for the project: 
‘Working together to develop practical solutions: an integrated approach to medication in care homes’. UK: CPA; 2012 [accessed 21 
Nov 2015]. Available from: 
http://www.cpa.org.uk/information/reviews/Managing_and_Administering_Medication_in_Care_Homes.pdf. 
3. Woolcott JC, Richardson KJ, Wiens MO, Patel B, Marin J, Khan KM et al. Meta-analysis of 9 medication classes on falls in elderly 
persons. Arch Intern Med. 2009 Nov 23;169(21):1952-60.  
4. Maguire A, Hughes C, Cardwell C and O’Reilly D. Psychotropic medications and the transition into care: A national data linkage 
study. J Am Geriatr Soc. 2013;61(2):215-221. 
 
 
Design and synthesis of novel opsin ligands to prevent retinal degeneration in 
Leber’s congenital amaurosis (LCA) disease 
Siti Nur Majidah Hj Md Jappar, M Basetto and A Brancale 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Leber’s congenital amaurosis (LCA) disease is an inherited form of retinal degeneration disease that cause 
visual loss mainly in children. It accounts for 3-5% of childhood blindness and affects 180,000 of world’s 
population. 20% cases are due to genetic mutation, RPE65 and LRAT. In LCA disease, there is less formation 
of rhodopsin that is vital for vision. This is due to mutations that caused less production of 11-cis-retinal, 
chromophore, to bind tightly with opsin. As a result, it caused accumulation of unbound and misfolded opsin 
that led to ER stress and eventually retinal cell death.1-2 Thus this project aims to develop and synthesise novel 
opsin ligands to form a stable rhodopsin-ligand complex, in the absence of 11-cis-retinal, to prevent further 
retinal degeneration. 
Bovine rhodopsin was used to study binding interaction between 11-cis-retinal and opsin.3 Eight lead 
compounds were used for identification of main chemical features for inhibition and binding activities.4 Eight 
new scaffolds were designed and only four were selected based on its conformation and Lipinski’s rule of five 
drug candidates. All compounds were validated and run through molecular docking using Glide docking and 
Maestro. The end products structure was confirmed using NMR spectroscopy. All scaffolds were synthesised 
in five synthetic stages: formation of intermediates and conversion to three different groups.  
The results show that all scaffolds are able to form interaction with key lysine residue and have consistent 
binding behaviour. Three scaffolds were successfully synthesised with acceptable yields. Amide group of 
scaffold 2 shows to be the most potential ligand as it forms more interaction with binding pocket. Scaffold 1 
showed to be the least stable and difficult to synthesise.  
In conclusion, all four scaffolds showed promising predicted binding mode. All compounds synthesised will be 
sent for biological evaluation to test for its binding activity and opsin’s aggregation. 
 Chacon-Camacho OF, Zenteno JC. Review and update on the molecular basis of Leber congenital amaurosis. World J Clin Cases. 
2015 Feb 16;3(2):112-24. 
 den Hollander AI, Roepman R, Koenekoop RK, Cremers FP. Leber congenital amaurosis: genes, proteins and disease 
mechanisms. Prog Retin Eye Res. 2008 Jul;27(4):391-419. 
 Kiser PD, Golczak M, Palczewski K. Chemistry of the retinoid (visual) cycle. Chem Rev. 2014 Jan 8;114(1):194-232. 
 Ohgane K, Dodo K, Hashimoto Y. Structural development study of a novel pharmacological chaperone for folding-defective 
rhodopsin mutants responsible for retinitis pigmentosa. Yakugaku Zasshi. 2011;131(3):325-34. 
 
 
Assessing patient inhaler technique in asthma and COPD 
Nicholas W Horas and WR Ford 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Asthma and Chronic Obstructive Pulmonary Disease (COPD) are diseases of increasing prevalence as there 
is no treatment as of yet. Inhalers used to deliver aerosolized drugs are the main avenues of therapy in the 
relief of disease symptoms.1,2 However it’s well established that patient inhaler technique is generally poor.3,4 
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The study was conducted in the Cardiff and Vale University Health Board. Patients were recruited from clinics 
in primary and secondary care settings and their inhaler techniques were assessed. This was done using a 
Vitalograph Aerosol Inhalation Monitor (AIMs) device. Patients were also asked regarding their condition and 
any guidance they received regarding their inhalers. The data collected as a group into a Microsoft Excel 
document for analysis. Statistical analysis was done using a Chi-Square test with the Graphpad Prism 6 
program to determine the significance of any differences obtained in the results. 
Results found that patients were better at using Dry Powder Inhalers (DPI) (33%fail rate) than pressurized 
Metered Dose Inhlaers (pMDI) (84%fail rate) but were best at using pMDIs plus spacers (9% fail rate). Findings 
also showed that patients who understood their treatments showed significantly better inhaler techniques than 
those who did not. (36% vs 67% Fail rate). The above findings were both statistically significant (p < 0.05). 
Findings also showed that patient age, gender and whether a patient was using BOTH pMDIs and DPIs or 
only ONE of the two had no effect on inhaler technique results. It was also found that the time since a patient 
last received guidance regarding inhaler technique did not significantly effect a patient’s ability to generate 
good results. 
Overall patient inhaler technique was poor. Patients demonstrated better AIMs results when demonstrating 
DPI techniques compared to pMDI. Competancy of healthcare professionals in demonstrating inhaler 
technique to patients may require a review. An emphasis should be put in ensuring patients understand their 
treatments and how they help their condition. 
 National Health Services. Asthma. 2014 [accessed 02 Nov 2015]. Available from: 
http://www.nhs.uk/conditions/asthma/Pages/Introduction.aspx. 
 National Health Services. Chronic Obstructive Pulmonary Disease. 2014 [accessed 19 Nov 2015]. Available from: 
http://www.nhs.uk/conditions/chronic-obstructive-pulmonary-disease/pages/introduction.aspx. 
 Crompton GK, Barnes PJ, Broeders M, Dekhuijzen C, Corrigan L, Corbetta R, et al. The need to improve inhalation technique in 
Europe: A report from the Aerosol Drug Management Improvement Team. Respir Med. 2006;100(9):1479-94. 
 Hardwell A, Barber V, Hargadon T, McKnight E, Holmes J, Levy M. Technique training does not improve the ability of most patients 
to use pressurised metered-dose inhalers (pMDIs). Prim Care Respir J. 2011;20(1):92-6. 
 
 
Measuring membrane pores in droplet interface bilayers 
James Hughes, G Bultynck1 and O Castell 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff CF10 
3NB, Wales, UK and 1Department of Molecular Cell Biology, K.U. Leuven, B-3000 Leuven, Belgium.  
Drug development is greatly assisted by in-vitro artificial mimics of the cell membrane to study the effects of 
potential drug targets or disease states on lipid-membranes.1 Droplet interface bilayers can be used to 
measure current through pores formed in artificial lipid bilayers.1 The aim was to characterise a pore formed 
by C-terminus peptide 2 (CTP2) from Bax-Inhibitor 1 (BI-1): a membrane protein that protects the cell from ER 
stress-induced apoptosis by acting as a calcium leak channel.2 At least three C-terminus sequences 
collectively are suspected to form this channel.2 A second aim was identifying if the aspartate at position 209 
of BI-1 is essential for pore formation. 
Droplet interface bilayers were made by pipetting two aqueous droplets onto two electrodes that were 
submerged in a lipid containing oil.1 The amphiphilic lipid made a monolayer around each aqueous droplet. 
Two monolayers were brought together forming a bilayer. The electrodes enabled a voltage to be applied and 
an ionic current across the bilayer was measured using a patch clamp amplifier.3 
When CTP2 was compared to a fixed conductance pore forming protein called α-hemolysin, and variable 
conductance pores formed by electroporation, there were close similarities to electroporation. Histograms 
revealed that there was a characteristic spread in current suggesting the pore may vary in size. On mutating 
the aspartate at position 4 to an alanine the amount of current transmitted was significantly reduced. 
CTP2 forms a pore that resembles the activity of electroporation. This suggests it may form a toroidal pore that 
varies in size. It has stochastic transient action; but once formed, tends to stay in the bilayer and likely 
transports calcium. On mutating the aspartate at position 4 current transmitted is reduced but not stopped, 
suggesting that aspartate is probably important but not essential for pore formation. 
 Leptihn S, Castell O, Cronin B, Lee E-H, Gross L, Marshall D, et al. Constructing droplet interface bilayers from the contact of 
aqueous droplets in oil. Nat Protoc. 2013;8(6):1048–57. 
 Bultynck G, Kiviluoto S, Henke N, Ivanova H, Schneider L, Rybalchenko V, et al. The C Terminus of Bax Inhibitor-1 Forms a Ca2+-
permeable Channel Pore. Am J Biochem Mol Biol. 2012;287(4):2544–57. 
 Bayley H, Cronin B, Heron A, Holden M, Hwang W, Syeda R, et al. Droplet interface bilayers. Mol Biosyst. 2008;4(12):1191–208. 
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Redistribution of patient returned prescription medicines: what’s stopping us?  
The patient’s view 
Natasha Hughes and R Price-Davies 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
The redistribution of patient returned prescription medicines (ROPRPM) is a concept that has been 
investigated by several studies already.1-3 It is popular within healthcare academia as it would reduce waste 
and this may ease the strain on local NHS Trust budgets.4 In order for the concept to become a practice, it is 
important to gauge how patients themselves may view it. As previous studies have focused on the healthcare 
professional’s stance on drug redistribution, this paper aims to provide an alternate perspective on the idea by 
gathering and analyzing the opinions of a sample of the local people. Interviewing people about the topic 
enables the researcher to ascertain whether such a scheme would be received and reacted to positively or 
negatively. 
 
Participants were randomly sampled from GP practices within the Cwm Taf University Health Board (CTUHB) 
and sent out invitation letters, 11 participants responded who were able to take part in the study. Semi-
structured interviews were held at the participant's local GP practice, these were recorded and later 
transcribed. 
 
Thematic analysis of the transcriptions proved the qualitative interviews were successful in getting an idea of 
how receptive the patients in the Cwm Taf area are to the idea of ROPRM which was positive overall, but 
raised some concerns about the hypothetical rolling out of ROPRM: risk of tampering, damaged packaging, 
storage conditions of medicines in the previous patient’s possession, the opportunity of fraud, certain forms of 
medicines returned being unacceptable (liquids, inhalers), the cost implications and cross-contamination. 
These coincide with barriers that have arisen in previous research. However, unlike previous research 
conducted with healthcare professionals few solutions for these barriers were suggested, which is 
understandable due to patient's lack of knowledge on prescription medicines.  
 
The concept of consent was identified in this study which had not been previously reported, where patients 
discussed whether they would personally want to know if they were receiving returned medicines and came to 
conclusions that it is likely that the public would need to be informed of ROPRM. Patients agreed they would 
have to put trust in the healthcare professionals to ensure the quality of returned medicines still meets 
standards. Future research is necessary to solve patient's concerns as well as taking ROPRM to a wider 
audience of patients to find more generalizable results. 
 
 McRae, D. 2015. The Redistribution of Patient Returned Medicines: What’s Stopping Us? Cardiff School of Pharmacy and 
Pharmaceutical Sciences.  
 Hendricks, A. et al. 2013. Prescribing Mrs. Smith's Medication to Mr. Jones: The Views of Patients and Professionals On The 
Redistribution Of Returned Medicines. Pharmacy Management 29:26-27. 
 Casey, F. 2013. Reusing sealed prescription medicines: The potential for NHS England primary health care. Masters, Imperial 
College London. 
 Nuffield-Trust. 2014. Decade of Austerity in Wales – NHS Funding Pressures [Online]. Available at: 
http://www.nuffieldtrust.org.uk/publications/decade-austerity-wales [Accessed: 12/10/15]. 
 
 
Canonical Wnt signalling in murine models of Alzheimer’s disease 
Alia Ibrahim and RS Thomas 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK  
Accumulation of beta-amyloid (Aβ) which is cleaved from amyloid precursor protein (APP), is a central event 
in Alzheimer’s disease (AD) neuropathology.1 A relationship between Aβ-induced neuronal dysfunction and 
dysregulation of the canonical Wnt signalling pathway has been observed in AD.2 There is some evidence that 
Aβ may downregulate the Wnt pathway, however it remains unclear whether Wnt signalling is up or 
downregulated in AD.3 Recent research has suggested activating Wnt signalling may be a novel therapy for 
AD.4 This study investigated whether key canonical Wnt protein levels are up or downregulated in transgenic 
(Tg) PDAPP murine models of AD which overexpress APP and accumulate Aβ with age. 
 
Western blotting was used to compare levels of APP, beta catenin (total and non-phosphorylated), GSK-3α, 
GSK-3β and TCF7L2 in cortical tissue extracted from 3, 11 and 18 month old Tg mice and their wild-type (Wt) 
litter mates. The changing patterns of protein levels with age were also compared within genotypes. 
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APP was overexpressed in all Tg mice. Although no changes in levels of total beta catenin were observed, the 
non-phosphorylated form was increased in 18 month old Tg mice when compared to 18 month old Wt mice. 
Levels of non-phosphorylated beta catenin decreased with age in Wt mice, however, Tg mice did not 
demonstrate this decrease with age. No differences in levels of GSK-3α, GSK-3β or TCF7L2 were observed. 
 
The raised levels of non-phosphorylated beta catenin imply there is an upregulation of Wnt signalling in Tg 
murine models of AD compared to Wt mice. Since this was only observed in the oldest mice it is likely to be 
an amyloid-related effect. The results of this study highlight that the activation of Wnt signalling as a therapy 
for AD should be treated with caution. 
 
 Hardy J, Allsop D. Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol Sci. 
1991;12(10):383-8. 
 Purro SA, Galli S, Salinas PC. Dysfunction of Wnt signaling and synaptic disassembly in neurodegenerative diseases. J Mol Cell 
Biol. 2014;6(1):75-80. 
 Boonen RA, van Tijn P, Zivkovic D. Wnt signaling in Alzheimer's disease: up or down, that is the question. Ageing Res Rev. 
2009;8(2):71-82. 
 Vargas JY, Fuenzalida M, Inestrosa NC. In vivo activation of Wnt signaling pathway enhances cognitive function of adult mice and 
reverses cognitive deficits in an Alzheimer's disease model. J Neurosci. 2014;34(6):2191-202. 
 
 
Changes in hypnotic and anxiolytic prescribing in Wales following introduction of 
an educational pack 
Zahrah Jenny Islam, PN Deslandes1 and RE Deslandes 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff CF10 
3NB, and 1All Wales Therapeutics and Toxicology Centre, University Hospital Llandough, Penlan Road, Llandough, 
Penarth, The Vale of Glamorgan CF64 2XX, Wales, UK 
The prescribing of hypnotics and anxiolytics was much higher in Wales compared to England in 2010.1 An 
educational pack was produced in April 2011 by the All Wales Therapeutics and Toxicology Centre in order to 
reduce the number of hypnotics and anxiolytics being prescribed in Wales.2 The aim of this study was to 
investigate whether there was a change in prescribing trend in the twelve months following the intervention 
compared to the previous twelve months and whether there was a change in the number of drug related deaths 
associated with these drugs. 
An Auto Regressive Integrated Moving Average Interrupted Time Series analysis was used to assess whether 
there were significant changes in prescribing trend pre and post intervention. Data were collected for 
benzodiazepines, Z drugs, pregabalin and gabapentin in terms of number of Defined Daily Doses prescribed 
per 1,000 patients per month from May 2010 to April 2012 for Wales as a whole and for each anonymised 
health board. A Fishers’ Exact test was used to compare the Fatal Toxicity Index of the drugs pre and post 
intervention for Wales, using England as a control group. 
There was a statistically significant decrease in the prescribing trend of Z drugs in two health boards in Wales 
(P=0.047, p=0.017), and a statistically significant increase in the prescribing trend of gabapentin in two health 
boards (p=0.002, p=0.024) in the twelve months’ post intervention. There was no statistically significant change 
in the number of drug related deaths post intervention. 
The changes seen in prescribing trend cannot be directly linked to the intervention due to the quasi 
experimental nature of this study3 as the contribution of other confounding factors that may influence 
prescribing trend cannot be accounted for. Despite this, the educational pack is still a useful resource for 
hypnotic and anxiolytic reduction strategies. 
 Welsh Medicines Partnership. Nature and scope of benzodiazepine and “Z” drug prescribing in Wales. Sep 2010. 
 Welsh Medicines Partnership. Educational Pack: Material to support appropriate prescribing of hypnotics and anxiolytics across 
Wales. Apr 2011. 
 Penfold RB, Zhang F. Use of interrupted time series analysis in evaluating health care quality improvements. Acad Pedatr. 2013 
Nov-Dec;13(6):S38-44. 
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Evaluation of patient’s inhaler technique in the Cardiff and Vale Univeristy Health 
Board 
Gethin Jenkins and WR Ford 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Inhalers currently play a major contribution in treating asthma and chronic obstructive pulmonary disease 
(COPD), and will remain to do so in the future.1 Asthma and COPD are amongst the most common chronic 
diseases in the world and are a major and growing health concern in the UK.2 Evidently inhaler technique is 
poor in the general public and in healthcare professionals.3,4 The aim is to evaluate the quality of inhaler 
technique in asthmatic and COPD patients of the Cardiff and Vale University Health Board. 
 
Convenience sampling was used in order to recruit participants. Structured interviews comprising of a 
questionnaire, and inhaler technique assessment were carried out. Quantitative data was entered into 
Microsoft excel, and frequency analysis was carried out. Statistical analysis was performed by using GraphPad 
Prism, using chi squared analysis. All data was anonymised. Both ethical approval and NHS service evaluation 
was granted prior to commencing. 
 
61 participants were recruited. Inhaler technique was poorest in MDI users with 83% demonstrating poor 
technique, compared to 17% (DPI users). Most participants (46%) were last demonstrated how to use their 
inhaler(s) over a year ago, with 15% never receiving guidance on how to use their inhalers correctly. Majority 
(75%) of participants were last educated by nurses. Pharmacists are massively underrepresented in terms of 
who is giving advice to patients, with only 2% of the participants previously having received guidance from a 
pharmacist. 
 
Participants’ inhaler techniques were generally poor. Using a MDI combined with a spacer provides potential 
for improvement in poor technique seen in MDI users. Thorough education and training is essential in order 
for participants to use inhalers correctly. The quality of technique rapidly deteriorates and therefore active re-
education is critical to maintain correct technique. 
 
 O’Connor BJ. The ideal inhaler: Design and characteristics to improve outcomes. Respir Med: 2004 Apr;98(1):S10-S16. 
 National Institute for Health Research (NIHR). Research Themes: Respiratory disease. London; 2015 [accessed 30 Dec 2015]. 
Available from: http://imperialbrc.org/our-research/research-themes/respiratory-disease 
 Crompton GK, Barnes PJ, Broeders M, Corrigan C, Corbetta L, Dekhuijzen R, et al. The need to improve inhalation technique in 
Europe: A report from the aerosol drug management improvement team. Respir Med. 2006;100:1479-1494. 
 Lenney J, Innes JA, Crompton GK. Inappropriate inhaler use: Assessment of use and patient preference of seven inhalation 
devices. Respir Med. 2000;94:496-500. 
 
 
Evaluation of patient’s inhaler technique in the Cardiff and Vale University Health 
Board 
Bethan Jones and WR Ford 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Five million people suffer with asthma and 3 million with COPD in the UK.1,2 Inhalers are the leading form of 
treatment used to treat these conditions,3 providing local effective treatment to the lungs, however, they can be 
difficult to use, with studies reporting up to 90% of people use their inhalers incorrectly.4 This study aims to 
assess patient’s inhaler technique within the Cardiff and Vale University Health Board and assess patient’s 
understanding of how their prophylactic inhalers help their condition. 
 
Patients were recruited from GP surgeries, respiratory clinics and Cardiff University Students Union. Patients 
were questioned on their use of their inhalers and understanding of how their prophylactic inhalers help their 
condition, through a structured interview. AIMS (Aerosol Inhalation Monitor) VitalographTM Devices were then 
used to assess patient’s technique. Chi-squared (χ2) tests were used for analysis with statistical significance 
accepted at p < 0.05. 
 
A total of 61 patients agreed to participate in the study. pMDIs were misused by 30 (84%) subjects with only 5 
(17%) DPI users and 2 (10%) subjects who used a pMDI with a spacer obtaining a fail result (p<0.0001). Of the 
52 subjects who had received tuition on inhaler technique, 39 (75%) last received tuition from a nurse with only 
1 (2%) from a pharmacist. A total of 38% of patient showed no or incorrect understanding of their prophylactic 
MPharm 
 
30 
inhalers, with only 9% describing the preventative treatment in some depth. 
 
Generally inhaler technique is poor, and is significantly problematic in pMDI use, throughout the population. 
Data from this study suggests that current methods of education on technique are ineffective and training of 
HCPs are is currently inadequate. Patients are not currently consistently informed on their use of inhaled 
medications. Future research into improving patient technique training needs to be considered. 
 
 British Lung Foundation;2015 [accessed 22 Oct 2015]. Available from: https://www.blf.org.uk/Page/About-us 
 NICE Pathways. Managing stable COPD; 2015 [accessed 22 Oct 2015]. Available from 
http://pathways.nice.org.uk/pathways/chronic-obstructive-pulmonary-disease#path=view%3A/pathways/chronic-obstructive-
pulmonary-disease/manging-stable-copd.xml&content =view-info-category%3Aview-about-menu  
 WHO. Media Centre. Chronic obstructive pulmonary disease (COPD; 2015 [accessed 29 Ded 2015]. Available from: 
http://www.who.int/mediacentre/factsheets/fs315/en/ 
 Jolly R, Mohan R, Guleria R, Poulose R, George R. Evaluation of Metered Dose Inhaler Use Technique and Response to 
Educational Training. The Indian journal of chest diseases and allied sciences. 2015 Jan;57(1):17-20 
 
 
esign and synthesis of new focal adhesion kinase inhibitors for metastatic breast 
cancer 
Emma Jones, S Kandil and AD Westwell 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Breast cancer is the most common cancer in the UK, with 1 in 8 women diagnosed in their lifetime.1 Metastatic 
breast cancer is a particular problem, with a 5-year survival rate of just 15%.1 Focal Adhesion Kinase (FAK) is 
a tyrosine kinase involved in cell signaling. It is up-regulated in several advanced stage tumors and promotes 
tumor progression and metastasis through its effects on cell adhesion, migration, proliferation and survival.2 
The antihistamine chloropyramine was found to inhibit the interaction between FAK and another tyrosine 
kinase important for cancer cell survival and tumor progression: vascular endothelial growth factor receptor 3 
(VEGFR3).3 Anticancer activity resulted both in vitro and in vivo, but at moderate concentrations.3 This project 
aimed to design and synthesize a range of potent chloropyramine analogues that inhibit the interaction 
between FAK and VEGFR3.   
 
Design of compounds was informed by previous work on structure activity relationships of chloropyramine 
analogues and synthetic feasibility.4 2 general structures with different modifications were designed. Molecular 
modeling was used to predict the strength of interactions between the compounds and the region of FAK where 
VEGFR3 binds. Compounds were synthesized via a 2-step process of reductive amination followed by either 
base-catalyzed acylation or alkylation.  
 
Several of the compounds were found to have better predicted binding interactions than chloropyramine. All 
intermediates were successfully synthesized. Of the acylation final products only 1 was successfully made and 
all alkylation final products were unsuccessful, being double alkylated to form quaternary ammonium 
compounds.   
 
A range of new compounds that appear to be able to inhibit the FAK/VEGFR3 interaction have been designed. 
Initial attempts to synthesize these were not entirely successful and procedures need to be repeated to 
optimize conditions. All compounds will be tested for activity in several breast cancer cell lines.  
 
 Cancer Research UK. 2012. Breast Cancer Statistics. [Online] Available at: http://www.cancerresearchuk.org/health-
professional/cancer-statistics/statistics-by-cancer-type/breast-cancer#heading-Zero [Accessed December 2015] 
 Sulzmaier, F. J., Jean, C., Schlaepfer, D. D. 2014. FAK in cancer: mechanistic findings and clinical applications. Nature Reviews 
Cancer 14, 598–610. 
 Kurenova, E. V. et al. 2009. Small Molecule Chloropyramine Hydrochloride (C4) Targets the Binding Site of Focal Adhesion Kinase 
and Vascular Endothelial Growth Factor Receptor 3 and Suppresses Breast Cancer Growth in Vivo. J. Med. Chem. 52, 4716-4724. 
 Gogate, P. N. et al. 2014. Design, synthesis, and biological evaluation of novel FAK scaffold inhibitors targeting the FAK-VEGFR3 
protein-protein interaction. Eur J Med Chem. 80, 154-66. 
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Exploring pharmacists’ views on the integration and use of e-DAL within the 
community pharmacy setting 
Gwenan Parry Jones, L Ellis, C Way,1 RE Deslandes, ML Hughes, KL Hodson and E Mantzourani 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff CF10 
3NB, and 1NHS Wales Informatics Service, Brunel House, 12th Floor, 2 Fitzalan Road, Cardiff CF24 0HA, Wales, UK 
Communication of medication changes between care settings presents a significant risk to patient safety upon 
discharge from hospital.1 A Discharge Advice Letter (DAL) containing clinical information is sent to their 
General Practitioner (GP) but not to their Community Pharmacist (CP). In Wales, CPs can complete a 
Discharge Medicine Review (DMR) upon receipt of the DAL, reviewing the patient’s medication after 
discharge.2 Currently in Wales, electronic discharge advice letters (e-DALs) and electronic discharge medicine 
reviews (e-DMRs) are piloted in 42 community pharmacies; e-DALs are sent directly to CPs via the Choose 
Pharmacy Application (CPA). The aim of this project was to explore whether or not community pharmacists 
consider e-DALs and e-DMRs provided via the CPA to be effective. 
A qualitative approach was used for this study. Face-to-face interviews were deemed most appropriate using 
semi-structured interview technique to explore participants’ thoughts, behaviours and experiences.3 The 
research was conducted by two research students. Interviews were recorded permitting sharing of transcripts 
between the researchers. The data was analysed separately using thematic analysis. 
A response rate of 48% was achieved: seventeen pharmacists piloting the e-DAL and e-DMR scheme were 
interviewed. The majority oh participants believed that e-DALs were superior to paper DALs but required 
further amendment. Their views confirmed the need to improve communication between healthcare 
practitioners to ensure continuity of care when a patient is discharged from hospital. These correlate to the 
recommendations stated by the Royal Pharmaceutical Society. 
Implementation of e-DALs and e-DMRs could improve the transition from secondary to primary care. Granting 
CPs access to patients’ discharge information may improve continuity and patient care. Evidently, DALs 
provide the highest quality of care to patients but must be delivered to the appropriate healthcare practitioners 
if they are to be effective. 
 Picton C and Wright H. Keeping patients safe when they transfer between care providers- getting medicines right. Final report. 
London. Royal Pharmaceutical Society. 2012. 
 Royal Pharmaceutical Society. Support for Discharge Medicines Review Service; 2015 [accessed 28 Dec 2015]. Available from: 
http://www.rpharms.com/nhs-community-pharmacy-contract-wales/discharge-medicines-review-service.asp 
 Smith F. Research Methods in Pharmacy Practice. London: Pharmaceutical Press; 2002 
 
 
Identifying and exploring factors affecting student motivation for the MPharm: a 
qualitative study 
Sara-Angharad Jones and DN John  
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
When an individual is “moved to do something” they are considered motivated.1 Motivation is an important 
concept for educators to understand. Motivation is an essential requirement for learning and lack of motivation 
within learning environments can have detrimental effects on student performance.2 Self-Determination Theory 
(SDT) distinguishes between two types of motivation. Intrinsic motivation is adopted when individuals 
participate in an activity due to interest. Extrinsic motivation is adopted to achieve a seperable outcome.1 
Research has shown that self-efficacy is effective for predicting students’ motivation.3 The aim was to explore, 
identify and analyse factors that affect the motivation of final year pharmacy undergraduates at Cardiff School 
of Pharmacy and Pharmaceutical Sciences (CSPPS). 
Final year MPharm undergraduates were identified using purposive and convenience sampling. The team of 
four researchers produced a topic guide after reviewing and discussing the literature and MPharm topics. 
CSPPS ethical approval was obtained for the topic guide, consent form, recruitment email and participant 
information sheet. Pilot interviews were conducted between the four researchers and transcribed verbatim. 
Semi-structured interviews were audio recorded with written consent. Interviews were transcribed by Virtutype, 
anonymised by each researcher and shared between the four researchers for independent, thematic analysis.4 
Twenty-four final year MPharm undergraduates participated. Eight themes were identified from the data: 
Assessments, Influence of Others, Final Year Project, Fear, Subject, Teaching Sessions, Plans After 
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Graduation and MPharm Structure. The results showed that students have both intrinsic and extrinsic 
motivation. 
Motivation differs between students depending on individual preferences, personal circumstances, current 
aims and goals for the future. The results of this research may be used by the CSPPS to improve student 
motivation, which may lead to improvements in student and school performance. A possible area for future 
research may include researching the motivation of final year MPharm undergraduates in other UK Pharmacy 
Schools. 
 Ryan RM, Deci EL. Intrinsic and Extrinsic Motivations: Classic Definitions and New Directions. Contemporary Educational 
Psychology. 2000;25(1):54-87 
 Murphy F. Motivation in Nurse Education Practice: A Case Study Approach. British Journal of Nursing. 2006;15(20):1132-1135. 
 Zimmerman BJ. Self-Efficacy: An Essential Motive to Learn. Contemporary Educational Psychology. 2000;25(1):82-91. 
 Braun V, Clarke V. Using Thematic Analysis in Psychology. Qualitative Research in Psychology. 2006;3(2):77-101. 
 
 
Rivastigmine usage in Lewy body dementias 
Nina Kainth and RS Thomas 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Parkinson’s disease dementia (PDD) and dementia with Lewy bodies (DLB) are similar diseases which present 
with motor and cognitive impairments.1 Rivastigmine, a cholinesterase inhibitor, can be used to treat the 
cognitive symptoms experienced in these diseases.2 The aim of the study was to explore the effect of 
Rivastigmine use in PDD and DLB as it has not been thoroughly investigated.3 
 
Data on PDD and DLB patients were extracted from ‘The Electronic Clinical Network Parkinson’s Disease and 
Related Disorders Database’. This database contained information on patients who attended movement 
disorder clinics at two different hospitals in Wales between 2000 and 2015. The demographics and level of 
motor and cognitive impairments were explored in PDD and DLB patients. We then explored any links with 
these findings and Rivastigmine use. The effect of Rivastigmine was measured through Clinical Global 
Impression (CGI) which assesses motor function, cognitive function and aspects of daily living. It was also 
measured through cognitive test scores which included Mini-Mental State Examination (MMSE) and 
Addenbrookes Cognitive Examination-Revised (ACE-R).  
 
292 patients were included in the study. 84% were PDD and 16% were DLB patients. Both disorders were 
more prevalent in males. PDD patients demonstrated greater motor impairments and DLB patients 
demonstrated greater cognitive impairments. Only PDD Patients currently taking Rivastigmine scored higher 
in MMSE compared to those who had previously or never taken Rivastigmine. ACE-R scores did not vary in 
relation to Rivastigmine use in either PDD or DLB patients. In terms of CGI, the only patients who demonstrated 
an improvement were either currently or previously taking Rivastigmine.  
 
Rivastigmine may improve cognitive function in PDD patients. The effect of Rivastigmine on cognitive function 
in DLB patients is unclear. However, Rivastigmine usage appears to be beneficial in PDD and DLB patients 
by having a positive impact on CGI.  
 
 Dodel R, Csoti I, Ebersbach G, Fuchs G, Hahne M, Kuhn W, et al. Lewy body dementia and Parkinson’s disease with dementia. J 
Neurol. 2008;255(5):39-47 
 Walker Z, Possin KL, Boeve BF, Aarsland D. Lewy body dementias. Lancet. 2015;386(10004):1683-97 
 Raha S, Hathaway C, Ebenezer L. Role of Rivastigmine in treatment of Parkinson’s disease and Lewy body dementia [abstract]. 
Mov Disord. 2014;29(1):601 
 
 
Analysis of Welsh plant extracts to find novel glioma treatments 
Darun Kaliray and AW White 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Plants have been known for their medicinal properties for thousands of years. Hippocrates the renowned Greek 
physician advised the use of certain plants to treat uterine tumours.  
Two samples were obtained from native Welsh plants, from a reverse osmosis concentrate, which had been 
treated with 2.5% cellulase enzyme addition and a fluid sample taken from a tank of decomposing plants, 
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which had been naturally composting for around two years, were extracted using ethyl acetate. The extractions 
were analysed using different techniques, such as, analytical thin layer chromatography, preparative 
chromatography, size exclusion chromatography and mass spectrometry. A web application, LLAMA was used 
to suggest drug-like products in silico. 
The presence of secondary metabolites was determined by mass spectrometry. LLAMA generated 1649 
products, of which 785 had logP values between 1.5 and 2.7, but none had a polar surface area suitable for 
blood brain barrier penetration. 
 
 
The membrane poration of droplet interface bilayers with an EGFR derived cell-
penetrating peptide, EJP-18 
Lydia Kellett, D Jamieson, AT Jones and O Castell 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK . 
Delivery of drugs intracellularly is a vast area of research, which has been aided by artificial bilayers, for the 
observation of energy-independent processes. Droplet-interface bilayers (DIBs) are a recent, more stable 
system.1 Hundreds of cell-penetrating peptides (CPPs) are being studied due their ability to internalise 
cargoes.2 This study aims to use DIBs to increase knowledge of the penetration mechanisms of EJP-18, a 
new CPP derived from a receptor tyrosine kinase. If EJP-18 forms membrane pores, subsequent permeability 
can be recorded.  
 
This study makes electrophysiological measurements of CPP-induced pore formation in DIBs, when a fixed 
potential is applied across the membrane. This method was first validated with protein pore alpha hemolysin 
before the well characterised CPP octaarginine (R8).3 Secondly, EJP-18 was investigated. The DIB technique 
creates a bilayer between two aqueous droplets suspended on agarose coated electrodes in an oil/lipid 
environment.4 Conductance data was analysed to confirm bilayer formation and observe poration.  
 
Controls of stable bilayers without peptide, electroporation and fixed conductance pores with α-hemolysin were 
characterised, as seen previously. Both R8 and EJP-18 formed pores between 2-20µM at lower potentials 
than electroporation, with poration that was similar in nature. Lengthened bilayer formation was observed. With 
EJP-18, higher concentrations caused increased conductance, large variability in poration states across time 
occurred and no difference in conductance seen between positive or negative applied potentials.  
 
Lengthened bilayer formation suggests CPP disrupts the monolayer. Escape of R8 through micelle formation 
during incubation is hypothesised. EJP-18 induced pores are variable, stochastic and transient in nature which 
may indicate mixed pore-forming translocating mechanisms. While energy-independent model membrane 
disruption is clear, translocation is not conclusive though likely from the extent of membrane permeability. Total 
Internal Reflection Fluorescence Microscopy would image pore nature and size and EJP-18’s translocation 
and interactions.4 
 
 Bayley H, Cronin B, Heron A, Holden M, Hwang W, Syeda R, et al. Droplet interface bilayers. Molecular BioSystems. 
2008;4(12):1141-224. 
 Jones AT, Sayers EJ. Cell entry of cell penetrating peptides: tales of tails wagging dogs. Journal of Controlled Release. 
2012;161(2):582-91. 
 Herce HD, Garcia AE, Litt J, Kane RS, Martin P, Enrique N, et al. Arginine-rich peptides destabilize the plasma membrane, 
consistent with a pore formation translocation mechanism of cell-penetrating peptides. Biophysical Journal. 2009 Oct 7;97(7):1917-
25. 
 Leptihn S, Castell O, Cronin B, Lee E-H, Gross L, Marshall D, et al. Constructing droplet interface bilayers from the contact of 
aqueous droplets in oil. Nature Protocols. 2013;8(6):1048-57. 
 
 
The evaluation of the management of medications containing paracetamol in care 
homes 
Ewe Jon Koh and MW Smith 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
There has been some evidence that care home residents are experiencing suboptimal pain management, 
particularly those with cognitive impairment.1-3 The aim of this study is to evaluate the prescribing and 
management of medications containing paracetamol in care homes. 
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A literature review was conducted to determine the issues faced by medications containing paracetamol in 
care homes. Provisional error categories were then agreed upon and piloted on a set of data from the 19th of 
October 2015. With the results of the pilot study, a group consensus was achieved on the error categories that 
was feasible and the error categories were finalised. The analysis was carried out on data for the period of 1st 
July - 31st September 2015. The SPSS statistical package was applied to determine if there is a correlation 
between the total number of administrations and the total number of care home errors for medications 
containing paracetamol. 
 
A total of 24356 administrations were given to 123 patients over the three-month period. One prescribing error 
was identified, while 6848 care home errors were found. “Dose-Omission” and “Frequency-Attendant” errors 
contributed the significant majority of errors. A statistically significant (p<0.05) positive correlation was found 
between the total number of administrations and the total number of care home errors for medications 
containing paracetamol. 
 
Almost all errors were care home related, with omissions contributing to nearly half the errors identified. This 
is supported by the Care Home Use of Medicines Study (CHUMS) which found that 49.1% of error were due 
to omissions as well.4 The statistically significant positive correlation can be explained by the high number of 
administrations, where a high number of administrations will tend to lead to a higher number of errors. In 
conclusion, the management and prescribing of medications containing paracetamol needs to be drastically 
improved. 
 
 Ferrell B, Ferrell B, Rivera L. Pain in cognitively impaired nursing home patients. Journal of Pain and Symptom Management. 
1995;10(8):591-598. 
 Ford S. Care homes found wanting in pain management for dementia [Internet]. Nursing Times. 2014 [cited 17 January 2016]. 
Available from: http://www.nursingtimes.net/clinical-subjects/pain-management/care-homes-found-wanting-in-pain-management-for-
dementia/5067928.fullarticle 
 Ferrell B. Pain Evaluation and Management in the Nursing Home. Annals of Internal Medicine. 1995;123(9):681. 
 Alldred DP, Barber N, Buckle P, Carpenter J, Dickinson R, Franklin BD et al. Care Home Use of Medicines Study (CHUMS): 
Medication errors in nursing & residential care homes ‐ prevalence, consequences, causes and solutions. BMJ Qual Saf. 2009;18. 
 
 
Exploring the public’s opinion of medication wastage, cost and attaching a price to 
dispensed medication labels 
Christabel Jones, TA Mitoko and R Yemm 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff CF10 
3NB, Wales, UK  
Approximately £300 million is wasted on partially or completely unused prescribed medication every year in 
the UK.1 The Government has proposed introducing a price on dispensed medication labels to increase 
adherence and reduce waste. MPs claim this intervention could save the NHS £100 million a year.2 The 
primary objective of this study was to explore the public’s reaction to including the NHS cost of prescribed 
medicines on the dispensing label.  
 
Focus groups were conducted in order to allow discussion of opinions on the cost and waste of prescribed 
medications and the addition of the medication price on the dispensing label. A purposive sample of 
participants were recruited from key population groups to take part in focus groups via a gatekeeper. Focus 
group discussions were audio recorded and transcribed verbatim. The data was thematically analysed and 
key themes were generated.  
Thirty-four participants took part in six focus groups. The six emergent themes were: knowledge of the problem; 
barriers to adherence; motivations for adherence; prescribing issues; patient-centered care; and overall 
reactions to proposal. Participants suggested that better communication between patient and prescriber about 
medication and their concerns would help improve wastage rather than adding the price on the label: “It’s about 
putting things into context for the patient and the patient understanding exactly the benefits of what they’re 
taking and having that really good patient-centered conversation” STP3. Furthermore, different reasons for 
non-adherence to medication were identified by participants, on which knowing the medication cost would 
have little impact: “So the reason you would not take a medicine is either because you forget- knowing the cost 
won’t make your memory better -or because you feel better and you don’t need it.” STP2 
 
The overall consensus was that the participants did not think that including the price on the dispensing label 
of prescription medication labels would help to increase adherence and reduce waste. The proposal hoped to 
tackle medicines wastage by making the public aware of the cost of medicines. One of the root causes of 
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wastage was identified to be non-adherence, therefore if this is not tackled, the proposal to make the public 
aware of the cost of medicines may be ineffective.  
 
 Anonymous (2015) ‘Order what you need’, [online] Available at: http://www.medicineswaste.com/ (Accessed: 16/12/15) 
 Anonymous (2011) ‘Action on medicine wastage and improving medicines use’, [online]. Available at : 
https://www.gov.uk/government/news/action-on-medicine-wastage-and-improving-medicine-use (Accessed: 16/12/15). 
 
 
Evaluation of patients’ inhaler technique in the Cardiff and Vale University Health 
Board 
Rebecca Lambert and WR Ford 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Inhalers can be used to treat respiratory conditions, and they are beneficial as they deliver medication directly 
to the target site of action, the lungs.1 Good inhaler technique is required to get drug deposition in the lower 
airways. Inadequate technique can therefore lead to suboptimal dose delivery.2 This study aims to evaluate 
asthma and chronic obstructive pulmonary disorder (COPD) patients’ inhaler technique in the Cardiff and Vale 
University Health Board (UHB). 
 
The study was approved as a service evaluation by Cardiff and Vale University Health Board and ethical 
approval was obtained from the Cardiff School of Pharmacy and Pharmaceutical Sciences ethics panel. A 
structured, quantitative interview form gathered information about the patients’ current prescribed inhaler(s) 
and their use. Technique on a pressurised metered dose inhaler (pMDI) (with or without a spacer) and dry 
powder inhalers (DPIs) were assessed using a Vitalograph AIM™ device which predicts drug deposition in the 
lungs. The anonymous data was collated to enable frequency analysis and Chi-squared statistical tests. 
 
Of all patients assessed, only 26% managed to achieve good inhaler technique. The standard of technique 
was device dependant (p= <0.05). Only 17% of DPI assessments obtained a fail result, compared to 83% of 
patients on a pMDI. Using a spacer with a pMDI reduced fail results to 9%. No other factors, including technique 
training and different patient subgroups, had any significant impact on the standard of inhaler technique (p= 
>0.05). 
 
Overall, inhaler technique is of a poor standard amongst patients in the Cardiff and Vale UHB. The standard 
of technique is device dependant. Current HCP advice does not appear to impact on the success of patients’ 
inhaler technique, and the current opportunities to educate patients on good technique are not being utilised 
and fully optimised. 
 
1. Taylor KMG. Pulmonary Drug Delivery. In: Aulton ME, Taylor KMG editors. Aulton's Pharmaceutics The Design and Manufacture of 
Medicines. 4 ed. London: Churchill Livingstone Elsevier; 2013. p. 638-656 
2. NICE Guidance. Asthma NICE quality standard [QS25]. London: National Institute for Health and Care Excellence; 2013 [accessed 
27 Dec 2015]. Available from: http://publications.nice.org.uk/quality-standard-for-asthma-qs25/quality-statement-4-inhaler-technique 
 
 
Comparing tau phosphorylation in models of Down Syndrome and Alzheimer’s 
disease 
Alexandra Langberg, B Newth, M Alsaqati and EJ Kidd 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK  
Alzheimer’s disease (AD) is a progressive, neurodegenerative disorder.1 Amyloid Precursor Protein (APP) is 
cleaved to form neurotoxic beta-amyloid (Aβ).2 Aβ activates kinases DYRK1A and GSK-3α/β which 
phosphorylate tau, contributing to the development of neurofibrillary tangles and neuronal cell death.3 My aim 
was to compare differences in protein levels of APP, DYRK1A, GSK-3α and β, and phosphorylated tau 
(residues Thr212, Ser396/Ser404), and total tau across 4 littermate mouse lines: Tg2576 (AD model), Tc1 (Down 
syndrome model trisomic for human chromosome 21 but lacking APP), ‘Double’ (offspring of Tg2576 and Tc1), 
and wild-type (Wt) as controls. The ‘Double’ mice were studied to illustrate that these mice would demonstrate 
changes in protein expression as a product of their parents’ protein expression. 
 
Mice brains were harvested at 10 months old. Cortical brain tissue was extracted and protein levels were 
measured using Western blotting. Data were analysed using one-way ANOVA, followed by Tukey’s post-hoc 
test. 
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Overexpression of APP was significant and confirmed transgenicity of Tg2576 and ‘Double’ mice. Changes in 
kinase levels and corresponding levels of phosphorylated tau were not significant across groups. 
 
Data collected suggests that increasing APP levels did not affect the kinases and phosphorylation sites 
studied, but there are a number of variables which limit the conclusions which can be drawn. Future work may 
include using older mice, looking at the active form of the kinases and other kinases, and working with 
alternative mouse models. This study, however, supports reviews that other mouse models should be used in 
the study of Down syndrome, and also highlights the importance of using an established genetic background 
in animal research4 as the mice had a unique background due to the Tg2576/Tc1 cross. 
 
 Karran E, Mercken M, De Strooper B. The amyloid cascade hypothesis for Alzheimer’s disease: an appraisal for the development of 
therapeutics. Nat Rev Drug Discov. 2011;10(9):698-712. 
 Hardy JA, Higgins GA. Alzheimer’s disease: the amyloid cascade hypothesis. Science. 1992;256(5054):184–5 
 Kremer A, Louis J V, Jaworski T, Van Leuven F. GSK3 and Alzheimer’s Disease: Facts and Fiction…. Front Mol Neurosci. 
2011;4(17). 
 Yoshiki A, Moriwaki K. Mouse Phenome Research: Implications of Genetic Background. ILAR J. 2006;47(2):94–102. 
 
 
Identifying and exploring factors affecting student motivation for the MPharm 
Chris Lee and DN John 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK   
Motivation is the driving force that drives a person towards a goal.1 There are many published studies 
examining motivation but few that examine motivation in UK MPharm courses.2 Understanding motivation is 
key to augmenting a student’s motivation in their studies. This investigation aims to identify and explore factors 
which may affect student motivation for the MPharm at Cardiff University. 
 
The research group of four final year MPharm students with a project supervisor designed a qualitative 
investigation to explore the project title. Semi-structured interviews were conducted with purposively sampled 
4th year MPharm students at Cardiff School of Pharmacy and Pharmaceutical Sciences. Interviews were 
conducted on 24 participants using one to one interviews. Each researcher conducted a pilot interview with a 
fellow researcher and transcribed that interview. Then a list of potential participants were developed, the 
researcher then interviewed an additional five participants each, these interviews were recorded and 
transcribed verbatim by Virtuetype®, anonymised and checked by the researcher before sharing with the 
research team to individually thematically analyse.3 Ethical approval was obtained.  
 
Twenty-four participants were interviewed and six themes were developed from the data: ‘Failure’, ‘Structure 
of MPharm course’, ‘Feedback and Guidance’, ‘Perceived relevance’, ‘Effort’ and ‘Interest’. Students had 
expressed many factors that affect their motivation and to what degree with the majority having a strong 
intrinsic drive towards their studies. 
 
The investigation highlights that no student is the same, motivation is an important and multifaceted element 
of an MPharm student’s studies. It is important to consider both positive and negative motivational factors to 
better understand why a change is effective. Findings from this investigation should be considered to 
investigate motivational factors in more of the MPharm student population in the UK. 
 
 Colman, A. M. 2001. A dictionary of psychology. Oxford: Oxford University Press. 
 Alrakaf, S. Abdelmageed, A. Kiersma, M. et al. 2014. An international validation study of two achievement goal measures in a 
pharmacy education context. Advances in Medical Education and Practice 2014(5), pp. 339-345. 
 Braun, V. and Clarke, V. 2006. Using thematic analysis in psychology. Qualitative Research in Psychology 3(2), pp. 77–101. 
 
 
Solid phase extraction of natural compounds from Greek marine sponges 
Nicholas Teck Tim Lee and AW White 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Natural compounds extracted from marine sponges are evidently structurally unique and possess various 
pharmacological activities.1 However, the environmental niche of marine sponges and the lack of 
understanding of its matrix complexity poses a hindrance towards marine sponge drug development.1 This 
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research experiment aims to use a chemoselective isolation by utilization of electrophilic sulfonyl chloride and 
isothiocyanate resins to extract natural compounds from Greek marine sponges.2 It is hypothesized that most 
natural compounds from marine sponges contain nucleophilic functional groups which can be extracted 
through electrophilic solid phase extraction.3 The objective is to obtain as much natural compounds as possible 
from Greek marine sponges through a solid phase extraction technique. 
Extracts from the sponge Chondrilla nucula and a Sarcotragus sp. were neutralized to remove charge polarity. 
Sulfonyl chloride and isothiocyanate resins were swollen and sponge samples were added. The resin loaded 
with natural compounds was subjected to cleaving agents to obtain the natural compounds which were tested 
with mass spectrometry for the presence of compounds. 
Isothiocyanate resins cleaved in neat trifluoroacetic acid showed high yields of recovery but limited types of 
natural compounds. Sulfonyl chloride resins cleaved with diethylamine followed by sodium hydroxide shows 
the largest diversity of compounds extracted, however yield percentage ratio is low. Mass spectrometry shows 
that compounds were recovered from the solid phase extraction. 
The solvent used affects yield ratio but not the variety of compounds extracted. Electrophilic resins and 
cleaving agents are able to scavenge nucleophilic natural compounds from Greek marine sponges and give 
rise to contrasting natural compounds obtained. Solid phase extraction was demonstrated to be successful in 
recovering natural compounds from Greek marine sponges albeit a less efficacious method due to low yield 
ratios in combination with salts present. 
1. Monaco, R. and Quinlan, R. (2014). Novel Natural Product Discovery from Marine Sponges and their Obligate Symbiotic 
Organisms. BioRxiv Mini Review. 
2. Odendaal, A., Trader, D. and Carlson, E. (2011). Chemoselective enrichment for natural products discovery. Chemical Science, 
2(4), p.760. 
3. Trader, Darci J., and Erin E. Carlson. "Taming Of A Superbase For Selective Phenol Desilylation And Natural Product Isolation". 
The Journal of Organic Chemistry 78.14 (2013): 7349-7355. Web. 
 
 
Using optical coherence tomography as a novel method to characterise the 
puncture of hypromellose hard-shell capsules in a RS01 monodose dry powder 
inhaler 
Nixon Leung, B Jones, F Diez1, JC Birchall and SA Coulman 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff CF10 
3NB, Wales, UK  1Qualicaps Europe, S.A.U., Avenida Monte, Valdelatas, 4, 28108 Alcobendas, Madrid, Spain 
Dry powder inhalers (DPI) deliver drugs to the lungs upon breath-actuation and are becoming increasingly 
accepted for pulmonary drug delivery for local and systemic applications. Some DPIs emit powder from a 
punctured capsule. The puncture morphology may affect the subsequent delivery and deposition of drug after 
inhalation. Previous characterisation of punctures has used two-dimensional imaging (microscopy).1 The aims 
of the project were to characterise three-dimensional features of punctures in hypromellose capsules using 
Optical Coherence Tomography (OCT) and to determine the effect of the inhalation event on this puncture 
morphology. 
A method was developed, characterising capsule puncture by a Monodose RS01 DPI (PlastiApe, Italy) using 
multi-beam swept-source frequency domain OCT. Inhaler testing apparatus (inhaler adaptor, Next Generation 
Impactor™ (NGI™), flow meter and vacuum pump) was used to simulate an inhalation event and OCT images 
were taken both before and after simulated inhalation to investigate the effect of inhalation on puncture 
characteristics. The project examined twenty empty capsules conditioned over calcium chloride and twenty 
empty capsules conditioned over magnesium nitrate to determine performance at the lower and higher ends 
of the normal moisture specification range. Five capsules containing a model budesonide and lactose 
formulation were also examined and the NGI provided delivery and deposition information. 
OCT imaging was able to successfully determine the angle of the flap created in capsules following puncture 
by a DPI. Capsules showed an overall decrease in the angle of the flap created in capsules imaged before 
(34.8o±11.0) and after a simulated inhalation event (30.2o±10.1). Formulation containing capsules showed no 
significant difference between the flap angles before (51.8o±7.0) and after (50.4o±7.3) simulated inhalation. 
OCT imaging can provide sub-surface information about a capsule puncturing event and enables the position 
of the flap to be determined. Results indicate that the positioning of the flap created in capsules is variable. 
Punctures may also be affect by an inhalation event. The lack of statistical power limits the clinical significance 
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of the results but the use of a novel imaging system to capture information about the three-dimensional 
positioning of the flap provides encouraging possibilities for further DPI research. 
 Ferrand M, Fabrégue F, Cade D. Hard Capsules for Dry Powder Inhalers: Performance on Puncturing. In Annual Meeting and 
Exposition of the American Association of Pharmaceutical Scientists; 2009; Los Angeles: Capsugel. P. 1-4. 
 
 
An exploratory study of student engagement on the Cardiff MPharm degree 
programme 
Jack Lewis and MW Smith  
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
In higher education, there has been a recent focus on the enhancement of learning. After exploring the impact 
of ‘the student experience’ and ‘research-led teaching’ on educational outcomes, educators are addressing 
student engagement as a factor of student learning.1 
 
Student engagement is the: “interaction between the time, effort and other relevant resources invested by both 
students and their institutions intended to optimise the student experience and enhance the learning outcomes 
and development of students and the performance, and reputation of the institution.”.1 
The aim of this study was to assess the level of engagement of pharmacy students on the Cardiff MPharm 
degree programme.  
 
A self-completed survey2 was distributed to year 2, 3 and 4 students who participated anonymously. The 
survey consisted of 15 likert-scale questions and 3 qualitative free text comment boxes, all questions explored 
four domains – critical thinking, course challenge, collaborative learning and academic integration. It was 
distributed during lecture/workshop slots by purposive sampling. The quantitative data was analysed using 
SPSS, the qualitative data was exported into a word document and an inductive thematic analysis was 
undertaken retrospectively. Comparisons were made between the years with respect to the four domains using 
a one-way ANOVA test with Bonferroni post hoc test. Comparisons were also made within the years looking 
at student engagement of males versus females using a 2-tailed paired T test. Ethics approval was obtained 
for all of the above. 
 
The course produced positive engagement in three domains but not in the fourth (academic integration). The 
course challenge and level of academic integration were consistent in all years with no statistically significant 
differences being observed. Year 1 and 3 students engage more often in critical thinking compared with year 
2 students. Year 3 students engage most often in collaborative learning. In all years, female students find the 
course more challenging than male students. In year 2, male students communicate more with the staff, on 
the contrary, year 3 female students communicate more with the staff than male students. 
 
In conducting this study, it has become evident that Cardiff School of Pharmacy has produced an MPharm 
programme that by this measure delivers engagement in three domains, however, future work should focus 
on academic integration, in other words, the relationship between staff and students. 
 
 Trowler, V. 2010. Student Engagement literature review. The Higher Education Academy. 
 Buckley, A. 2013. Engagement for enhancement, Report of a UK survey pilot. The Higher Education Academy. 
 
 
Formulation of mucoadhesive films for the simultaneous delivery of chlorhexidine 
and diclofenac in the treatment of periodontal diseases 
Sim Yee Lim, K Sands1 and CM Heard 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff CF10 
3NB, and 1Cardiff School of Dentistry, Cardiff University, Heath Park, Cardiff CF14 4XY, Wales, UK 
The aim of this study was to formulate a mucoadhesive polymeric film containing chlorhexidine and diclofenac 
as a new treatment for periodontal diseases. Chlorhexidine has broad-spectrum activity against Gram-positive 
and Gram-negative bacteria1, and is approved to combat biofilm2. Simultaneous delivery of an antiinflammatory 
would reduce pain. 
Three drug loaded thin films were prepared using a polymer mixture3 containing 10mg diclofenac alone, 25mg 
chlorhexidine alone and 10mg Diclofenac/25mg Chlorhexidine (DCX) in combination. In vitro diffusional 
release properties were investigated. Microbiological testing was carried out to determine the antibacterial 
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potential against planktonic form and in a biofilm model. The test organisms included three Streptococcus 
species, P.gingivalis, F.nucleatum and A.actinomycetemcomitans. 
Chlorhexidine release was low at up to 4%, whereas diclofenac release was more rapid and reached 56% 
within 30min. Chlorhexidine was active and acting at an inhibitory level against all test microbes. A range of 3-
6 log10 reductions in biofilm cell recovery was seen after exposure to all films containing chlorhexidine. No 
antibacterial or potentiation activity was observed for diclofenac. 
Low release of chlorhexidine was attributed to interaction with the polymer matrix; however, the film 
demonstrated inhibitory effects against all test bacteria. Limited chlorhexidine release is beneficial regarding 
potential cytotoxicity4. Overall, this study supports further investigations into the antibacterial and antibiofilm 
properties as a product to treat periodontal diseases. 
 Löe, H. and Rindom Schiøtt, C. The effect of mouthrinses and topical application of chlorhexidine on the development of dental 
plaque and gingivitis in man. Journal of Periodontal Research, 1970;5(2):79-83. 
 Ryan, M.E. Nonsurgical approaches for the treatment of periodontal diseases. Dental clinics of North America, 2005;49(3):611-636. 
 Peh KK and Wong CF. Polymeric films as vehicle for buccal delivery: swelling, mechanical, and bioadhesive properties. J Pharm 
Pharm Sci. 1999;2(2):53-61. 
 Hidalgo, E. and Dominguez, C. Mechanisms underlying chlorhexidine-induced cytotoxicity. Toxicology in vitro, 2001;15(4):271-276. 
 
 
Using optical coherence tomography (OCT) to evaluate the puncture of gelatin 
capsules by a DPI 
Mayin Lo, B Jones, F Diez,1 JC Birchall and SA Coulman 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff CF10 
3NB, Wales, UK and 1Qualicaps Europe, S.A.U., Avenida Monte, Valdelatas, 4, 28108 Alcobendas, Madrid, Spain 
Dry powder inhalers (DPI) are devices that deliver active pharmaceutical ingredients (APIs) to the lungs in the 
form of a dry powder.1 A two-piece capsule is frequently used as the dose-holding system for the DPI. Capsules 
for DPIs are often made from gelatin or hydroxypropyl methyl cellulose (HPMC). Unit dose DPIs are designed 
to puncture capsule shells to enable powder release upon patient inspiration. Following puncture a ‘flap’ is 
often created in the capsule shell adjacent to the puncture site.2 Little is known about the position of this flap, 
or the effect it may have on powder release and hence inhaler performance. This study aims to use optical 
coherence tomography (OCT) to gather three-dimensional information about the capsule puncturing event in 
gelatin capsules in order to determine the angle of the ‘flap’ created. A secondary aim is to determine any 
changes in the position of the flap following an inspiration event. 
 
Gelatin capsules were conditioned over calcium chloride or magnesium nitrate for 2 weeks. This provided 
capsules at the lower and upper end of the normal moisture specification range.3 The conditioned capsules 
were loaded into a RS01 Monodose DPI (Plastiape, Italy) and punctured. After puncture with a single pin in 
each end of the capsule the capsule was scanned using OCT. The capsule was then re-positioned in the 
inhaler, which connected to an NGI associated with a vacuum pump. The vacuum pump was switched on and 
created a flow rate of 60L/min for 4 seconds to simulate an inhalation event. Capsules were then removed 
from the inhaler and re-imaged with OCT. OCT data were analysed using ImageJ software.  
 
OCT provided a non-destructive method to determine the position of the capsule flap below the capsule 
surface. There was no significant different in the angle of the gelatin capsule flap before and after the simulated 
inhalation event. Almost 50% of gelatin capsules that were conditioned at the lower humidity also had evidence 
of damage to the shell following the simulated inhalation event.  
 
The study indicates that the angle of the flap created in gelatin capsules by a DPI is not affected by an inhalation 
event. Future work should evaluate a larger sample size to confirm the finding. The variability of the flap angle 
was also notable and this also warrants further investigation. 
 
1. Groneberg DA, Witt C, Wagner U, Chung KF, Fischer A. Fundamentals of pulmonary drug delivery. Respir Med. 2003 
Apr;97(4):382. 
2. Birchall JC, Jones BE, Morrissey A. A comparison of the puncturing properties of gelatin and hypromellose capsules for use in dry 
powder inhalers. Drug Dev Ind Pharm. 2008 Aug;34(8):870-6. 
3. M. Ferrand, Cade FFD. Hard Capsules for Dry Powder Inhalers: Performance on Puncturing. Los Angeles, California: 2009 
[accessed 4/12/2015]. Available from: http://capsugel.com/media/library/hard-capsules-for-dry-powder-inhalers-performance-on-
puncturing.pdf 
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Adhesive interactions between antimicrobial coatings and gram positive (S. aureus) 
and gram negative (E. coli) bacteria: influence of surface energy and material 
properties 
Koobakwa Machiwana and P Prokopovich 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Bacterial cell adhesion to materials is the first step in the formation of a biofilm. The adhesion of bacteria to 
hospital medical equipment, medical devices, food processing equipment and packaging has been recognised 
as a widespread problem causing infectious diseases.1 Since microbial adhesion to materials is a prerequisite 
condition for biofilm production, prevention of microbial adhesion on equipment surfaces will have a major 
impact in preventing biofilm formation. An approach is to modify surface properties of materials to make the 
less attractive to microorganisms.2 The aim of the research was to find out the influence of surface energy 
parameters and material properties of antimicrobial coatings. 
 
A numerical procedure developed by Prokopovich and Perni3 was used to estimate the adhesive interactions 
between various antimicrobial coatings and E. coli ATCC 25922 or S. aureus NCTC 8532. The Johnson-
Kendall-Roberts (JKR) model was used to predict the forces of adhesion between the antimicrobial coatings 
and bacteria. Contact between real surfaces is carried out by the asperities on the surfaces. Each asperity 
was assumed to be hemispherical and had a height and a radius. Different antimicrobial coatings, such as Cu-
PTFE 8% PTFE, silver silicane, Ag-PTFE 4% PTFE and Ni-Cu-P-PTFE were used as model systems with 
different material properties. Statistical analysis was done using One Way Anova in IBM SSPS. 
 
Bacterial adhesion to antimicrobial coatings increased with increasing material surface energy and elastic 
modulus. E.coli had a much higher adhesion to all antimicrobial coatings compared to S. aureus. Adhesion 
forces increased with an increase in the contact area between asperities. Ag-PTFE 4%PTFE had the highest 
adhesion forces to antimicrobial coatings. Ni-Cu-p-PTFE had the lowest adhesion forces. 
There exist an optimum surface energy for controlling bacterial adhesion at 21-25mJ/m
2
.2 Materials can 
therefore be modified to reduce their surface energy so they do not attract bacteria. E. coli is good in forming 
biofilms and irreversible attachments to materials compared to S. aureus.1 Surface properties of antimicrobial 
coatings and bacterial strains can be used to predict adhesive forces based on the JKR theory. 
1. Soto, S. 2014. Importance of Biofilms in Urinary Tract Infections: New Therapeutic Approaches. Advances in Biology, 2014, pp.1-
13. 
2. Liu, Y. and Zhao, Q. 2005. Influence of surface energy of modified surfaces on bacterial adhesion. Biophysical Chemistry, 117(1), 
pp.39-45. 
3. Prokopovich, P. and Perni, S. 2010. Multiasperity Contact Adhesion Model for Universal Asperity Height and Radius of Curvature 
Distributions. Langmuir, 26(22), pp.17028-17036. 
 
 
Warm up times of injectable products 
Karen Mahy and R Price-Davies 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Medicines that are normally kept refrigerated to prevent unwanted microbial growth1 and slow degradation 
reactions,2 warm up at different rates when outside this controlled environment depending on volume and 
surface area. Information is required to aid decisions on when to remove medicinal products from a fridge prior 
to administration,3 or to determine when it is safe to use a product after removal from its controlled environment 
for a period of time. There is a paucity of information on how long liquids take to warm up during temperature 
excursions. 
0.9% sodium chloride solution was prepared, a range of syringes and infusion bags were filled and placed in 
the fridge to reduce in temperature. Conditions for the devices were changed to one of three scenarios; left 
out on a bench, fridge door left open or fridge switched off. Temperature change was monitored via probes 
and time taken to reach 8oC and 18oC was recorded. Temperature was recorded at different sites within the 
larger bags. Data was then analysed against surface area to volume ratio to look for trends. 
All syringes reached 18oC in less than 30 minutes when left out on a bench, but the 2 ml syringe took over 3.5 
hours in a switched off fridge. Bags took longer, 250 ml reached 18oC in just under 1 hour on the bench, and 
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4 L took nearly 13 hours in the switched off fridge. The general trend seen is that as surface area to volume 
ratio increases the time taken to warm up decreases. 
The relationship is not linear suggesting there are more factors at work than surface area and volume. Smaller 
volumes increase in temperature at a relatively constant rate throughout the liquid, larger volumes vary in 
temperature with distance from the surface. 
 Allison, D. Bacteria. In: Denyer SP, Hodges N, Gorman SP and Gilmore BF. eds. Hugo and Russell’s Pharmaceutical Microbiology. 
8th ed. West Sussex: Wiley-Blackwell;2011. pp 24-43 
 Matthew M, Gupta VD, Bethea C. Stability of piperacillin sodium in the presence of tazobactam sodium in 5% dextrose and normal 
saline injections. Journal of Clinical Pharmacy and Therapeutics. 1994;19:397-399 
 American Diabetes Association. Insulin administration. Diabetes Care. 2004;27(suppl 1): s106-s107. [Accessed:02/10/2015] 
Available from: http://care.diabetesjournals.org/content/27/suppl_1/s106.full 
 
 
Design and evaluation of a computer aided package to educate undergraduate and 
postgraduate pharmacists about the clinical features, prophylaxis and treatment of 
malaria 
Hazel Mangoche and RDE Sewell 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Computer Aided Learning (CAL) is often described as the process by which textual and graphic information is 
presented in some logical sequence by a computer.1,2 The aim of the project was to design and evaluate an 
animated CAL Package to educate undergraduate and postgraduate pharmacists about Malaria emphasizing 
the role of the pharmacist. 
 
The CAL package was constructed using Microsoft PowerPoint and contained relevant up to date information 
on Malaria.3 Aspects of the package such as the visual appearance, length and interactivity of the package 
were considered.4 Using a 5 point Likert scale4 and free text box, a questionnaire was designed to assess the 
overall impression, presentation/layout and contents of the package. 
 
A total of 30 online questionnaires were completed by Mpharm II students. Nineteen (63%) of the responders 
were female, eleven (37%) were male yielding a response rate of 29.7%. The mean, mode, frequency and 
standard deviations were obtained. The majority of students felt the package was well presented. 56% of 
students (n=17) stated that they would prefer it if CAL packages were used alongside traditional face-to-face 
transitional methods of teaching. Some students (20%, n=6) preferred traditional methods of teaching as it 
gave them the opportunity to ask questions. The CAL package was generally well received by the students, 
and 73% of students would recommend the package to other students as a revision aid, however, they were 
unlikely to use it solely without supporting lectures themselves. 
 
The malaria CAL package was shown to be a useful reference tool and it can be deduced that the teaching 
package was successful as an effective learning tool for the students that were involved in the survey. The 
students who participated in the study found the CAL package interesting, beneficial, and key to understanding 
the pathogenesis, transmission, and symptoms of malaria. 
 
 Nga, M H (1986). Design and implementation of a generalised computer aided learning system, Durham theses, Durham University. 
Durham E-Theses Online: http://etheses.dur.ac.uk/6825/ [Accessed 22 Dec 2015] 
 Daintith, J. (2004) computer-assisted learning. A Dictionary of Computing. Oxford University Press. Encyclopedia.com. 
http://www.encyclopedia.com [accessed 22 Dec. 2015 
 World Health Organization, (2016). Malaria. [online] Available at: http://www.who.int/topics/malaria/en/ [Accessed 11 Jan. 2016]. 
 England, E. (1984). Colour and layout considerations in cal materials. Computers & Education, 8(3):317-321 
 
 
The effects of a frankincense extract on breast cancer signalling pathways that 
control growth and migration 
Sebastian Masento, A Ali1 and SE Hiscox 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff CF10 
3NB, and 1School of Biosciences, Cardiff University, Life Sciences Building, Museum Avenue, Cardiff, CF10 3AX  
Natural products represent a rich source of medicinal compounds and have led to the discovery of many drugs 
we use today. Frankincense has shown to possess compounds that may possess some medicinal properties. 
The compound BF4 has been isolated from a species of frankincense, Boswellia frereana, and investigated 
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for its use in osteoarthritis.1 The aim of this study was to understand the mechanism of action of BF4 and 
explore its potential use as a breast cancer treatment in a triple negative breast cancer cell line, MDA231.  
The methods used in the study were Western Blotting to identify any changes in proteins that are known to be 
involved in TNBC cell migration and growth. Immuno-fluorescent microscopy was also used to look at the 
physical changes of the cells after BF4 treatment.  
 
BF4 was seen to decrease the amount of FAK, SRC and MAP Kinase after 24-hour treatment and at 
concentrations of 40μg/ml and 80μg/ml. This is shown in an average of densitometry values over three 
repeated results.  
 
Our data suggests that BF4 can modulate and inhibit the activity of SRC, FAK and MAP kinase, which are 
known to be involved in aggressive cellular behaviour implicated in TNBC. BF4 can also bring about apoptotic 
characteristics in the cells, which may result in cell death at higher concentrations and treatment times. As BF4 
is a novel compound, more research is required to support these findings before a definitive result can be 
made.  
 
1. Blain EJ, Ali AY, Duance VC. Boswellia frereana (frankincense) suppresses cytokine-induced matrix metalloproteinase expression 
and production of pro-inflammatory molecules in articular cartilage. Phytother Res. 2010;24(6):905-12. 
 
 
What are the opinions of the public of Wales on community pharmacists having 
access to their hospital discharge advice letter? 
Emily McDonald, ML Hughes, C Way1 and KL Hodson 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK and 1NHS Informatics Services, Cardiff, UK 
The involvement of a multidisciplinary team in the management of patient’s transfer from hospital to community 
has been shown to improve patient outcomes and reduce re-admissions.1 Community pharmacy Discharge 
Medicines Review aims to improve patient compliance and comprehension. NHS Wales Informatics Service 
(NWIS) are considering whether community pharmacists should be sent a copy of the discharge advice letter 
(DAL).2 However the importance of collecting the views of the public about the community pharmacist’s access 
to their discharge advice letter is key to gain consent for this process to happen. The study aimed to evaluate 
and quantify the views of the public on community pharmacist’s access to the patients’ DAL. 
A pre-piloted questionnaire3 was sent to a total of 923 participants across Merthyr Tydfil and Ceredigion. This 
group project used a multi-stage sampling technique to identify clusters based on population size, and then 
purposively assign categories to local authorities in order to get a representative sample of the whole of Wales. 
Random sampling using excel was used to select participants from the edited electoral roll. Data was analysed 
by SPSS 20. 
The majority of the public either agreed or strongly agreed with the sharing of their discharge information with 
the community pharmacist. However 15% (n=86) of participants in Ceredigion and 19% (n=53) in Merthyr 
Tydfil did not want to share information about drug allergies with the community pharmacist, which may have 
future clinical implications. The study revealed a low usage of pharmacy services and further education about 
the role of the pharmacist should help to integrate the services with that of other health professionals.4 
The results will be fed back to NWIS for review in the hope community pharmacists will gain access to DALs 
which would be expected to improve patient care and potentially save costs. 
1. Katikireddi SV, Cloud GC. Planning a patient’s discharge from hospital. BMJ. 2008 Dec 12;337:a2694 
2. Way, C. Improving communications with community pharmacists. PowerPoint Presentation 2014. 
3. Wirt E. Should Patient’s Discharge Advice Letters (DALs) be Sent to Community Pharmacists: The Views of the Public in Wales – 
Development and Piloting of the Questionnaire 2015, Msc Dissertation , Cardiff University.2014 
4. Jones I. Evaluation of the Choose Pharmacy common ailments service: Welsh Government 2015 [accessed 1 December 2015]. 
Available from : http://gov.wales/docs/caecd/research/2015/150730-evaluation-choose-pharmacy-common-ailments-service-en.pdf 
 
 
 
 
MPharm 
43 
Investigating the role of ZIP7 phosphorylation in breast cancer 
Sarah McGahon and KM Taylor 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Zinc has long been known to be biologically important in humans, but only recently has it been identified as a 
second messenger,1 transferring external stimuli into an intracellular signalling pathway. Zinc cannot travel 
freely in the body and employs transporters to cross plasma membranes, for example the ZIP7 transporter – 
which sits on the endoplasmic reticulum and releases zinc into the cytosol from stores when phosphorylated 
by CK22 at residues Ser275 and Ser276. The project aim was to investigate the importance of residues S275 
and S276 individually for ZIP7-mediated zinc release, and to explore the downstream signalling pathways and 
whether both of these residues were required or whether one alone would suffice.  
MCF-7 cells were transfected with recombinant wild-type ZIP7 or a mutated form of ZIP7: S275A/S276A 
(inactive), S275D/S276A (S275 active) or S275A/S276D (S276 active). They were treated with zinc for 0, 2, 
5, 10, 15 and 20 minutes, lysed and analysed by Western blot, and probed for: pAKTS473, pZIP7S275/S276 
pCREBS133, p-mTORS2448. Beta-actin was used to normalise the densitometry data. Data was analysed 
using a one-way ANOVA and a Dunnett’s post-hoc test, and significance was assumed if P<0.05. 
AKT was confirmed to be activated by ZIP7-mediated zinc release occurring due to the phosphorylation of 
residues S275 and S276. All results together suggested S276 may be more important for ZIP7-mediated zinc 
release than S275, but neither residue alone was as effective as the wild-type ZIP7, suggesting the need for 
both residues for maximal zinc release. For the first time CREB was shown to be activated by ZIP7-mediated 
zinc release as a direct downstream target.  
This project confirmed that a useful target of ZIP7-mediated zinc release (and the downstream proliferative 
pathways3) for breast cancer treatment should inhibit both S275 and S276. 
 Yamasaki S, Sakata-Sogawa K, Hasegawa A, Suzuki T, Kabu K, Sato E et al. Zinc is a novel intracellular second messenger. J Cell 
Biol. 2007;177:637-645. 
 Taylor KM, Hiscox S, Nicholson RI, Hogstrand C, Kille P. Protein kinase CK2 triggers cytosolic zinc signalling pathways by 
phosphorylation of zinc channel ZIP7. Sci Signal. 2012;5:101-111. 
 Hogstrand C, Kille P, Nicholson RI, Taylor KM. Zinc transporters and cancer: a potential role for ZIP7 as a hub for tyrosine kinase 
activation. Trends Mol Med. 2009;15:101-111. 
 
 
Risk aversion in pharmacists 
Hywel McGlinchy and R Price-Davies 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
This study set out to gather information on risk aversion in pharmacists and determine whether pharmacists 
are risk averse and what tools have been or may be used in the future to measure risk aversion in pharmacists. 
Very little research has previously been conducted on the personalities of pharmacists and even less has been 
conducted on risk aversion in pharmacists. 
 
A literature review was performed on a number of scientific databases searching for studies relevant to risk 
aversion in pharmacists and broadening the search to personality traits of pharmacists. Additionally, any tools 
used to measure personality found in these studies were themselves part of a parallel search.  
 
The results found no previous studies of risk aversion in pharmacists but nine studies researching pharmacists’ 
personality traits were found. Data relevant to the risk behaviour of pharmacists was extracted from this 
research and information was also gathered about the tools used in these studies. 
 
The current available literature points towards pharmacists having risk averse personalities. More research 
needs to be conducted to confirm or refute this finding and there is a need for more UK based research. Some 
research suggests that risk aversion may have negative effects in pharmacists, for example by hindering their 
confidence to undertake prescribing roles.1 This study concludes that, of all the tools used in studies so far, 
the best suited tool to use for further research into risk aversion in pharmacists is the Gordon Personal Profile 
Inventory (GPP-I).2 Other, more risk-behaviour specific tools, are also suggested as candidates for measuring 
risk aversion in pharmacists in future research. 
 
MPharm 
 
44 
1. Rosenthal, M., Austin, Z. and Tsuyuki, R.T. 2010. Are pharmacists the ultimate barrier to pharmacy practice change? Canadian 
Pharmacists Journal 143(1), pp. 37-42. 
2. Gordon, L.V. 2015. The Gordon Personal Profile Inventory, Global Edition (Global GPP-I) [Online]. Available at: 
https://shop.acer.edu.au/acer-shop/group/QCF [Accessed 21 Nov 2015]. 
 
 
Public opinion of the cost of medicines and strategies to reduce medicines wastage 
Tryphosa Anyango Mitoko, C Jones and R Yemm 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Medicines wastage is a considerable problem in the NHS, with approximately £300 million discarded annually, 
and is a multi-faceted problem requiring complex patient-centred policies.1 In 2015, the Health Secretary 
announced plans for a policy that would put the cost of medication on dispensing labels followed by “funded 
by the UK taxpayer”.2 The lack of evidence supporting this policy3 resulted in this study and its aim was to 
explore public opinion of medicines wastage and potential effects of medication prices on dispensing labels 
on patient behaviour. 
The inclusion criteria were current students, the elderly and working age professionals. Recruitment was 
conducted via purposive, convenience and snowball sampling. Participants were contacted via gatekeepers 
and provided with a covering letter and participant information leaflet, detailing what was involved in the study. 
The focus groups consisted of 5-7 individuals and were facilitated by researchers using a topic guide and 
labelled medication boxes as props. The discussions were audio recorded, transcribed verbatim and 
anonymised. 
Overall opinion surrounding medicines wastage was that healthcare professionals contributed more than 
patients. There was an overall negative reaction to the presence of the cost on dispensing labels, with some 
participants equating it to a “guilt trip”. The majority believed it would have little to no effect long term effect on 
patient adherence and that policies that engaged the patient more and focused on education would be more 
effective in curbing medicines wastage due to non-adherence. 
This study shows that the public acknowledges medicines wastage as an issue but would not be favourable 
to the addition of the cost on dispensing labels, preferring a more patient-centred approach. Limitations of this 
study are the inclusion of professionals allied to the pharmaceutical industry as well as the lack of participants 
suffering from long term chronic illnesses.  
 
 York Health Economics Consortium and School of Pharmacy, U.o.L, 2010. Evaluation of the Scale, Causes and Costs of Wate 
Medicines: Final Report, London: University Of London. 
 Robinson, A., 2015. How is Putting 'Taxpayer Funded' on Drugs Meant to Make us Feel? Grateful? Guilty?-The Telegraph. [Online]  
Available at: http://www.theguardian.com/commentisfree/2015/jul/02/price-nhs-drugs-health-labelling-medicine-patient 
[Accessed 02 October 2015] 
 Wilcock, M., 2015. It's not Just About the Money, Money, Money. British Medical Journal, 53(8), p. 1 
 
 
Evaluation of inhaler technique 
Lucy Miller and WR Ford 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Inhaler devices are used to administer drugs in asthma and COPD. Correct inhaler technique is crucial in 
delivering drug to the optimal location in the lower airways.1 Observational studies have shown that inhaler 
technique in patients is poor2 and patients do not understand the need for preventative inhalers.3 The aim was 
to use airflow measurements to test and classify inhaler technique quality for dry powder inhalers (DPI) and 
metered dose inhalers (MDI) with and without a spacer device. 
 
Clinics were held across Cardiff and Vale University Health Board (UHB). Information was obtained about 
patient’s inhaler use prior to assessing their inhaler technique using a Vitalograph Aerosol Inhalation Monitor™ 
(AIM). This records inspiratory flow rate and co-ordination to predict the region of drug deposition. Researchers 
observed participants to see if they shook the device and held their breath. Participants were also asked if they 
understood how their regular inhaler helped to improve their condition. 
 
61 participants were recruited who used a total of 88 devices. 26% of all inhaler demonstrations were classed 
as being good, defined as having drug deposition in the lower airways. DPI technique was better than MDI’s 
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and use of a spacer significantly improved MDI technique (p<0.0001). Previous training, frequency of inhaler 
use, the use of multiple device types, age and gender did not influence the quality of inhaler technique. 40% 
of participants did not understand how their regular inhaler therapy helped their condition. 
 
Inhaler technique was poor for all devices; introduction of spacers should improve MDI technique. Current 
training does not influence technique and evidence suggests that professionals are currently not adequately 
educated [2]; it is necessary to implement new training tactics and regimes across all healthcare professions, 
ensuring that patients understand how to use their device properly to maximise the benefits of 
pharmacotherapy. 
1. Tena AF, Clarà PC. Deposition of Inhaled Particles in the Lungs. Archivos de Bronconeumología (English Edition). 2012;48(7):240-
6. 
2. Fink J, Rubin B. Problems With Inhaler Use: A Call For Improved Clinician and Patient Education. Respiratory Care. 2005 Oct 1; 
50(10):1360-75. 
3. Menckeberg T, Bouvy M, Bracke M, Kaptein A, Leufkens H, Raaijmakers J, et al. Belief About Medicines Predict refill Adherence to 
Inhaled Corticosteroids. Journal of Psychosomatic Research. 2008;64:47-54. 
 
 
The effects of frankincense extract on breast cancer growth and migration 
Dillan Mistry, A Ali1 and SE Hiscox 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff CF10 
3NB, and 1School of Biosciences, Cardiff University, Life Sciences Building, Museum Avenue, Cardiff, CF10 3AX  
Recent research by Cardiff University into Somalian frankincense, Boswellia frereana, has shown promise as 
a novel drug candidate for the treatment of inflammatory diseases where it can affect cell proliferation.1 
Currently, little is known as to its potential as an anti-cancer agent. The aims of this project were thus: to 
investigate the effect of BF4 on the migratory and proliferative capacity of breast cancer cells models reflecting 
the dominant clinical sub-types.  
To carry out this investigation four cell lines were used: MDA-231 (TNBC), MCF-7 (Luminal A), SKBR-3 
(HER2+) and BT-474 (Luminal B) cells, with four different concentrations of BF4: 10,20,40 and 80µg/ml. 
Cellular migration was assessed using a scratch assay where the extent on closure of wounds was measured, 
whilst a MTT assay was carried out to look at cell viability after treatment. Statistical analysis was carried out 
using ANOVA followed by a post hoc Tukey’s test, showing that there were statistically significant differences 
between the means in the data sets at p<0.05.  
Upon carrying out the assays it was determined that 80µg/ml was the most potent concentration to affect all 
cell lines in both assays. Cell wounding data indicated a dose dependent inhibition on migration in TNBC cells, 
with limited effects on the other cell lines. Likewise, MTT assays revealed dose dependent inhibiton of growth 
in TNBC cells again with limited effects on other cell lines.  
BF4 may be useful in the treatment of aggressive breast cancers such as those defined as TNBC, either 
through the inhibition of MMP-91 or inducing apoptosis via a number of different mechanisms.2,3 Ultimately 
more research is required in order to determine intricate details as to its mechanism of action upon breast 
cancer cells.  
 Blain E, Ali A, Duance V. Boswellia frereana (Frankincense) suppresses cytokine-induced Matrix Metalloproteinase expression and 
production of pro-inflammatory molecules in articular cartilage. Phytother Res. 2010;25:905-12. 
 Liu Y, Bi T, Shen G, Li Z, Wu G, Wang Z et al. Lupeol induces apoptosis and inhibits invasion in gallbladder carcinoma GBC-SD 
cells by suppression of EGFR/MMP-9 signalling pathway. Cytotechnology. 2014;1:1-11. 
 Salminen A, Lehtonen M, Suuronen T, Kaarnirata K, Huuskonen J. Terpenoids: natural inhibitors of NF-kB signalling with antii-
inflammatroy and anticancer potential. Cell Life Mol Sci. 2008;65:2979-99. 
 
 
Involvement of oestrogen receptor signalling in Alzheimer’s disease in women 
Meh Jabeen Moghal, M Alsaqati and EJ Kidd 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK  
Oestrogen is known to be neuroprotective, therefore its post-menopausal loss has been presumed to account 
for higher incidence of Alzheimer’s disease (AD) in women than age-matched men.1-4 At least part of ER 
signalling and thereby some neuroprotection is mediated through its receptors (ERs).3,4 The aim of this study 
was to compare expression levels of ERs and other AD-associated proteins in AD and non-AD (control) 
samples of both genders. 
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Western blotting analysis determined levels of both ER subtypes (ERα & ERβ) along with an ER signalling 
protein (GSK3α/β) and AD hallmark pathological proteins (amyloid precursor protein, APP and total & 
phosphorylated tau) in human brain cortex samples. Comparisons were made across both disease status and 
gender. 
Levels of ERα & ERβ were significantly increased in AD-women compared to control-women whereas in AD-
men there was a significant decrease of ERβ compared to control-men. Additionally, levels of ERβ were 
significantly lower in AD-men compared to AD-women, whereas in control-men levels of ERα were significantly 
higher compared to control-women. Levels of APP (as expected), phosphorylated and total tau & GSK3 (α/β) 
showed no differences between men and women with AD. However, in control-women GSK3β expression was 
significantly increased compared to control-men. 
Overall, this study indicates that there are differences in ER expression with regard to both gender and disease 
status. The data suggest that differential expression levels of ER and some ER signalling molecules may affect 
the extent of neuroprotection, which may explain gender-based differences of prevalence. However, future 
investigations are needed to support these findings and ascertain if ER signalling-mediated changes could be 
considered as a prominent risk factor to develop AD. If conclusive evidence is achieved it could be a valid 
basis for its investigation as a potential target for future AD therapies. 
 Dalvi A. Alzheimer’s disease. Disease-a-month. 2012; 58(12): 666–677. 
 Li R and Singh, M. Sex differences in cognitive impairment and Alzheimer’s disease. Frontiers in neuroendocrinology. 2014; 35(3): 
385–403. 
 Cui J, Shen Y, Li R et al. 2013. Estrogen synthesis and signalling pathways during aging: from periphery to brain. Trends in 
Molecular Medicine. 2013; 19(3): 197–209. 
 Green P and Simpkins J. Neuroprotective effects of estrogens: potential mechanisms of action. International Journal of 
Developmental Neuroscience. 2000; 18(4–5): 347–358. 
 
 
Spore adhesion of purified 002 and 027 ribotype C. difficile spores to stainless steel 
surfaces 
Aliki Morthanassi, D Malyshev and L Baillie 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Clostridium difficile is an anerobic, gram-positive, spore-forming bacterium. Hospitalized patients treated with 
broad-spectrum antibiotics are more susceptible to C. difficile infection (CDI) due to alterations in their colonic 
microbiota. Sporulation of C.difficile is induced by environmental stresses e.g environmental oxygen. The 
spores may survive for months on inanimate surfaces found throughout healthcare environments, one of these 
being stainless steel. Once the spores are ingested, they germinate in the small intestine and release toxins 
that can cause bloody diarrhea and colonic ulceration.  
 
During the past decade, CDI rates have been increasing worldwide, this is largely thought to be due to a 
‘hypervirulent’ ribotype of C.difficile, 027. Previous studies have suggested that strains that possess the 027 
ribotype produce spores that have greater relative hydrophobicities, possibly aiding them to adhere to stainless 
steel more strongly. The aim of this study is to compare the adherence of purified 027 strain spores 
(1801,1813) to stainless steel against that of the less virulent purified 002 strain spores (1748). 
 
Three spore suspensions were created for each strain to be investigated and their concentrations of colony 
forming units per ml recorded. 10μl from these spore stocks were further cultivated on the appropriate agar or 
in the appropriate broth and were subjected to two separate purification methods. The Lawley method 
produced spores of higher purity than the Sorg, but the reagents used in the Lawley method possibly disrupt 
the spore exosporia, altering the spores’ ability to adhere to stainless steel.  
 
The stainless steel transfer assay was used to determine the spore samples adherence to stainless steel. The 
one-way ANOVA found no significant differences between the adherences for the unpurified, Sorg and Lawley 
1801 strain spore samples. Unpaired students t-test was used to compare adherence of the different strain 
spores to stainless steel against each other. The only significant result obtained was that the Sorg 1813 spore 
samples adhered less strongly to stainless steel.  
 
By gathering more information regarding how and to what extent the spores adhere to inanimate surfaces 
found throughout healthcare settings, CDI rates may be able to be combated more efficiently.  
 
1. Steglich, M. et al. 2015. Tracing the spread of Clostridium difficile ribotype 027 in Germany based on bacterial genome sequences. 
PLoS ONE 10 (10). pp 1-11. 
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2. Joshi, L.T, et al. 2012. Contibution of Spores to the ability of Clostridium Difficile to adhere to surfaces. Applied and environmental 
microbiology. [Online]. Available at: http://aem.asm.org.abc.cardiff.ac.uk/content/78/21/7671 [Accessed: 7th October 2015] 
3. Aitken, S.L, et al. 2015. In the endemic setting, Clostridium difficile ribotype 027 is virulent but not hypervirulent. Cambridge 
journals [Online]. Available at: 
http://journals.cambridge.org.abc.cardiff.ac.uk/action/displayAbstract?fromPage=online&aid=9916247&fulltextType=RA&fileId=S08
99823X15001877 [Accessed: 6th October 2015] 
4. Permpoonpattana, P. et al. 2013. Functional Characterization of Clostridium difficile spore coat proteins. Journal of Bacteriology 
195 (7). pp 1492-1503. 
 
 
 
Development of a molecularly imprinted polymer sensor for detection of PSA 
Richard Joshua Moule and JL Bowen 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK  
Successful treatment of Prostate cancer (PCa) relies on early diagnosis (detection of elevated prostate specific 
antigen (PSA) levels). Currently this process can take several weeks.1 The aim was to develop a highly 
selective biochemical sensor for the detection of PSA using molecular imprinting to allow rapid detection, 
diagnosis and monitoring of PCa within a primary care setting. 
 
Epitope imprinting was adopted due to the issues associated with protein imprinting.2,3 An epitope sequence 
of PSA was synthesised following solid phase Fmoc synthesis on a 0.3 mmol scale. It was then immobilised 
to ED-SE1-AuPt electrodes with the use of aminothiophenol (ATP) and 3, 3'-dithiobis (sulfosuccinimidyl 
propionate) (DTSSP). Electropolymerisation of dopamine or aminophenol onto the peptide modified electrodes 
took place to create molecularly imprinted polymers (MIPs). Electrical impedance spectroscopy (EIS) was then 
used to detect possible rebinding interactions with the MIP and the peptide. 
 
High performance liquid chromatography (HPLC) and mass spectrometry (MS) confirmed the synthesised 
peptide was both pure and matched the desired sequence. Dopamine MIP displayed increased rebinding in 
comparison to polydopamine alone. However, when compared to a dopamine non imprinted polymer (NIP) it 
was evident that a specific imprinting effect had not been achieved. Non-specific binding was observed with 
polyaminophenol at low concentrations (>10 µM). Similarly to polydopamine, there was little to differentiate 
between polyaminophenol MIP and NIP. 
 
It is evident from the results that an imprinting effect could not be established on this occasion. This could be 
due to a number of reasons including lack of imprinting to the length of the peptide or overcrowding at the 
electrode surface, resulting in non-specific binding sites due to polymer porosity. Future work should include 
extra polymerisation cycles and decreased concentrations of molecules on the surface of the electrodes in the 
hope to overcome these issues. 
 Nice.org.uk. Prostate cancer: diagnosis and management | Introduction | Guidance and guidelines | NICE [Internet]. 2014 [accessed 
23 November 2015]. Available from: https://www.nice.org.uk/guidance/CG175/chapter/introduction 
 Kempe M, Glad M, Mosbach K. An approach towards surface imprinting using the enzyme ribonuclease A. J Mol Recognit. 
1995;8(1-2):35-39. 
 Hjertén S, Liao J, Nakazato K, Wang Y, Zamaratskaia G, Zhang H. Gels mimicking antibodies in their selective recognition of 
proteins. Chromatographia. 1997;44(5-6):227-234. 
 
 
Determining intravenous lipid emulsion stability – an examination of sensitivity of 
analytical methods 
Chloe Murphy and AG Cosslett 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Parenteral lipid emulsions are used clinically as nutritional supplements.1 Emulsifiers are used in emulsions to 
stop or slow down the separation of an emulsion into its original state, therefore keeping the emulsion stable2. 
When an emulsion becomes unstable the lipid globules flocculate, causing a cream layer to be formed and 
then eventually they coalesce causing cracking of the emulsion, which is irreversible.3 It is important that an 
emulsion is stable when given to a patient as globules greater than 5μm can harm patients. This is why the 
limit of 5μm has been set to determine if an emulsion is stable or not.2 This stability testing is essential for 
patient safety, so that when patients receive parenteral lipid emulsions in clinical practice they are not harmed 
by unstable emulsions containing large globules4. 
 
MPharm 
 
48 
To test the emulsions stability calcium chloride was added in different concentrations to Intralipid® 20% and 
SMOFlipid® 20% to destabilise them. Their stability was then tested using three different techniques. Visual 
inspection looked for signs of creaming and cracking. Microscopy measured the size of individual globules and 
looked for signs of aggregation and flocculation. Laser diffraction was used to measure the maximum size and 
mean volume weighted diameter of globules. 
 
Intralipid® had the most destabilisation at 6mmol/L of calcium chloride and SMOFlipid® had a wider range of 
concentrations that showed destabilisation, which was between 4 and 8mmol/L of calcium chloride. The 
difference in stability between the emulsions is likely due to the different composition of their lipid phases. 
 
The project has limitations, namely it does not answer the second part of the research question, how sensitive 
are the analytical methods. This was due to time constraints. The project does provide a good base for future 
work and is important in keeping patients safe from adverse affects of unstable emulsions.4 
 
 Driscoll D. Lipid Injectable Emulsions: Pharmacopeial and Safety Issues. Pharmaceutical Research. 2006; 23(9): 1959-1969. 
 Akasah T. Some studies on globule size distributions in parenteral lipid emulsions [Ph.D.]. Cardiff University; 2002. 
 Washington C. Stability of lipid emulsions for drug delivery. Advanced Drug Delivery Reviews. 1996; 20(2-3): 131-145. 
 Müller R, Heinemann S. Fat emulsions for parenteral nutrition II: Characterisation and physical long-term stability of Lipofundin 
MCTLCT. Clinical Nutrition. 1993; 12(5): 298-309. 
 
 
Comparing tau phosphorylation in mouse models of Alzheimer’s disease and 
Down’s Syndrome 
Benedict Newth, A Langberg, M Alsaqati and EJ Kidd 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK   
The Alzheimer’s disease pathophysiological hallmarks are Amyloid-β (Aβ) inclusions and neurofibrillary 
tangles containing tau.1 Amyloid precursor protein (APP) becomes cleaved to create Aβ. Increasing Aβ levels 
upregulates kinases such as DYRK1A, phosphorylating tau at Thr212, and GSK-3, phosphorylating tau at 
Ser396/404. Here three 10 month-old mouse models and wild-type control mice were used. The Tg2576 
mouse overexpresses human APP. Down’s syndrome (DS) subjects have three copies of human chromosome 
21 (Hsa21), encoding APP and DYRK1A. Tc1 mice are partially trisomic for Hsa21 excluding the APP encoding 
region. The Doubles mouse contains the mutations from both Tg2576 and Tc1 mice, reintroducing APP into 
the Tc1 model. I hypothesise Doubles mice will have higher kinase and phosphorylated tau protein levels than 
all other groups.  
 
Western blotting technique was used to analyse the protein expression of APP, DYKR1A and Thr212, GSK-3 
and Ser396/404 in cortex samples from all mice. Data were analysed with one-way ANOVA and Tukey post-
hoc test. 
Results showed increased APP levels in Tg2576 and Doubles compared to Tc1 and wild type. No significant 
differences were seen between DYRK1A, GSK-3 and GSK-3 and their associated phosphorylated tau 
residues between any of the groups. 
 
The expected increases in DYKR1A and Thr212 levels were not seen in Doubles and Tc1 mice. The Tc1 
mouse exhibits mosaicism,2 causing sporadic gene uptake and affecting results. The genes on Hsa21 are 
present on mouse chromosomes 10, 16 and 17.3 Therefore manipulation of Hsa21 in Tc1 mice will not cause 
DS. The expected increases in GSK-3 and Ser396/404 levels in Tg2576 and Doubles mice were also not seen, 
possibly as they were too young to have phosphorylated tau widespread in the cortex.4 DYRK1A and GSK-3 
were unaffected by increasing levels of APP in the Doubles mice, however, recent improved DS models will 
facilitate analysis of this hypothesis.  
 
 Mckhann, G., Drachman, D., and Folstein, M. (1984). Neurology, 34(7), 939–944 
 Ahmed, M. M et al. (2013). Human Molecular Genetics, 22(9), 1709–24 
 Ruparelia, A., Pearn, M. L., and Mobley, W. C. (2013). Developmental Disabilities Research Reviews, 18(1), 43–50 
 Braak, E. V.A et al. (1995). Neurobiology of aging, 16(3), 271–278  
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Design and synthesis of inhibitors of CYP24A1 as potential cancer therapeutics 
Jasmine CM Ngai and C Simons 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Calcitriol, the active metabolite of vitamin D, can be potentially used as an anticancer agent due to its 
antiproliferative, pro-apoptotic and antiangiogenic activities.1 However, this therapy still remains a challenge 
due to hypercalcaemia caused when used in high dose.2 CYP24A1, the enzyme for metabolising and 
inactivating calcitriol, is thus explored as inhibiting this target can increase the body’s endogenous level of 
calcitriol. CYP24A1 inhibitors can also tackle drug resistance to calcitriol caused by the up-regulation of 
CYP24A1 found in cancer patients.1 The aim of this project is to design and synthesise CYP24A1 inhibitors 
and obtain compounds for establishing structure-activity relationships of N-(2-(1H-imidazol-1-yl)-2-
phenylethyl)-4-benzamides derived from the lead compound, VID-400. 
Through molecular modeling, the p-substituents of benzamide of the proposed inhibitors were modified for 
better docking with the CYP24A1 homology model. The final compounds, imidazole-benzamides, were then 
synthesised with a three-step reaction method. All compounds including the intermediates were characterised 
to confirm their purities before proceeding to the next step. 
All six computer models of the (R)- and (S)-imidazole-benzamides could bind to the haem Fe of the enzyme 
in optimal distances (2.04-2.25Å) by a N-Fe interaction and interact with hydrophobic amino acids. The reaction 
scheme successfully produced two pure imidazole-benzamides in low yields (~7%). 
The proposed inhibitors show promising modelling results due to the essential N-Fe interaction at optimal 
distance found in all computer models, as well as the hydrophobic interactions that are also present between 
calcitriol and CYP24A1. However, their actual inhibitory effects have to be evaluated in cell-based assays and 
these results are not yet available. The reaction method produced pure imidazole-benzamides, except when 
the benzamide was the p-methoxylated benzene because the strong electron-donating OCH3 was 
unfavourable in the syntheses of imidazole and the oxazoline intermediate. 
 Deeb KK, Trump DL, Johnson CS. Vitamin D signalling pathways in cancer: potential for anticancer therapeutics. Nature Reviews 
Cancer. 2007;7(9):684-700. 
 Trump DL, Hershberger PA, Bernardi RJ, Ahmed S, Muindi J, Fakih M, et al. Anti-tumor activity of calcitriol: pre-clinical and clinical 
studies. The Journal of Steroid Biochemistry and Molecular Biology. 2004;89:519-26 
 
 
Feasibility of using an iPad to assess patient measures in a movement disorder 
clinic among Parkinson’s disease patient cohort 
Cynthia WS Ngu and EL Lane 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Integration of electronic devices into healthcare services is becoming more common.1 This study aims to 
evaluate the feasibility of using an iPad to assess patient measures as part of routine in a movement disorder 
clinic (MDC), particularly for Parkinson’s disease (PD) patients. The main objectives are to explore patient’s 
and staff’s perspectives towards the integration and to find out what support is required for this to run routinely. 
 
Ethics approval was granted and the study was carried out as a service evaluation. All PD patients were invited 
to complete an iPad activity that would record their health status via EQ-5D,2 non-motor symptoms (NMS) via 
the electronic NMS questionnaire3 and speed with the simple finger-tapping task. A short semi-structured 
interview was later conducted by students to evaluate the service. Staff members in the clinic are also 
interviewed. 
 
Of 24 patients participated, 67% were able to use the iPads on their own. Some patients still required help 
from others, but they usually come in with their carers. Majority of patients felt comfortable and preferred the 
electronic approach over paper-based questionnaire after trying the iPad. There was no issue for PD patients 
to complete the iPad activity in time. 
Patients and staff were open to the idea of implementation. Staff were more concerned about the extra 
workload they might be having. The reliability of this study was limited by the small cohort size (n=24) and 
short study period. The approach outlined in this study should be replicated with other MDCs to see if there is 
any shortcomings. In conclusion, the use of iPads is acceptable by PD patients and is feasible in a MDC given 
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that sufficient assistance is readily provided to patients, in helping them to use or to complete the iPad activity. 
 
 Lee Ventola C. Mobile Devices and Apps for Health Care Professionals: Uses and Benefits. P T. 2014; 39(5): 356-64. 
 Szende A and Williams A. Measuring Self-Reported Population Health: An International Perspective based on EQ-5D. EuroQol 
Group; 2004 [accessed 21 Nov 2015]. Available from: 
http://www.euroqol.org/fileadmin/user_upload/Documenten/PDF/Books/Measuring_Self-Reported_Population_Health_-
_An_International_Perspective_based_on_EQ-5D.pdf 
 Non-Motor Symptoms Questionnaire. Parkinson’s UK; 2015 [accessed 9 Nov 2015] Available from: 
http://www.parkinsons.org.uk/content/non-motor-symptoms-questionnaire. 
 
 
Evaluation of CHST11 and HES1 gene expression in endocrine resistant breast 
cancer 
Anisa Noorani, RA McClelland, A Bojkowski, LA Des Clayes and JMW Gee 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Breast cancers can express oestrogen receptor (ER+), accounting for 70%,1 while others are ER-. ER+ 
disease comprises luminal A and B sub-types. Anti-hormones are the most important therapy for all ER+ 
patients, but effectiveness is limited due to acquired resistance.2 11 new long-term endocrine-treated cell lines 
have been developed from luminal A (MCF7, T47D) and luminal B cells (BT474, MDA361) to investigate 
resistance. Affymetrix microarrays discovered up-regulated CHST11 and HES1 in some luminal A-derived 
lines. To investigate whether these genes might contribute to resistance, the aims of this study were to verify 
the Affymetrix profile in the MCF7-derived cells and extend study to other luminal A and  
B-derived models, to examine if there is any link with ER, and evaluate gene ontology and clinical profile.  
 
RT-PCR determined expression of CHST11, HES1 and ER in luminal A (MCF7, T47D) and luminal B (BT474, 
MDAMB361)-derived resistant models versus controls. KMplotter related gene expression level with clinical 
tamoxifen outcome using publicly-available datasets. Ontological information was obtained using PubMed and 
Genecard. 
 
CHST11 expression was induced only in MCF7-derived and T47D-derived resistant models. In contrast, HES1 
increased in luminal A and luminal B-derived resistant models. No relationship was found between induced 
expression and ER. Clinical profiling showed high intrinsic expression of CHST11 (luminal A) and HES1 
(luminal A and B) associated with shorter relapse-free survival in ER+ tamoxifen-treated patients. Ontological 
research showed increased CHST11 (involved in synthesis of chondroitin sulphate) and HES1 (effector of 
Notch signalling) play a role in cancer growth, progression3 or drug resistance.4 
 
These experimental and clinical data showed there might be a contribution for increased CHST11 in luminal 
A-derived resistance and for HES1 in all endocrine resistant states. Further studies to explore the role in driving 
resistance are warranted to determine whether their pathways have targeting potential. 
 
 Murray JI, West NR, Murphy LC and Hatson PH. Intratumoral inflammation and endocrine resistance in breast cancer. Endocr Relat 
Cancer 2015 Feb;22(1):R51-67. 
 Osborne CK and Schiff R. Mechansims of endocrine resistance in breast cancer. Annu Rev Med 2011;62:233-247. 
 Herman D, Leakey TI, Behrens A, Yao-Borengasser A, Cooney CA, Jousheghany F et al. CHST11 gene expression and DNA 
methylation in breast cancer. Int J Oncol 2015 Mar;46(3):1243-51. 
 Simoes BM, O’Brien SC, Eyre R, Silva A, Lu Y, Sarmiento Castro-A et al. Anti-estrogen resistance in human breast tumors is driven 
by JAG1-NOTCH4-dependent cancer stem cell activity. Cell Rep 2015 Sep;12(12):1968-77. 
 
 
Is there a role for a veterinary pharmacist in the management of dairy mastitis? 
William Northwood, CJ Allender and S Cockbill 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Dairy mastitis is inflammation of the mammary gland (udder tissue) in response to bacterial infection.1 Mastitis 
is the largest dairy health problem in the UK,2 causing reduced milk yield and quality.3 Veterinary pharmacists 
can support farmers treating mastitis, encouraging prudent use of antibiotics. This study aims to explore factors 
influencing dairy mastitis incidence, understand rationale behind antibiotic treatment and explore requirements 
for veterinary pharmacists to educate farmers. 
A semi-structured interview was undertaken with a representative sample of 18 dairy farmers. Qualitative 
questions looked at causative factors, diagnosis and treatments. Quantitative data for monthly mastitis cases 
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was collected and analysed using GraphPad Prism. A one-way ANOVA with Tukey’s post hoc test compared 
mastitis rates between farms. A t-test determined the significance of farm mastitis rates against the overall 
mean. Differences in individual farm mastitis rates were attributed to variations in farming practices. Ethics 
approval was obtained. 
Mastitis rates varied significantly between farms but no clear correlation was seen with farming practices. The 
quality of staff and harsh culling policies had major impacts on mastitis incidence. Standard Operating 
Procedures for the use of antibiotics were exhibited by 79% of farms. Furthermore, 21% of farmers weren’t 
aware of antibiotic resistance. Current treatments hadn’t been changed for over 24 months at 63% of farms, 
indicating emergence of resistant bacterial strains. One farm used a veterinary pharmacist and only 16% knew 
what one was.  
Veterinary pharmacists aren’t currently playing an active role in dairy mastitis. Limited advice means farmers 
adopt a ‘trial and error’ approach to reduce mastitis incidence. Antibiotics are routinely supplied to farmers with 
little instruction on appropriate usage protocols. Education is key to preventing emergence of resistant bacterial 
strains. There is clearly scope for a veterinary pharmacist to work alongside veterinarians in the management 
of dairy mastitis. 
 Agriculture and Horticulture Development Board. Mastitis in dairy cows; 2015 [Accessed: 24 Nov 2015]. Available at: 
http://dairy.ahdb.org.uk/technical-information/animal-health-welfare/mastitis/#.Vlg6667hAcg. 
 Roderick S, Short N, Hovi M. VEERU. Organic livestock production: animal health and welfare research priorities; 19th Sept 1996 
[Accessed: 24 Nov 2015]. Available at: http://www.veeru.reading.ac.uk/research/Animal%20Health.htm. 
 Blowey R, Edmondson P. Mastitis control in dairy herds, 2nd Ed. Oxford: CAB International; 2010.  
 
 
The relationship between endocytosis and wnt signaling in Alzheimer’s disease 
Katie E Oakes and RS Thomas 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Alzheimer’s disease (AD) an age-related, neurodegenerative disease has two hall mark pathological features, 
amyloid-β (Aβ) plaques and neurofibrillary tangles.1 The amyloid cascade hypothesis suggests that the buildup 
of Aβ is the pathological cause of AD. Aβ is formed from the processing of the amyloid precursor protein (APP) 
by β-and γ-secretase in early endosomes.2 Both endocytosis and Wnt signaling dysfunction have been 
observed in AD pathophysiology.2,3 This study examined clathrin-mediated-endocytosis (CME) and clathrin-
independent-endocytosis (CIE) in order to study the effects these have on the Wnt signaling pathway. 
 
siRNA targeting endocytic-related proteins, clathrin and PICALM (CME), and caveolin-1 (CIE) were transfected 
into neuroglioma cells. Culture media and siRNA targeting non-coding green fluorescent protein (GFP) were 
used as negative controls. Once sufficient endocytic-related protein knockdown was achieved, levels of key 
Wnt-related proteins, beta catenin (total and non-phosphorylated), GSK 3α, GSK 3β, TCF7L2 and LEF 1 were 
examined by Western blotting. All data were expressed relative to untreated control values after normalisation 
to GAPDH. 
 
Statistically significant knockdown of the CME and CIE related proteins was achieved. Levels of non-
phosphorylated beta catenin were statistically significantly increased following treatment with siRNA targeting 
clathrin. Levels of GSK 3β were significantly decreased following treatment with siRNA targeting caveolin-1. 
 
Previous studies have shown that silencing these endocytic-related proteins inhibits the relevant endocytic 
pathway. Inhibition of CME, specifically via clathrin, leads to an increase in non-phosphorylated beta catenin 
the key effector of the Wnt pathway and inhibition of CIE leads to a decrease of the Wnt inhibitory mediator 
GSK 3β which both imply an upregulation of the Wnt pathway.3 This suggests that endocytosis may suppress 
the Wnt pathway and potentially by endocytic internalization of receptors.4 However further studies are 
required to better understand this complex relationship and how exactly endocytosis mediates Wnt signaling.  
 
 De Ferrari GV, Inestrosa NC. Wnt signaling function in Alzheimer’s disease. Brain Research Reviews. 2000 August 2000;33:1–12. 
 Nixon RA. Endosome function and dysfunction in Alzheimer's disease and other neurodegenerative diseases. Neurobiology of 
Aging. 2005 March 2005;26(3):373–82. 
 Hoppler SP, Moon RT. Wnt Signaling in Development and Disease:Molecular Mechanisms and Biological Functions: Wiley-
Blackwell; 2014. 
 Gagliardi M, Piddini E, Vincent J. Endocytosis: A Positive or a Negative Influence on Wnt Signalling? Traffic. 2008;9(1):1-9. 
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Does copper ibuprofenate have potential to be a new topical treatment for arthritis? 
Jee Nie Ong and CM Heard 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Arthritis is a disease related to the inflammation of joints and there is no cure to date. However, non-steroidal 
anti-inflammatory drugs(NSAIDs) are given as first line treatment. Copper has long been associated with 
arthritis due to its anti-inflammatory properties and the synergistic activity of copper with drugs such as 
NSAIDs.1 Cu-NSAIDs has been synthesized and investigated2,3 but not investigated for topical delivery. This 
study aimed to: (i) determine the association constant(Ka) of ibuprofen and diclofenac metal ion complexes, 
(ii) determine whether topically applied copper ibuprofenate can deliver both ibuprofen and copper(II) 
simultaneously across the skin. 
The Benesi-Hildebrand (BH) equation was used to determine the Ka of metal-NSAIDs from UV 
spectrophotometry results. Copper ibuprofenate was prepared and an ethanolic solution formulated; equimolar 
ibuprofen in ethanol served as control. Porcine skin was prepared as native and tape-stripped membranes. In-
vitro permeation studies were carried out using Franz diffusion cells by dosing the skin for 6, 20 and 48 hours. 
The receptor phase was analysed using HPLC and UV spectrophotometry for ibuprofen and copper(II) 
permeation respectively. 
The Ka for Cu(II)-diclofenac and Cu(II)-ibuprofen were 26.46M-1 and 196.46M-1 respectively. Cu(II)-ibuprofen 
was prepared as copper ibuprofenate and used in skin permeation experiments. Ibuprofen and copper(II) 
permeation increased with time, slightly greater ibuprofen permeation was observed across tape-stripped skin 
compared to native, although p>0.05. Similar results found for copper(II) permeation across tape-stripped skin 
and native using copper ibuprofenate, except for at 6 hours. Ibuprofen control treated on native showed similar 
results as copper ibuprofenate treated on tape-stripped skin (p>0.05). 
This study showed that the association constant of metal-NSAID could be obtained using the BH equation. 
Topically applied copper ibuprofenate can deliver ibuprofen and copper(II) simultaneously across skin. Overall, 
the data support the further development of this complex as a potential new topical delivery system for arthritis. 
 Dimiza F, Perdih F, Tangoulis V, Turel I, Kessissoglou DP, Psomas G. Interaction of copper(II) with the non-steroidal anti-
inflammatory drugs naproxen and diclofenac: synthesis, structure, DNA- and albumin-binding. Journal of Inorganic Biochemistry 
2011;105:476-489.  
 Abuhijleh AL. Mononuclear and binuclear copper(II) complexes of the anti-inflammatory drug ibuprofen: synthesis. characterization, 
and catecholase-mimetic activity. Journal of Inorganic Biochemistry. 1994;55:255-262.  
 Weder JE, Dillon CT, Hambley TW, Kennedy BJ, Lay PA, Biffin JR et al. Copper complexes of non-steroidal anti-inflammatory 
drugs: an opportunity yet to be realized. Coordination Chemistry Reviews. 2002;232:95-126. 
 
 
Development and manufacture of high strength loperamide capsules 
Siamac Parker, A Hallam,1 A Sully,1 K Pothecary1 and JC Birchall 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff CF10 
3NB, and 1Saint Mary’s Pharmaceutical Unit, 20 Field Way, Cardiff CF14 4HY, Wales, UK 
This project was developed in response to Saint Mary’s Pharmaceutical Unit in Cardiff & Vale University Health 
Board receiving requests from clinicians for a high strength capsule formulation of loperamide. Commercially, 
the only loperamide capsule formulation available is a 2mg capsule, therefore, an 8mg capsule formulation 
was proposed. This high dose formulation will be used to treat stoma patients who are routinely prescribed 
large doses, and with fewer capsules to achieve the therapeutic dose, there will be improved patient 
convenience and compliance.  
 
Three excipients (lactose monohydrate 100M, maize starch and microcrystalline cellulose) were studied with 
loperamide hydrochloride for their flow, filling and mixing properties and three potential formulations were 
developed. Bulk powder was produced by mixing individually weighed ingredients in a pestle and mortar, 
followed by multiple inversions in a sealed plastic bag. Capsules were filled using a size 2 ProFill encapsulator 
at SMPU under Good Manufacturing Practice (GMP) conditions. Samples were taken from the bulk mix and 
manufactured capsules for analyses. A High Pressure Liquid Chromatography (HPLC) method was developed 
and validated for accurate loperamide quantification. 
 
The results showed that one of the three formulations, containing lactose monohydrate 100M and maize starch 
met the bulk mix and capsule content specification of ±5% of the expected loperamide content. 
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This lead formulation warrants scale up to a batch size of 1000 capsules, provided manufactured capsules 
meet the dissolution test specification. Further analyses are required to confirm the suitability of the 
manufacturing process to produce a homogenous bulk mix and uniformly filled capsules. Saint Mary’s 
Pharmaceutical Unit has confirmed that this formulation will be further developed as a new unlicensed product. 
 
 
Evaluation of patient’s inhaler technique in the Cardiff and Vale University Health 
Board 
Ekta Vipul Patel and WR Ford 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Observational studies have confirmed that one of the key reasons behind poor asthma and COPD control is 
due to poor inhaler technique,1 leading to minimal deposition of the medication in the smaller airways of the 
lungs, diminishing the therapeutic effect.2,3 Therefore, we conducted a study to identify and quantify patient’s 
inhaler technique through the use of a Vitalograph Aerosol Inhalation monitor device.4 
Patients were recruited from GP asthma/COPD clinics, hospitals as well as the Student’s Union of Cardiff 
University. After a short initial questionnaire, the patient’s inhaler technique using a dummy Dry powder inhaler 
and /or meter dose inhaler with or without a volumetric spacer was assessed and recorded using the Aim 
device. The quantitative data produced was analysed by chi-squared test, in which statistical significance was 
taken at P<0.05. The total number of study patients was n=61. 
The results of the study indicated that 83% of the patients failed the inhaler technique test whilst on a MDI. 
However patients were significantly better with volumetric spacers used with MDIs, in which only 9% of the 
patients attained a “fail” technique. The Technique for DPIs was significantly better than MDIs (P-value 
<0.0001) although 50% of DPI users fell under the suboptimal category as they failed to generate sufficient 
inspiratory airflow. Majority of the patients reported nurses as the last healthcare professional to give them 
guidance on inhaler technique (75%); however 78% of these patients attained a fail technique. 
The results clearly illustrate that patients had a poor inhaler technique in the Cardiff and Vale University Health 
Board particularly for MDIs. However with the spacer device they were significantly better. The study is 
conducted in a limited geographical area; therefore future work needs to be conducted through expansion to 
other areas in the UK through collaborations with other health boards. 
1. Chorão P, Pereira AM, Fonseca JA. Inhaler devices in asthma and COPD--an assessment of inhaler technique and patient 
preferences. Respir Med. 2014 Jul;108(7):968-75. 
2. Hesselink AE , Penninx BW, Wijnhoven HA, Kriegsman DM, van Eijk JT. Determinants of an incorrect inhalation technique in 
patients with asthma or COPD. Scand J Prim Health Care. 2001 Dec;19(4):255-60. 
3. M. Molimard, C. Raherison, S. Lignot, F. Depont, A. Abouelfath, N. Moore. Assessment of handling of inhaler devices in real life: an 
observational study in 3811 patients in primary care. J Aerosol Med, 2003 Sep;16(3):249-54. 
4. Vitolograph. Vitolograph Aim the effective training on dry powder and meter dose inhaler; 2011-2015 [accessed 9 Dec 2015]. 
Available from: https://vitalograph.co.uk/products/inhaler-training/aim. 
 
 
The publics’ opinion on pharmacists having access to patients’ hospital discharge 
advice letters 
Jay Patel, ML Hughes, C Way1 and KL Hodson 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff CF10 
3NB, Wales, UK and 1NHS Informatics Services, Cardiff, UK 
Prior to patients being discharged from hospital, a discharge advice letter (DAL) is produced stating the reason 
for admission, diagnosis, medication changes and follow up instructions.1 A copy is sent to the patients’ GP 
following discharge and a summary is provided to the patient. It is not sent to the patients’ regular community 
pharmacy. The aim of this research project was to gather the publics’ opinion on community pharmacists 
having a copy of the patients’ DALs. It investigated what information they were happy to share and by what 
method. The project was conducted as a group across Wales in which each member of the group (n=4) was 
assigned a specific area. This particular project focused on Ewloe, Flintshire.  
 
A pre-designed piloted questionnaire was used to gather the publics’ opinion.2 A total of 893 questionnaires 
were sent out to Ewloe. Questionnaires, cover letters and pre-paid returned envelopes were sent out on 2nd 
November and a two-week deadline was given. Returned questionnaires were inputted and analysed using 
SPSS version 23.  
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A total of 118 usable questionnaires were returned, giving a response rate of 13.3%. The vast majority of the 
respondents were happy to share their hospital DAL with their community pharmacy. Almost 65% of the 
respondents felt that it would be useful for the pharmacist to receive a copy of their DAL. ‘Allergies’ was the 
most preferred information respondents were happy to share with around 30% either ‘agreeing’ or ‘strongly 
agreeing.’ The method respondents preferred to transfer the information could not be clearly identified. 
 
All the group findings now need to be combined together to see the overall trend throughout Wales. This will 
help to decide whether or not community pharmacists should have access to patients’ DALs. As this project 
was conducted in Wales, no generalisation can be made across the UK. 
 
 Scottish Intercollegiate Guidline Network (SIGN). The SIGN discharge document. 2012. [Accessed: 16th October 2015] Available at: 
http://www.sign.ac.uk/pdf/digh128.pdf 
 Wirt, E. Should Patient’s Discharge Advice Letter (DALs) be sent to Community Pharmacists; The views of the Public in Wales – 
Development and Piloting of the Questionnarie [MSc/MA Dissertation’. Cardiff; Cardiff University; 2015 
 
 
Investigating the role of ZIP7 phosphorylation in breast cancer: the importance of 
S275 and S276 
Elizabeth Pook and KM Taylor 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
ZIP7 is a zinc transporter found on the endoplasmic reticulum membrane,1 known to be upregulated in 
tamoxifen resistant breast cancer cells,2 responsible for the release of zinc from intracellular stores as a “zinc 
wave”. ZIP7 mediated zinc release activates multiple downstream pathways via protein tyrosine phosphatase 
inhibition which leads to processes such as cell proliferation and migration involved in cancer growth.3 Previous 
research has found that ZIP7 activation is dependent on phosphorylation of the channel by CK2 at two specific 
serine residues, S275 and S276.4 This study looked at the differential importance of the individual residues for 
ZIP7 phosphorylation and activation of downstream pathways involving AKT and GSK-3ß. 
Cells transfected with; wild-type ZIP7 (S275/S276), S275A/S276A (null-mutant), S275D/S276A (active S275 
residue) or S275A/S276D (active S276 residue) were treated with zinc for 0, 2, 5, 10, 15 or 20 minutes. 
Samples were probed with pZIP7, pAKT and pGSK-3ß antibodies by Western Blot Analysis.  
The results confirmed previous findings that AKT and GSK-3ß are phosphorylated downstream of ZIP7 
mediated zinc release.4 Data suggests that GSK-3ß is phosphorylated directly by zinc. ZIP7 phosphorylation 
is possible with only one functioning residue, however downstream activation of AKT is decreased in 
S275D/S276A and S275A/S276D mutants compared to wild-type, suggesting both residues must be 
phosphorylated to activate AKT. Results suggest that residue S276 is not required for, and may interfere with, 
downstream GSK-3ß inhibition, suggesting that phosphorylation at S275 is responsible for downstream GSK-
3ß inhibition.   
Lack of statistical significance means no solid conclusion can be drawn as to whether S275 and S276 residues 
have different impacts on ZIP7 phosphorylation and AKT activation. However, if as the results suggest, S275 
is more significant for GSK-3ß inhibition downstream of ZIP7, this would indicate a more specific biomarker or 
possible therapeutic target with regards to ZIP7 mediated upregulation of certain cancer pathways.  
 Taylor KM, Kille P, Hogstrand C. Protein kinase CK2 opens the gate for zinc signaling. Cell Cycle. 2012;11(10):1863–4 
 Taylor KM, Vichova P, Jordan N, Hiscox S, Hendley R, Nicholson RI. ZIP7-mediated intracellular zinc transport contributes to 
aberrant growth factor signaling in antihormone-resistant breast cancer cells. Endocrinology. 2008;149(10):4912–20 
 Haase H, Maret W. Intracellular zinc fluctuations modulate protein tyrosine phosphatase activity in insulin/insulin-like growth factor-1 
signaling. Exp Cell Res. 2003;291(2):289–98 
 Taylor KM, Hiscox S, Nicholson RI, Hogstrand C, Kille P. Protein kinase CK2 triggers cytosolic zinc signaling pathways by 
phosphorylation of zinc channel ZIP7. Sci Signal. 2012 Feb 7;5(210):ra11 
 
 
Can Welsh plants yield potential compounds for the treatment of glioma? 
Bethany Powell and AW White 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
The aim of the study was looking at whether plants cultivated in Wales are able to provide new treatments for 
glioma. Techniques used for purification were ethyl acetate extraction and chromatographic techniques. These 
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included preparative TLC and size exclusion column chromatography using sephadex LH-20. Results were 
analysed using a combination of analytical TLC and mass spectrometry. LLAMA (Lead likeness and molecular 
analysis) was used to investigate the modification of isolated compounds and assess how ‘drug-like’ its 
derivatives can be. From that, a semi-synthesis was run in an attempt create an isopropyl derivative. 
 
This study found reasonable quantities of lead compounds in both plant extracts. High levels of plastic 
impurities were discovered in the samples, which was due to the storage of the extracts. The mass 
spectrometry analysis identified known compounds alongside a whole range of unidentified masses. These 
could well be unidentified compounds that may have therapeutic promise. The semi-synthesis was 
unsuccessful but this was probably due to the fact that only one attempt was made.  
 
The plants studied have shown good potential to yield lead compounds for future research and this should be 
continued to be explored. 
 
 
Evaluation of medicines administration and errors associated with the use of 
antidepressants in care homes 
Resego Rabana and M Gumbleton 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
There is a high prevalence of antidepressant use by residents in care homes, with the likelihood that their use 
is associated with significant medication administration errors.1,2 The aim of this study was to determine the 
extent of antidepressant use, and to identify the nature and frequency of associated medication errors incurred 
as a result of prescriber and administration errors in the care homes. 
This was a retrospective study of residents’ electronic medication administration records (eMAR) from care 
homes located in South Wales. The findings reported represent only a 3-month period. The eMAR database 
was investigated against error types that had been decided through a pilot study and group consensus prior 
to conducting the full analysis. These errors types, either made by the prescriber or the care home, were; 
‘Dose’, ‘Drug Choice’, ‘Duration’ and ‘Frequency’ and were further divided into sub-categories. Results were 
tabulated or graphed accordingly and analysed statistically. 
A total of 84 residents and 6201 administrations from 11 care homes had been analysed which resulted in 
28.7% of residents on different antidepressants. There was a total of 4 out of 84 Prescriber Errors; 3 Dose and 
1 Drug Choice, which resulted in an incident rate of 4.76%. The Care Home Errors were a total of 1761 out of 
6201 with an incident rate of 28.4%. 77% of the Care Home Errors were due to Frequency Errors and 23% 
due to Dose Errors. The Pearson Correlation statistical test revealed a positive correlation between the Total 
number of Administrations per Care Home and the Total Number of Antidepressant Errors per Care Home.3 
The study reveals that medication management is still a challenge, more so for care homes.2,4 Further research 
is needed to determine the root cause of these errors in care homes and ensure a more effective system is 
adopted.  
 Nishtala P, McLachlan A, Bell J, Chen T. Determinants of antidepressant medication prescribing in elderly residents of aged care 
homes in Australia: A retrospective study. The American Journal of Geriatric Pharmacotherapy. 2009;7(4):210-219 
 Harris T, Carey I, Shah S, DeWilde S, Cook D. Antidepressant Prescribing in Older Primary Care Patients in Community and Care 
Home Settings in England and Wales. Journal of the American Medical Directors Association. 2012;13(1):41-47 
 Statistics.laerd.com. Pearson Product-Moment Correlation - When you should run this test, the range of values the coefficient can 
take and how to measure strength of association; 2016 [Accessed: 25 November 2015]. Available from: 
https://statistics.laerd.com/statistical-guides/pearson-correlation-coefficient-statistical-guide.php 
 Tariq A, Georgiou A, Westbrook J. Medication errors in residential aged care facilities: A distributed cognition analysis of the 
information exchange process. International Journal of Medical Informatics. 2013;82(5):299-312 
 
 
The evaluation of anti-infective medicines management and associated errors in 
Care Homes 
Helena Sakota and M Gumbleton 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Care Homes accommodate some of the most vulnerable residents that often have multiple health problems, 
putting them at high risk of medication errors.1 The aim of the present study is to identify the prevalence and 
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types of prescribing and administration errors relating to anti-infective agents in Care Homes and to quantify 
the extent of anti-infective prescribing.  
A retrospective study was conducted in 12 Care Homes in South Wales over an eight month period (Feb-Oct). 
Anonymised real-time data was collected from an electronic medicines management system. A total of 142 
residents on anti-infectives were identified and 9499 administrations were analysed against pre-defined 
medication error categories. These errors were broadly classified into Care Home Administration errors and 
Prescribing errors. Within both categories, a set of sub-categories were further identified. The type and 
frequency of medication errors were recorded in Excel and selected data was transferred into SPSS for further 
analysis. 
A total of 2247 medication errors were recorded for the 142 residents; 79.6% of residents were exposed to at 
least one error. The most frequent administration error types were ‘duration’ errors (44.5%), followed by 
‘omission’ errors (38.9%). Similarly the most common prescribing error type was ‘duration’ errors (74.3%) for 
a shortened period of time (65.7%). Out of 329 residents, 142 (43.16%) were prescribed one or more anti-
infective agents during the eight-month sampling period. The most frequently prescribed was Trimethoprim, 
which accounted for nearly one quarter (24.6%) of all anti-infective prescriptions. 
The evaluation of the management of anti-infectives in Care Homes in South Wales reveals that the incidence 
of administration and prescribing errors is high. Future work should include a clinical impact assessment to 
determine the severity of these errors and root cause analysis to understand why these errors are occurring 
to aid in the development of preventative strategies.  
 Barber ND, Alldred DP, Raynor DK, Dickson R, Garfield S, Jesson B et al. Care Homes’ Use of Medicines Study: Prevalence, 
Causes and Potential Harm of Medication Errors in Care Homes for Older People. Qual Saf Health Care. 2009; 18:341-346  
 
 
Formulation factors affecting the precipitation of selenium in parenteral nutrition 
admixtures 
Daniel Salmon and AG Cosslett  
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Selenium is a trace element used in parenteral nutrition admixtures. Selenium acts as a component of 
glutathione peroxidase which is an important antioxidant.1 Little is known about the stability of selenium in 
parenteral nutrition other than that ascorbic acid can act as a reducing agent, reducing it to elemental selenium, 
this effect being henced by copper.2 Due to their buffering action amino acids can prevent this reduction 
suggesting that pH plays a role in the stability of selenium.3 
31 batches of test admixtures were prepared, containing amino acids, glucose at 20 and 70%, ascorbic acid 
and copper, whilst some were buffered to pH 3, 7 and 9. All were observed and tested at time points 0, 24, 48 
and 72 hours. There were three samples in each batch. Controls were made for each batch with the 
components being tested but without the selenium to determine if selenium was the cause of any precipitation 
found in the study. All admixtures were prepared aseptically in a laminar flow unit to minimise any 
contamination. Visual inspection using fibre optic lights was used to determine if any precipitation was present 
and the extent. A Hach turbidimeter was used to give an accurate value of turbidity, whilst an Orion pH meter 
was used to record the pH of the admixtures. 
No visible signs of precipitation were observed in any of the test batches. All test batches containing selenium 
with ascorbic acid and copper, one sample from the batch of selenium with ascorbic acid at acidic pH and all 
samples from the batch of selenium with ascorbic acid at neutral pH had a change in turbidity >0.5 suggesting 
possible precipitation was undergoing, however there was also a >0.5 change in NTU in the control batches 
suggesting that this change wasn’t necessarily due to the selenium. 
The results showed that selenium is generally stable when mixed with a wide range of range of parenteral 
nutrition components and stored for a period of three days. 
 Nichoalds GE. Selenium.In: TG Baumgartner. Clinical Guide to Parenteral Micronutrition. 2nd ed. Lyphomed; 1991:323-341. 
 Postaire E, Le Hoang MD, Anglade P, Brion F, Navarro J, Prognon P and Pradeau D. Stability and behaviour of selenium in total 
parenteral nutrition solutions. International Journal of Pharmaceutics. 1989; 55(2-3) 99-103 
 Ganther H, Kraus R. Chemical stability of selenious acid in total parenteral nutrition solutions containing ascorbic acid. Journal of 
Parenteral and Enteral Nutrition. 1989; 13(2):185-188. 
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An evaluation of the management of dementia & Parkinson’s disease medication in 
care homes 
Karndeep Saran and M Gumbleton 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
There is evidence to suggest that medicines management within care homes is a problem.1 This study aims to 
evaluate the prescribing and administration of dementia and Parkinson’s Disease medication in a sample of 
care homes in Wales. 
A literature review was conducted to find clinical guidance. Error categories were defined broadly as either 
prescribing or care home errors and then further subcategorised. The data to be analysed was then collected 
from an electronic medicines management system. Prescribing rates of Dementia and Parkinson’s Disease 
medication were extracted and all 6052 administrations were analysed individually to identify and record both 
prescribing and care home errors. SPSS was used to apply the Pearson correlation co-efficient test to identify 
if there was a correlation between the total administrations for all drugs (per care home) and the total care 
home errors for Dementia and Parkinson’s Disease medication (per care home). 
 
47 of 52 patients encountered errors and 31.3% of administrations had an error. In terms of prescribing, there 
were only dosing errors, which affected 7 patients. In care home errors, dose and frequency errors occurred. 
Frequency attendant errors, where the drug was given over 2 hours early or late, were most prevalent and 
affected 17.2% of administrations. On average, for every 4 administrations there was a care home error. A 
significant positive relationship existed between total administrations and the total Dementia and Parkinson’s 
Disease errors in a care home, however caution has to be taken with this as there was an outlier affecting the 
results. 
A high number of care home errors indicate that medicines management in care homes is challenging. Further 
work is needed to undertake a root cause analysis to establish why these errors are occurring, how they can 
be resolved and to ensure that patient safety is not being compromised. 
 Alldred DP, Barber N, Buckle P, Carpenter J, Dickinson R, Franklin BD et al. Care Home Use of Medicines Study (CHUMS): 
Medication errors in nursing & residential care homes ‐ prevalence, consequences, causes and solutions. BMJ Qual Saf. 
2009;18:341-346 
 
 
Depression in Lewy body diseases 
Chandni Shah and RS Thomas 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Parkinson’s disease dementia (PDD), Lewy body dementia (LBD) and Parkinson’s disease (PD) are all classed 
as Lewy body diseases and are associated with both motor and non-motor symptoms. The four cardinal motor 
symptoms include bradykinesia, rigidity, postural instability and a resting tremor.1,2 Non-motor symptoms can 
include dementia and depression, which can significantly reduce the quality of life in these patients.3 
Polypharmacy (use of four or more drugs simultaneously) can be an indication of comorbidities. It is linked to 
chronic diseases such as PDD, LBD and PD and could be a cause of depression in these patients.4 The aim 
of this research is to determine whether there is a link between polypharmacy, depression and the three Lewy 
body diseases. 
 
A retrospective study was carried out using “The Electronic Clinical Network Parkinson Disease and Related 
Disorders Database”, which contained information on PDD, LBD and PD patients. Demographics and 
incidence rates were compared. Depression, polypharmacy and Levodopa equivalence (LED) (a measure of 
drug equivalence) were all studied and compared between the diseases and related to their depression 
classification. 
Out of a total of 1033 patients, 71.64% had PD and 28.36% had either PDD or LBD, with a higher proportion 
of males in each disease. Levels of polypharmacy were significantly higher in patients with PDD than PD. 
Within PDD and PD levels were higher amongst patients taking antidepressants than in depressed patients 
not taking antidepressants or non-depressed patients. Significant differences were seen in LED between PDD, 
LBD and PD patients. Within PD, patients who showed signs of depression (whether on antidepressants or 
not) had a significantly higher LED compared to patients who were not depressed. 
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There is a strong relationship LED and depression in PD patients. However polypharmacy is linked closely to 
whether a patient is being treated with antidepressants or not.  
 
 Jankovic J. Parkinson’s disease: clinical features and diagnosis. Journal of Neurology, Neurosurgery and Psychiatry. 2008 Apr; 
79(4): 368-76. 
 Agid Y. Parkinson’s disease-Pathophysiology. Lancet.1991 Jun 1; 337(8753): 1321-4.  
 Poewe W. Non-motor symptoms in Parkinson’s disease. European Journal of Neurology. 2008 Apr; 15:14-20. 
 Larsen PD, Martin JL. Polypharmacy and elderly patients. Aorn J. 1999 Mar; 69(3):619-22.25.27-8. 
 
 
Design and synthesis of novel mycobacterial CYP121 inhibitors as potential 
tuberculosis inhibitors 
Darren Smith and C Simons 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Tuberculosis (TB) is an infectious, bacterial disease caused by Mycobacterium tuberculosis. Despite an 
estimated 47% mortality reduction (1990-2014), TB caused 1.5 million deaths in 2014, partly due to the 
emergence of multi-/extremely-drug resistant (M/XDR) bacterial strains.1 The currently recommended 
treatments, isoniazid, rifampicin, ethambutol and pyrazinamide, present other issues relating to toxicity, drug-
drug interactions and duration of treatment.2 Considering this, there is an increasing need to develop either 
novel TB agents or to repurpose existing agents. The bacterium’s genome encodes for 20 cytochrome-P450 
(CYP) enzymes, one in particular, CYP121, is essential and specific.3 The aim of this project was to design 
and synthesise at least one compound that could inhibit this intriguing target and become a TB therapeutic of 
the future. 
Molecular Operating Environment software was used initially to understand how cYY (the natural substrate), 
fluconazole (a high affinity ligand) and a series of four compounds (F, G, H and I) bind within the CYP121 
active site. Compounds F and G were synthesised via a four step reaction scheme starting with 3-
acetylpyridine (compounds H and I were not made successfully due to a failed chlorination step). 
 
Theoretical computer models showed that compounds G, H and I could form a direct haem interaction in the 
CYP121 active site, and suggested that compound F would bind indirectly via water (similarly to cYY [3]). Phe-
168, Gln-385 and Arg-386 were identified as key binding residues. 1H/13C-NMR were used to confirm the 
identity of compounds F and G, and despite low recrystallised yields (46% and 25% respectively) both 
compounds passed microanalysis.  
If activity is observed in further assays against CYP121 and M. tuberculosis, the favourable drug-like properties 
(according to Lipinski’s ‘Rule of Five’),4 the relative ease of synthesis and the potentially novel mechanism of 
action suggests great potential for compounds F and G. 
 World Health Organisation. Tuberculosis. 2015 [accessed 15 Oct 2015]. Available from: 
http://www.who.int/mediacentre/factsheets/fs104/en/  
 Zumla A, Nahid P, Cole ST. Advances in the development of new tuberculosis drugs and treatment regimens. Nat Rev Drug Discov. 
2013;12:388-404. 
 Belin P, Le Du MH, Fielding A, Lequin O, Jacquet M, Charbonnier JB, et al. Identification and structural basis of the reaction 
catalyzed by CYP121, an essential cytochrome P450 in Mycobacterium tuberculsosis. Proc Natl Acad Sci U S A. 2009;106:7426-31 
 Lipinski C, Lombardo F, Dominy B, Feeney P. Experimental and computational approaches to estimate solubility and permeability in 
drug discovery and development settings. Adv Drug Del Rev. 1997;23:3-26 
 
 
The public’s opinion on community pharmacists (chemists) having access to 
patients’ hospital discharge information 
Janeece Taj, KL Hodson, C Way1 and and ML Hughes 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK and 1NHS Informatics Services, Cardiff, UK. 
A Discharge Advice Letter (DAL) from hospital contains information on medication changes and diagnoses. 
This is currently sent from hospitals to a patient’s GP surgery, but not community pharmacies, after discharge. 
Research shows that 85% of the British public said that they wanted any healthcare professional treating them 
to have secure electronic access to key data from the GP record.1 Currently, ten community pharmacies are 
being piloted in Wales where they receive a summary of the DAL electronically, however this is limited to 
information about patients’ medication. The aim of this study was to quantify the opinions of the public of Wales 
on community pharmacists having access to patients’ full hospital DALs. 
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Approval was granted by the Cardiff School of Pharmacy and Pharmaceutical Sciences Ethics Committee. A 
questionnaire was designed previously by an MPharm student and 4000 questionnaires were distributed (with 
covering letter and freepost envelope) across Wales to a purposive sample of residents in five different local 
authorities.  
 
This dissertation focuses on Cardiff where a 10.3% (n=134) response rate was achieved. Although results 
cannot be generalised due to the low response rate, majority of respondents agreed to share information 
including their time spent at hospital and other clinical and personal information with their community 
pharmacists providing information was kept confidential. Many respondents felt that verbal consent alone was 
not enough and that both verbal and written consent should be given. 
 
With access to these full DALs, pharmacists could help improve overall patient care and safety. Findings from 
the full scale study will be passed on to NHS Wales Information Service to help them make a decision on 
whether the full hospital DAL can be accessed by community pharmacists.  
 
1. Emishealth. 2016. Public support wider access to GP record. [Online]. Available at: https://www.emishealth.com/news-and-
events/news/public-support-wider-access-to-gp-record/ [Accessed: 6 January 2016]. 
 
 
Synthesis of purine-based inhibitors of αB-crystallin as potential therapy against 
triple-negative breast cancer 
Wei Ting Tan, N Fosu-Mensah and AD Westwell 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Triple-negative breast cancer (TNBC) has a particularly inferior prognosis and is the only 
immunohistochemistry subtype lacking targeted therapy.1,2 Protein-protein interaction (PPI) between alpha-B 
crystalline (CRYAB) and vascular endothelial growth factor (VEGF) has evolved as a promising target for 
TNBC. Targeting this pathway bears significant potential in suppressing tumour invasion and sensitising 
tumours to anti-cancer treatments without causing the side effects associated with affecting CRYAB 
expression.3 Through virtual screening, a purine-based lead compound was identified and optimised to give a 
target compound scaffold. The aim of this study was to prepare a series of target compound analogues for 
biological evaluation against TNBC cell lines. Other objective includes evaluating the compounds’ potential in 
binding to CRYAB-VEGF interaction hotspot using molecular docking.  
 
Synthesis of target compounds was first attempted through a four-step procedure starting from 4,5-diamino-2-
mercaptopyrimidin-6-ol. It involved Traube synthesis, desulphurisation at position-2, dithiation at position-6 
and 8, and subsequent alkylation at the 6-thio group. A second synthetic route consisted of three steps. The 
first two steps were achieved via alkylation of 6-mercaptopurine at the 6-thio group, followed by bromination 
at position-8. In both routes, purification was performed via recrystallisation and/or column chromatography 
and characterisation of products was achieved using NMR. Molecular docking was performed by docking the 
ligands into a pocket of human CRYAB crystal structure containing the hotspot. 
 
The first synthetic route was unsuccessful. The second synthetic route successfully afforded a number of 
intermediates, which when undergoing nucleophilic substitution at position-8, would give a series of desired 
target compounds. Results from docking studies were encouraging, with three target compounds 
demonstrated better docking scores than the lead compound. 
 
Upon successful completion of the synthesis of target compounds via the final plausible step provided, all 
target compounds will be tested against TNBC cell lines and the anticipated results will reveal their therapeutic 
potential.  
 
 Engebraaten O, Vollan HK, Børresen-Dale AL. Triple-negative breast cancer and the need for new therapeutic targets. The 
American Journal of Pathology. 2013;183(4):1064-74. 
 Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA et al. Triple-negative breast cancer: clinical features and 
patterns of recurrence. Clinical Cancer Research. 2007;13(15):4429-34. 
 Chen Z, Ruan Q, Han S, Xi L, Jiang W, Jiang H et al. Discovery of structure-based small molecular inhibitor of αB-crystallin against 
basal-like/triple-negative breast cancer development in vitro and in vivo. Breast Cancer Research and Treatment. 2014;145(1):45-
59. 
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The impact of using the Welsh language in community pharmacy services: the 
pharmacists’ views 
Emma Todd, E Jones, W Davies and L Doyle 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK   
Communicating with patients in a way that they understand is a key skill for pharmacists.1 Wales is a bilingual 
country and patients have the right to public services in Welsh. Welsh language initiatives have been put in 
place in order to strengthen Welsh language services in healthcare. Research involving patients’ views on the 
Welsh language in pharmacy has provided evidence to show that being able to communicate in their first 
language does make a difference to them as they feel more at ease and are therefore more likely to open up 
about their healthcare and medication.2 
 
Quantitative data was required for the study. Data was collected through the use of self-complete postal 
questionnaires. Questionnaires were sent to community pharmacies in areas with over 40% Welsh speakers: 
Carmarthenshire, Ceredigion, Gwynedd and Anglesey. The questionnaire was adapted from previous 
research investigating patient’s views to now investigate pharmacists’ views on the use of the Welsh language. 
Results show that pharmacists believe that language choice is important and makes a difference to patients 
but does not always affect the quality of care received. When referring to the Welsh language specifically 
results vary as the majority of Welsh speakers are fluent in English. Patients will not ask for their services in 
Welsh and Welsh speaking staff aren’t well advertised. Attitudes towards Welsh language initiatives were 
positive. 
 
Some pharmacists consider Language choice to be less important when referring to Welsh, however this 
conflicts with views of patients who feel that it still makes a difference as they are able to communicate more 
effectively in Welsh.3 The results highlight the importance of offering services in Welsh without patients having 
to ask or rely on prior knowledge as to whether or not staff can speak Welsh. Positive attitudes towards Welsh 
language initiatives could suggest high levels of participation in schemes. 
 
 General Pharmaceutical Council. Standards of conduct, ethis and performance; 2012 [accessed 14 Nov 2015]. Available at: 
https://www.pharmacyregulation.org/sites/default/files/standards_of_conduct_ethics_and_performance_july_2014.pdf  
 Hughes, M. L., Brooks, C., Cocker, C., John, D. and Jones, A. The role of the Welsh language in community pharmacy service 
provision in Wales. Pharmacy Practice Research Trust. 2008. [accessed 26 Oct 2015]. Available at: 
https://www.researchgate.net/publication/228778308_The_role_of_the_Welsh_language_in_community_pharmacy_service_provisi
on_in_Wales 
 Hughes, M. L., John, D. N, Jones, A. T., Jones, E.H. and Wilkins, M.L. Language issues in the community pharmacy: A perspective 
from Wales, International Journal of Pharmacy Practice, 2009. 17(3), pp. 157-163. 
 
 
An analysis and evaluation of research regarding hospital patient medicines-related 
experience in Wales 
Nia Thomas and RS Dewdney 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK  
Patient satisfaction is used as an indicator of health service quality.1 The measurement of patient satisfaction 
and experience in hospitals is essential to improve services and since reports have identified patient care as 
unsatisfactory2 professional pharmacy standards have increased emphasis on patient-centred care and patient 
involvement in decisions about their care.3,4 This study collated results from a satisfaction survey conducted 
in Wales in autumn 2014 by previous MPharm students and compared the results to a similar study from spring 
2014. A sample of pharmacists was interviewed to gather opinions on the provisional findings of the studies, 
information gathering from patients and how to improve transition of care. 
 
Data collation and analysis was conducted within SPSS. Chi-squared, Kruskal-Wallis and Mann-Whitney U 
statistical tests were used to identify whether demographics or aspects of patients’ hospital experience affected 
satisfaction. Interviews were transcribed and responses were categorised and analysed using a content theme 
analysis. 
 
In the autumn 2014 study satisfaction was unaffected by demographics, day of discharge, Health Board or 
changes to medication. Satisfaction was higher in those taking fewer medications, who discussed medication 
with a doctor, who experienced no problems, who received verbal and written information and information 
about how their medication works and its potential problems. Overall satisfaction was over 80% in both 2014 
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studies and although results were similar, differences in the questionnaires used make them incomparable. 
Pharmacist interviews indicated that the best way to gather patient opinions is by a postal questionnaire 
(although it was highlighted that the questionnaires used could be enhanced). Transitional care between 
hospital and community pharmacies was believed to be poor. 
 
Patient satisfaction in Wales is high and should be maintained. Further study with a redesigned questionnaire 
is recommended. Current transfer of information between care settings needs to be improved. 
 
 Pascoe, G. 1983. Patient satisfaction in primary health care: a literature review and analysis. Evaluation and Program Planning 6(3-
4), pp. 185-210. 
 Andrews, J. and Butler, M. 2014. Trusted to Care An Independent Review of the Princess of Wales Hospital and Neath Port Talbot 
Hospital at Abertawe Bro Morgannwg University Health Board [Online] Available at: 
http://gov.wales/docs/dhss/publications/140512trustedtocareen.pdf [Accessed 10 January 2016]. 
 Picton, C. 2014. Professional Standards for Hospital Pharmacy Services [Online]. Available at: http://www.rpharms.com/support-
pdfs/rps---professional-standards-for-hospital-pharmacy.pdf [accessed 10 January 2016]. 
 NHS Wales. 2010. Doing Well, Doing Better [Online]. Available at: 
http://www.wales.nhs.uk/sites3/Documents/919/ENGLISH%20WEB%20VERSION.pdf [accessed 11 January 2016]. 
 
 
Bacteriophage as a novel antimicrobial agent for dermal Staphylococcus aureus 
infections 
Jonathan Tugbobo and J-Y Maillard 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
 
Bacteriophages can be use as antibiotic substitutes in the treatment of drug resistant bacteria. Bacteriophage 
have demonstrated efficacy in the treatment of Staphylococcus aureus infections in animal wounds1 and 
clinical trials of patients with antibiotic resistance infections.2 This study aims to determine the comparable 
efficacy of bacteriophages against antibiotics and skin disinfectants used in methicillin resistant 
Staphylococcus aureus (MRSA) decolonisation protocols.3 An ex vivo skin model 4 was used to compare the 
bactericidal properties of a Staphylococcus bacteriophage, the antibiotic mupirocin and chlorhexidine 
gluconate skin cleanser. 
 
A traditional streak assay was used to determine the efficacy of bacteriophage Card1 against a range of S. 
aureus clinical isolates The levels of bacteriophage mediated lysis against each strain was scored to determine 
the host range activity. An ex vivo assay using diffusion cells was used to determine the ex-vivo efficacy of the 
bacteriophage. Pig skin inoculated with S. aureus was treated with Card1, mupirocin, or chlorhexidine 
digluconate for 24 hours. Surviving bacteria were enumerated to compare the reduction of viable bacteria 
between antimicrobial interventions. 
 
Card1 demonstrated broad spectrum activity against a range of S. aureus isolates. There was no significant 
difference in the reduction of bacteria between the bacteriophage Card1, mupirocin, and chlorhexidine 
digluconate using the ex-vivo test.  
 
The bacteriophage demonstrated equal efficacy to antimicrobials currently used in MRSA decolonisation 
protocols.3 Based on an ex vivo skin model,4 bacteriophage therapy has comparable bactericidal antimicrobial 
efficacy to conventional decolonisation agents in the treatment of S. aureus infections of the skin. Further 
optimisation of bacteriophage using multi-phage cocktails with wide host range activity would enhance 
bactericidal activity further. The implementation of bacteriophage therapy potentially widens the spectrum of 
antimicrobial agents alongside conventional decolonisation agents for resistant S. aureus infections.  
 
1. Seth, A.K., Geringer, M.R., Nguyen, K.T., Agnew, S.P., Dumanian, Z., Galiano, R.D., Leung, K.P., Mustoe, T.A. and Hong, S.J. 
2013. Bacteriophage therapy for Staphylococcus aureus biofilm-infected wounds: a new approach to chronic wound care. Plastic 
and reconstructive surgery 131(2), pp. 225–34. 
2. Slopek, S., Weber-Dabrowska, B., Dabrowski, M. and Kucharewicz-Krukowska, A. 1987. Results of bacteriophage treatment of 
suppurative bacterial infections in the years 1981-1986. Archivum immunologiae et therapiae experimentalis 35(5), pp. 569–83.  
3. McConeghy, K.W., Mikolich, D.J. and LaPlante, K.L. 2009. Agents for the decolonization of methicillin-resistant Staphylococcus 
aureus. Pharmacotherapy 29(3), pp. 263–80.  
4. Messager, S., Goddard, P.A., Dettmar, P.W. and Maillard, J.Y. 2001. Determination of the antibacterial efficacy of several 
antiseptics tested on skin by an ‘ex-vivo’ test. Journal of medical microbiology 50(3), pp. 284–92.  
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Investigating if patient training could influence the force people would use to apply 
a dummy microneedle patch 
Dhiren Ullal, DN John, JC Birchall and SA Coulman 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
First conceived in 1976,1 microneedles are needles up to 1mm in length that are designed to breach the skin 
barrier. Microneedles overcome the drawbacks posed by conventional injections through painless delivery of 
drugs with a low risk of infection.2-4 Microneedle patches are being designed which require patients to manually 
apply a downward pressure to the patch to facilitate microneedle insertion into the skin. This study investigates 
whether patient training affects the forces used to apply a dummy microneedle patch and the short-term 
longevity of training effects. 
 
50 subjects, aged 18-24 years old, were recruited through convenience sampling. Subjects were asked to 
apply what they perceived to be a suitable downward force to ‘microneedle patches’ to enable microneedle 
penetration (intuitive force). This force was recorded to either themselves or to another person, on both the 
forearm and deltoid. Subjects were then trained and asked to re-apply the force (trained force). Training 
consisted of counselling about microneedle application and the opportunity to practice application using a skin 
mimic. A questionnaire gathered the subjects’ views towards the training. A follow up was carried out after 1-
2 weeks to evaluate any changes in the application forces. 
 
There was an overall reduction in the mean application forces and standard deviation after training, on both 
the forearm and deltoid (11.87±8.84N to 9.53±6.15N and 12.86±9.72N to 9.95±5.50N respectively). A 
feedback questionnaire revealed a positive response regarding the training and counselling.  
 
Although there were positive indications, signifcant variability makes it difficult to conclude that training and 
counselling changes the application force used to apply microneedles in this small sub-group of the population. 
Despite subjects displaying a good attitude towards the training, further work is required to determine the 
potential benefit of training for the manual application of microneedles.  
 
 Gerstel MS, Place VA. Drug Delivery Device, US Patent No. 3,964,482. 1976. 
 Bariya S, Gohel M, Mehta T, Sharma O. Microneedles: An emerging transdermal drug delivery system. Journal of Pharmacy and 
Pharmacology. 2011;64(1):11-29 
 Gupta J, Gill H, Andrews S, Prausnitz MR. Kinetics of skin resealing after insertion of microneedles in human subjects. Journal of 
Controlled Release. 2011;154(2):148-155 
 Donnelly RF, Singh TRR, Tunney MM, Morrow DIJ, McCarron PA, O’Mahoney, et al. Microneedle arrays allow kower microbial 
penetration than hypodermic needles in vitro. Pharmaceutical Research. 2009;26:2513-2522  
 
 
Synthesis of 2'-fluoro ProTides as potential therapeutic agents and PET imaging 
probes 
Janki Varsani, A Cavaliere and AD Westwell 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Nucleoside analogues (NA) are extensively used antiviral and anticancer agents that have several limitations 
in their application. To overcome these, ProTides were designed to deliver the monophosphate form of the NA 
directly into the target cell using amino acid esters and aryl moieties to mask the negative charges.1,2 Since 
the failure of fialuridine (1-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)-5-iodouracil, or FIAU) in its phase II clinical 
trial,3 its corresponding radiolabeled compound has been used in reporter-gene imaging in Positron emission 
tomography (PET),4 but no further research has been carried out on it or its isomer 2'-deoxy-2'-fluoro-5-
iodouridine. Therefore, the aim of this project is to firstly synthesise 2'-deoxy-2'-fluoro-5-iodouridine ProTides 
which will be evaluated for therapeutic activity and used as cold reference standards for the radiochemical 
synthesis of 18F-FIAU ProTides in the future and secondly, to start the synthesis of the 18F-FIAU ProTide 
precursor. 
In the first part of the project, ProTide synthesis was based on phosphorochloridate chemistry via four major 
steps. It involved the reaction of L-alanine ester salts with phenyl dichlorophosphate to form the 
phosphorochloridates. These were further reacted with 2'-deoxy-2'-fluoro-5-iodouridine and NMI to form the 
ProTides. In the second part of the project, the initial step in the synthesis of 18F-FIAU ProTide precursor 
involved the reaction of 5-iodouridine with 1,3-dichloro-1,1,3,3-tetraiospropyldisiloxane (TIPDSiCl2). 
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The methyl, ethyl and tert-butyl derivatives of the ProTides were obtained as mixtures of diastereoisomers at 
low yields. The isopropyl, neopentyl and benzyl phosphorochloridates have been synthesised and need to be 
coupled in the final step and lastly, the initial step in the synthesis of the precursor was successfully completed. 
To conclude, the ProTide derivatives were successfully synthesised, purified and characterised but several 
other derivatives still need to be synthesised and in order to be analysed in-vitro for potential activity. Finally, 
the 18F-FIAU ProTide precursor synthesis needs to be completed and radiolabeled for further development 
into a novel PET imaging probe in the future. 
 Derudas M, Brancale A, Naesens L, Neyts J, Balzarini J, McGuigan C. Application of the phosphoramidate ProTide approach to the 
antiviral drug ribavirin. Bioorg Med Chem. 2010 Apr;18(7):2748–2755. 
 McGuigan C, Bourdin C, Derudas M, Hamon N, Hinsinger K, Kandil S et al. Design, synthesis and biological evaluation of 
phosphoramidate prodrugs of antiviral and anticancer nucleosides. Eur J Med Chem. 2013 Dec;70:326-340. 
 McKenzie R, Fried MW, Sallie R, Conjeevaram H, Di Bisceglie AM, Park Y et al. Hepatic failure and lactic acidosis due to fialuridine 
(FIAU), an investigational nucleoside analogue for chronic hepatitis B. N Engl J Med. 1995 Oct;333(17):1099-1105. 
 Alauddin M. Positron emission tomography (PET) imaging with18F-based radiotracers. Am J Nucl Med Mol Imaging. 2012;2(1):55–
76. 
 
 
An evaluation of inhaler technique in patients of the Cardiff and Vale Health Board 
Bethany Walton and WR Ford 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Inhaled medications are effective in treating respiratory conditions; they provide local delivery, a fast onset of 
action and a reduction in side effects.1 In order to receive a sufficient dose inhaler technique needs to be 
correct. Poor inhaler technique is a common barrier resulting in reduced therapeutic benefit and compromised 
disease control.2 
 
This study aimed to evaluate how effective inhaler technique is in the patient population and investigate for 
factors that may influence this. Participants were recruited from primary and secondary care sites. Information 
about inhaler use, training and knowledge was obtained. A test of inhaler technique was performed using a 
Vitalograph Aerosol Inhalation Monitor (AIM) device. This measured: inspiratory acceleration, timing of 
activation, inspiratory flow rate, inhalation time and breath hold time.3 Data was analysed using Chi-squared 
with P<0.05 accepted as statistically significant. 
 
Poor inhaler technique was observed in 59% of the participants. Significantly, more patients using a pMDI 
failed the inhaler test (83%) than those using the pMDI with a spacer (9%) or a DPI (17%). Older patients 
demonstrated significantly worse inhaler technique with pMDIs. Receiving device training from a health care 
professional made no impact on how well participants could use their inhaler. Most patients had been trained 
by a nurse, only one patient was shown by a pharmacist.  
 
Incorrect technique with a pMDI alone is common however; technique with a spacer is better suggesting 
spacers can help. Results demonstrate that the training given is ineffective at providing patients with the ability 
to use inhalers correctly. To combat this, health care professionals may need better training too.4 Community 
pharmacists need to be more engaged in providing inhaler technique training; they are conveniently located 
for patients and have the expert knowledge for them to do so successfully.  
 
 Virchow JC, Crompton GK, Dal Negro R, Pedersen S, Magnan A, Seidenberg J, et al. Importance of inhaler devices in the 
management of airway disease. Respiratory Medicine. 2008;102(1):10-19. 
 Crompton GK, Barnes PJ, Broeders M, Corrigan C, Corbetta L, Dekhuijzen R, et al. The need to improve inhalation technique in 
Europe: A report from the Aerosol Drug Management Improvement Team. Respiratory Medicine. 2006;100(9):1479-1494 
 Vitalograph. Vitalograph AIM (Aerosol Inhalation Monitor) Model 4500 User Training Manual: Vitalograph; 2013 [accessed 4 Nov 
2015]. Available from: https://vitalograph.co.uk/downloads/view/07608 
 Baverstock M, Woodhall N, Maarman V. Do healthcare professionals have sufficient knowledge of inhaler techniques in order to 
educate their patients effectively in their use? Thorax. 2010;65(Suppl 4):A117-A118. 
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Paliperidone long-acting injection: one-year outcomes in a retrospective naturalistic 
follow up study 
Elan Ward, PN Deslandes1 and RDE Sewell 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff CF10 
3NB, and 1Pharmacy Department, Whitchurch Hospital, Cardiff & Vale University LHB, Park Road, Cardiff CF14 7XB, 
Wales, UK. 
Paliperidone long-acting injection (PLAI) is licensed for maintenance of schizophrenia and schizoaffective 
disorder in patients who were previously responsive to risperidone or paliperidone.1 There are a limited number 
of studies available that assess the efficacy of PLAI which are reflective of the patients seen in practice.2,3 The 
main aim of this naturalistic study was to assess the effectiveness of PLAI using outcomes relevant to clinical 
treatment. The outcome measures used to determine effectiveness were treatment continuation at one year, 
and for continuers, inpatient stay prior to and following treatment initiation. 
A retrospective case note review was conducted at Whitchurch Hospital including patients who had received 
PLAI prior to 1st December 2014 in the Cardiff and Vale area. Patients were categorised as either continuers 
or discontinuers. Demographic factors which may have influenced outcomes were analysed. Secondary 
outcomes for discontinuers included subsequent treatment strategy, final dose of PLAI and reason for 
treatment discontinuation. 
In total, 62 patients were identified as receiving PLAI and 65% of them were continuers at one year. The most 
common reason for discontinuation was lack of effect (41% of discontinuers). Out of all patients, 15% 
discontinued due to side effects. A mirror image comparison disclosed no statistically significant reduction in 
the number of inpatient days prior to and post PLAI initiation. Age on initiation of discontinuers were younger 
than continuers (p=0.0178). The use of oral risperidone prior to PLAI led to a higher likelihood of 
discontinuation within the unlicensed users (p=0.0242), but there were only 11 patients within this group. 
Factors that determined discontinuation in this study were a younger age on initiation and previous treatment, 
within unlicensed use. A larger patient cohort and a longer study period are needed to further evaluate the 
long term effectiveness of this drug. 
 
 Joint Formulary Committee. British National Formulary 70th ed. London: BMJ Group and Pharmaceutical Press; 2015. 
 Deslandes PN. Norris K. Sewell RDE. Early experience with paliperidone: a novel, long-acting antipsychotic injection. British 
Association for Psychopharmacology. [accessed 20 Oct 2015] Available at:: 
http://www.bap.org.uk/pdfs/2015_Summer_Meeting_Programme2.pdf 
 Attard A. Olofinjana O. Cornelius V. Curtis V. Taylor D. Paliperidone palmitate long-acting injection – prospective year-long follow-up 
of use in clinical practice. Acta Psychiatr Scand. 2014;130:1-6. 
 
 
Identifying and exploring factors affecting student motivation for the MPharm: a 
qualitative study 
Nia Westlake and DN John 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK  
Motivation has been defined as what ‘moves you to do something’.1 The distinction between intrinsic and 
extrinsic motivational factors has been important in the development of various educational practices, 
particularly as a student’s performance is affected by their motivation for studying and their ability to attain 
knowledge. Students displaying intrinsic motivation perform activities because of inherent interest whereas 
extrinsically motivated students perform activities to achieve a desirable outcome.2 As limited research has 
been conducted in the context of pharmacy, the aim of this study is to investigate factors that affect the 
motivation of final year MPharm students. 
 
Students were selected by non-probability (purposive and convenience) sampling to achieve a broad 
demographic. After conducting a literature review the research team developed a topic guide. After gaining 
ethics approval and participant consent, 24 one-to-one semi structured interviews were conducted and audio 
recorded by the research team. Qualitative data was transcribed ‘ad verbatim’ and analysed primarily using 
inductive thematic analysis,3 deductive reasoning and Deci and Ryan’s self determination theory [1] where 
appropriate. 
 
Five main themes were identified from the data set: assessments, influence of others, interest in subject, 
competing interests and session attendance. There were several key motivating factors for final year students. 
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Most were extrinsically motivated towards higher weighted assessments. Changes in motivation through the 
degree were also reported. They were also intrinsically motivated towards assessments they found interesting 
and enjoyable. The participants also mentioned demotivational factors; these could be addressed by Cardiff 
School of Pharmacy and Pharmaceutical Sciences (CSPPS) to help improve overall student motivation. 
 
This study has shown that student motivation is individualistic and multifactorial. The results have identified 
factors that have both positive and negative effects on student motivation with students also suggesting 
methods that CSPPS can adopt to increase motivation. As student motivation changes throughout the MPharm 
degree, further longitudinal studies are required. 
 
 Deci EL and Ryan RM. Intrinsic motivation and self-determination in human behaviour. Contemp Educ Psychol. 2000; 25;1: 54-67. 
 Ratelle C, Guay F, Vallerand R, Larose S, Senécal C. Autonomous, controlled, and amotivated types of academic motivation: a 
person oriented analysis. J Educ Psychol. 2007;99:734-746. 
 Braun V and Clarke V. Using thematic analysis in psychology. Qual Res Psychol. 2006;3:77-101. 
 
 
Non-medical prescribing: models in pharmacy  
Victoria Whelton, RE Deslandes, KL Hodson 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Non-medical prescribing is defined as prescribing undertaken by a healthcare professional who is not a doctor.1 
It began with the Cumberlege report in 1986 followed by the Crown Reports in 1989 and 1999 which led to the 
introduction of supplementary prescribing and independent prescribing.2 There is limited research into 
pharmacy prescribing models therefore the aim of this project is to explore these models in both primary and 
secondary care.  
 
Ethical approval was granted by the Cardiff School of Pharmacy and Pharmaceutical Sciences’ school Ethics 
committee. Qualitative methodology was deemed most appropriate and semi-structured interviews were used 
to collect data. Purposive and convenience sampling methods were used and the interview schedule was 
adapted from that of the previous project, which this was a continuation of. Recruitment was by advertisements 
and the interviews were analysed using thematic analysis.  
 
The main facilitators identified included positive working relationships and support. Identified barriers included 
lack of support and role recognition, concerns about assessment skills and funding and the results also 
demonstrated a need for promotion of the role. The main driver for pharmacists to prescribe and their 
advantages and disadvantages of prescribing were also highlighted. Case studies for models of practice were 
successfully developed to highlight how and where pharmacists were prescribing.  
 
This research explored the views and experiences of prescribing pharmacists and several key facilitators and 
barriers have been identified. It has established key areas of support which are needed and highlighted the 
need for promoting the role more effectively. All of the above should be shared within the profession to help it 
to develop and expand. Additionally, it would be appropriate to explore this area further with a larger number 
of participants by conducting a survey of all registered pharmacist prescribers. 
 
 Peniston-Bird, F. Non-medical prescribing; 2015 [Accessed 12 October 2015]. Available from: 
http://www.nmprescribing.co.uk/nmp.html   
 Cooper R, Anderson C, Avery T, Bissell P, Guillaume L, Hutchinson A et al.  
Nonmedical Prescribing in the United Kingdom: Developments and Stakeholder Interests. J Ambul Care Manage. 2008;31(3):244-
252.  
 
 
A comparison of the puncture properties of two types of hypromellose capsules 
Elin Williams, N Leung, M Dul and BE Jones 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Simple single-unit dosage systems such as two-piece hard capsules in dry powder inhalers (DPIs) are widely 
used for pulmonary drug delivery.1 Hypromellose capsules have shown superior puncture properties over 
gelatin capsules in previous studies.2 Hypromellose capsules chosen for their mechanical properties, Quali-V-
I® capsules, are currently used in single-unit DPI devices. There is another commercially available 
hypromellose capsule of a different grade, used for oral drug delivery, Quali-V® capsules.3 The aim of this 
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study is to compare puncture properties of Quali-V-I® and Quali-V® capsules within their approved moisture 
specifications. 
Capsules were conditioned in desiccators containing saturated salt solutions controlling the relative humidity 
(RH) adjusting moisture content to each end of the moisture specification. Both types of capsules were stored 
in a desiccator containing either CaCl2 (33% RH) to reduce the moisture content or Mg(NO3)2 (56% RH) to 
increase moisture content. Capsule samples (n=10) of Quali-V® and Quali-V-I® taken from the desiccators 
were placed in a Zwick® materials testing machine. Force taken to puncture each capsule using a conical-
tipped pin was recorded. Puncture holes created in the capsules were photographed using light microscopy 
with an integrated camera. Puncture holes were assessed for size, circularity and flap attachment for 
comparison between the capsule samples. 
 
Conditioned capsule samples fell within the moisture specification lower end but slightly above at the upper 
end. Further studies are required to compare puncture properties within their moisture content specification. 
Quali-V-I® capsule samples required increased puncture forces compared to Quali-V® capsules. Quali-V-I® 
capsules’ puncture hole characteristics were superior, with increased area and circularity. Puncture force 
required was greater in capsule samples of lower moisture content, however the resulting puncture hole was 
more uniform with increased area. 
Overall, Quali-V-I® capsules required increased puncture force but showed superiority in the resulting capsule 
puncture compared to Quali-V® capsules. 
 Torrisi BM, Birchall JC, Jones BE, Diez F, Coulman SA. The development of a sensitive methodology to characterise hardshell 
capsule puncture by dry powder inhaler pins. International Journal of Pharmaceutics. 2013;456(2):545-52. 
 Birchall JC, Jones BE, Morrissey A. A Comparison of the Puncturing Properties of Gelatin and Hypromellose Capsules for Use in 
Dry Powder Inhalers. Drug Development & Industrial Pharmacy. 2008;34(8):870-6. 
 Jones BE, Basit AW, Tuleu C. The disintegration behaviour of capsules in fed subjects: A comparison of hypromellose 
(carrageenan) capsules and standard gelatin capsules. International Journal of Pharmaceutics. 2012;424(1–2):40-3. 
 
 
Investigating the role of ZIP7 phosphorylation in breast cancer 
Greg Williams and KM Taylor 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK  
Zinc is a crucial trace element with a key role in regulation of normal cell growth and proliferation.1 The 
homeostasis of zinc relies heavily on transporters to move zinc in and out of the cytoplasm, these transporters 
including ZIP and ZnT channels.2 ZIP7 is a transporter moving zinc into the cytoplasm; this zinc release drives 
downstream effects and cell proliferation.3 Tamoxifen resistant breast cancer cells overexpress ZIP7 compared 
to normal cells, suggesting a role in driving breast cancer.4 The aim of this study was to discover if there was 
any difference between two residues on ZIP7, S275 and S276, in their role in ZIP7 activation and subsequent 
downstream effects. 
Western blotting was used to detect proteins of interest from cell samples. Cells were transfected with ZIP7 
mutants, before treatment with zinc and sample collection at various time points. The mutants used were 
S275D/S276A, S275A/S276D and S275A/S276A. Desirable proteins were probed for using specific antibodies 
and detected via chemiluminescence. Densitometry was used to quantitatively analyse the proteins presence 
in the sample. 
Results for both the pZIP7 and one of the main downstream effector proteins, pAKT, agreed with previous 
data. pAKT was activated in response to ZIP7 activation which explains its role in driving cell growth and 
proliferation. GSK-3Beta appears to be directly inhibited by zinc and pAKT has less impact on this effector 
protein. Both residues S275 and S276 appear necessary for ZIP7 activation. A lack of pZIP7 and decreased 
pAKT occurred in the samples with a removed phosphorylation site.  
The importance of both residues for activation suggests antagonism at one residue may be enough to inhibit 
ZIP7 activation. Further research is needed to statistically back up the evidence and to further explore the 
plausibility of ZIP7 as a therapeutic target in anti-endocrine resistant breast cancer. 
 MacDonald.RS. The role of zinc in growth and cell proliferation. Nutr J. 2000;130:1500S-1508S 
 Schweigel-Rontgen.M. The families of Zinc (SLC30/39) and Copper (SLC31) channels. Curr Top Membr. 2014;73:321-355 
 Taylor.KM, Vichova.P, Jordan.N, Hiscox.S, Hendley.R, Nicholson.RI. ZIP7-mediated intracellular zinc transport contributes to 
aberrant growth factor signalling in antihormone-resistant breast cancer cells. Endocrinology. 2008;149:4912-20  
 Taylor.KM, Hiscox.S, Nicholson.RI, Hogstrand.C, Kille.P. Protein kinase CK2 triggers cytosolic zinc signalling pathways by 
phosphorylation of zinc channel ZIP7. Sci Signalling. 2012;5:ra11 
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A service evaluation on the use of an electronic portal to assess patient measures 
in a Parkinson’s disease clinic 
Karlie Williams and EL Lane 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
For patients with Parkinson’s disease, non-motor symptoms, such as depression, urinary incontinence and 
dizziness have been found to be the largest contributor to quality of life.1 Such symptoms are currently 
identified by completion of a non-motor symptom paper questionnaire.2 It has been recognised that an 
electronic portal, such as an iPad application, encompassing the non-motor symptom questionnaire may aid 
the monitoring of such symptoms. The majority of Parkinson’s patients are elderly, most being over 50 years 
old,3 with many individuals suffering from dyskinesia and tremor.1 This raises concerns over the usability of an 
iPad application. The main aim of this study was to evaluate the feasibility of using an iPad application within 
a Parkinson’s disease clinic. 
A service evaluation was carried out to gain understanding of how patients and staff felt about the use of an 
electronic portal within their clinic. Interview questions were formulated, comprising of both closed and open-
ended questions. Patients were invited to use the iPad application and subsequently partake in an interview. 
Staff members were also asked to partake in interviews. 
Of the patients who were interviewed (N=24) it was found that although 54% of patients (N=13) had never 
used an iPad before, 88% of patients (N=21) felt comfortable using the application provided. All staff members 
interviewed (N=5) felt that patients would need assistance to use the iPads and provisions need to be made 
for this. 
Throughout the course of the service evaluation, potential issues were identified, such as staff concerns 
regarding time constraints within clinic and patient concerns over usability of the application. All of which can 
be addressed with simple changes as recommended. The results from this service evaluation have proven 
useful and with the recommendations made the service shows promise in being introduced in the near future. 
 Chaudhuri KR, Healy DG, Schapira AHV. Non-motor symptoms of Parkinson’s disease: diagnosis and management. The Lancet 
Neurology 2006 Mar;5(3):235-245. 
 Chaudhuri KR, Martinez-Martin P, Schapira AHV, Stocchi F, Sethi K, Odin P et al. An international multicentre pilot study of the first 
comprehensive self-completed non motor symptoms questionnaire for Parkinson’s disease: The NMSQuest study. Movement 
Disorders 2006;21(7):916-923. 
 Parkinson’s UK. What is Parkinson’s? 2015 [accessed 28 Dec 2015] Available from: http://www.parkinsons.org.uk/content/what-
parkinsons. 
 
 
How does patient training affect the application forces that people use to apply 
microneedle patches? 
Mun Yee Wong, DN John, JC Birchall and SA Coulman 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK  
First proposed in 1976,1 microneedles (MNs) can deliver drugs across the skin without causing pain or 
bleeding2 and have minimal infection risk. The use of MNs by patients is less understood, with two previous 
studies demonstrating successful application following instructions.3,4 A previously unpublished study indicates 
a wide variability (2-60N) in the intuitive forces people use to apply “dummy” MNs, which may lead to 
inconsistent amounts of drug delivered. Our study aims to determine the impact of training on the forces 
volunteers use to apply “dummy” MNs, and the short-term longevity of any training effect. 
Volunteers (n=50; aged 18-25) applied intuitive forces with a digital pressure gauge on “dummy” MN patches 
on the forearm and deltoid. Training comprised verbal instruction and practice applications on a skin mimic. 
Volunteers then applied force again after training. A feedback questionnaire was administered to gather 
volunteers’ views on the training. After 7-14 days, the same volunteers made another application without any 
re-training given. 
Training reduced the magnitude and standard deviation of forces for both application sites, with the deltoid 
showing a statistically significant reduction (12.86±9.72N to 9.95±5.50N). After 7-14 days, there was a small 
increase in the magnitude and standard deviation of application forces for both sites, but it was not statistically 
significant. Responses from the feedback questionnaire indicated that 78% volunteers had increased 
confidence in the suitability of the application force they used after training.  
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This study indicates that training can reduce the variability of the application forces used, thus enhancing 
usability of potential MN products. Improvements to the skin mimic is needed for future studies. Training is still 
effective after 7-14 days, suggesting that it has some longevity and re-training for patients in future clinical 
settings may not be needed, saving time and cost. 
 Gerstel MS, Place VA. Drug Delivery Device, US Patent No. 3,964,482. 1976. 
 Haq MI, Smith E, John DN, Kalavala M, Edwards C, Anstey A et al. Clinical administration of microneedles: skin puncture, pain and 
sensation. Biomed Microdevices. 2009;11:35-47. 
 Norman JJ, Arya JM, McClain MA, Frew PM, Meltzer MI, Prausnitz MR. Microneedle patches: usability and acceptability for self-
vaccination against influenza. Vaccine. 2014;32(16):1856-62. 
 Donnelly RF, Moffatt K, Alkilani AZ, Vicente-Pérez EM, Barry J, McCrudden MTC, et al. Hydrogel-Forming Microneedle Arrays Can 
Be Effectively Inserted in Skin by Self-Application: A Pilot Study Centred on Pharmacist Intervention and a Patient Information 
Leaflet. Pharm Res. 2014;31(8):1989-9. 
 
 
Determination of skin biomechanical properties on human volunteers 
Foong Yee Yong, X Zhao and JC Birchall 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Microneedles (MNs) exploit the advantages of transdermal drug delivery route.1,2 One approach to use the 
MNs is to coat the drug onto individual MN surfaces and insert them into the skin. There are several relevant 
parameters that could possibly affect MN delivery such as skin biomechanical properties, degree of skin 
hydration and possibly skin temperature. Skin is elastic therefore ensuring MN penetration is challenging. 
Thus, this study involves looking into these parameters in human volunteers and understanding more about 
biomechanical properties of skin, hydration and temperature at two different application sites, the palms and 
forearms. We then compare the human volunteer data with an ex vivo human skin model that is currently used 
as a laboratory surrogate for in vivo human skin to confirm comparable skin biomechanics. 
 
An indentation technique was used to measure skin displacement as a function of force.3,4 Skin hydration was 
measured as transepidermal water loss (TEWL) and temperature of the skin was also measured. In order to 
create hydrated skin, the forearm was occluded with cling film for 3 hours. Elevated TEWL values were 
measured after occlusion.  
 
Results demonstrated that biomechanical properties of skin differ significantly at different body regions. 
Regional variation was also observed on hydration state of skin. An occlusion effect was determined as TEWL 
values were significantly increased after application of cling film. The adapted ex vivo skin model in this study 
is currently not representative of in vivo skin from a biomechanical perspective.  
 
In conclusion, this study provided meaningful information on skin mechanical behaviour, which can be used to 
optimise the ex vivo skin model for future MN testing. Relevant parameters such as biomechanical properties 
of skin, skin hydration and skin temperature should be taken into consideration when measuring MN 
performance.  
 
 Clancy NT, Nilsson GE, Anderson CD, Leahy MJ. A new device for assessing changes in skin viscoelasticity using indentation and 
optical measurement. Skin Research and Technology. 2010;16:210-28. 
 Zahounani H, Pailler-Mattei C, Sohm B, Vargiolu R, Cenizo V, Debret R. Characterization of the mechanical properties of a dermal 
equivalent compared with human skin in vivo by indentation and static friction tests. Skin Research and Technology. 2009;15:68-76 
 Ghadge T, Dhole S. Microneedle: an Advanced Technique in Transdermal Drug Delivery System. Asian Journal of Pharmaceutical 
Sciences. 2013;3:141-8. 
 Akhtar N. Microneedles: an innovative approach to transdermal delivery- a review. International Journal of Pharmacy and 
Pharmaceutical Sciences. 2014;6(4):18-25. 
 
 
Synthesis of CYP24A1 Inhibitors as Potential Cancer Therapeutics 
Fuan Chin Yong and C Simons 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Calcitriol (1α,25-(OH)2D3), the most potent metabolite of Vitamin D has been proven to have an anti-
proliferative and anti-inflammatory effect against malignant cells in cancer therapy.1 Studies have shown that 
increased calcitriol levels decrease the risk of prostate cancer, colon cancer1 and breast cancer.2 However, 
calcitriol treatment is limited by the up-regulation of the CYP24A1 enzyme, which is responsible for catabolism 
of calcitriol.3 Hence, this research aimed to identify and synthesise new, potent and selective CYP24A1 
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inhibitors which will decrease the catabolism of calcitriol, extend calcitriol half-life, and increase the calcitriol 
exposure for cancer therapy. 
In this research, molecular modelling using MOE was done to visualise the possibility of interactions between 
the target compounds with the homology model of CYP24A14 and identify compounds with potential CYP24A1 
inhibitory effect. Then a three-step synthesis which involved formation of amide; then cyclisation to oxazole 
and lastly nucleophilic ring opening to imidazole, was performed in the laboratory. All the end products in each 
step of the synthesis were analysed using TLC, NMR, and then microanalysis to check on the purity of the 
compounds. 
All the products were successfully synthesised with good yield except for the final compounds, which have low 
yield. Considerable amounts of the product were lost during the trial and error of finding a suitable solvent for 
recrystallisation. Nevertheless, high purity compounds were obtained at the end of the project according to the 
NMR and microanalysis results. 
Since the results from molecular docking showed theoretically promising outcomes, biological evaluation 
should be done to determine activity. If any inhibitory activity were shown in the compound, structure-activity 
relationship analysis by modifying the chemical structure should be performed. 
 Chen H. H. Calcium and phosphate metabolism management in chronic renal disease. New York: Springer; 2006. 
 Christakos S, Vitamin D and breast cancer. Advance in Experimental Medicine and Biology 364. 1994. 
 Vuolo L, Somma C. D, Faggiano A, Colao A. Vitamin D and cancer. Frontier Endocrinol. 2012. [Accessed 18 Nov 2015]. Available 
from: http://journal.frontiersin.org/article/10.3389/fendo.2012.00058/full 
 Aboraia A. S, Yee S. W, Gomaa M. S, Shah N, Robotham A.C, Makowski B et al. Synthesis and CYP24A1 inhibitory activity of N-(2-
(1H-imidazol-1-yl)-2-phenylethyl)arylamides. Bioorg. Med. Chem., 18. 2010; 4939-4936. 
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The following abstracts have been withheld as they have been or will be published 
elsewhere, and/or due to intellectual property or confidentiality issues: 
 
Analysis of the physico-chemical properties of peptide cargo delivered into cells by 
cell penetrating peptides  
Rheanna Colyer and AT Jones 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK  
 
Analysis of the peptide EJP18 as a potential Epidermal Growth Factor Receptor 
(EGFR) targeting bioportide 
Jessica Damrel and AT Jones 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
 
Developing methods for characterising cell penetrating-peptide non-covalent 
complexes 
Harris Ali Din, AT Jones and E Sayers 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff CF10 
3NB, and School of Medicine, Cardiff University, UHW Main Building, Heath Park, Cardiff CF14 4XN, Wales, UK 
 
 
Co-formulated chloramphenicol and sodium fusidate for treating acute bacterial 
conjunctivitis 
Ai Wee Tan, K Sands1 and CM Heard 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff  
CF10 3NB, and 1School of Dentistry, Cardiff University, Heath Park, Cardiff, CF14 4XY, Wales, UK  
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Do oral HMG-CoA reductase inhibitors (statins) reduce the incidence of surgical site 
infections (SSI’S) in patients, who have undergone an elective primary hip or knee 
arthroplasty procedure? 
Harjit Kaur Virdee and RDE Sewell 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Hip and knee replacement surgery is the most prevalent and successful type of surgical intervention that is 
performed on both the majority of the elderly and some young NHS and private patients who have experienced 
the debilitating symptoms of osteoarthritis (OA). 
 
The majority of OA patients find that the clinical symptoms of OA are only alleviated after they have had primary 
hip or knee arthroplasty. However even though a total hip or knee arthroplasty is normally a safe and effective 
surgical procedure, this type of surgery carries the risk of patients developing post-operative surgical site 
infections (SSI).  
 
Surgical site infections (SSI) can be very difficult to treat and there have not been many potential preventative 
treatment options available until fairly recently. A potential treatment option involves the use of HMG-CoA 
reductase inhibitors which are more commonly known as statins.  
 
This retrospective clinical trial used the Royal Orthopaedic Hospital, Birmingham’s surgical site infection 
database which continued 202 surgically infected primary hip and knee patients and matched them with 202 
non-surgically infected primary hip and knee patients from the Royal Orthopaedic Hospital Birmingham’s health 
informatics hip and knee database using specific risk factors and propensity score matching to analyse if there 
was a difference in statin use. 
 
The results from the clinical trial demonstrated that the non-SSI hip and knee cohort were less likely to develop 
a surgical site infection because they were on statin treatment (95% confidence interval, P<0.0001) and that 
of those in the SSI and non-SSI hip and knee cohort that did take a statin (52 patients and 68 patients) 58% 
in the SSI knee and hip cohort and 75% in the non-SSI knee and hip cohort took simvastatin at night. This 
indicates that statin use was associated with a reduced incidence in the development of a surgical site infection 
in those patients who had undergone an elective primary hip or knee arthroplasty procedure. 
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SK Potassium and TRPM7 ion channel role in CNS cell survival and breast cancer 
cell death decisions 
Zana Abdulkareem, GF Baxter and KT Wann 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Cell survival is modulated by a cocktail of ion channels engaging cell life and death decisions through 
controlling key cellular messages such as apoptosis and proliferation. Unnatural regulation of these processes 
results in various disorders, for example neurodegenerative diseases, as well as the cancers. Nowadays, these 
pathologies are affecting millions of people per year in the world. Potassium (K+) ion channels appear to play 
a potent role in such illnesses since they control many cellular gates in cell physiology such as ionic 
homeostasis and signalling cascades. Amongst the K+ channels, small (SK1-3) and intermediate (SK4) 
conductance Ca2+ - activated potassium ion channels have recently been shown to save cells, thereby 
protecting mitochondrial function which serves as a cell survival platform. In the case of other ion channels, for 
instance transient receptor potential melastatin 7 (TRPM7), it is also repeatedly stated that such membrane 
channels shows an impressive and differential role in excitable and non-excitable cell survival. This channel 
also modulates ionic homeostasis of crucial species in cellular physiology such as Ca2+. This study reveals 
that central nervous system (CNS) and breast cancer cells differentially express SK1-4 ion channel subtypes, 
and their functional presence is pharmacologically confirmed, however, in most cases these results were 
further clarified through small interference RNA (siRNA) methods. Similarly, functional TRPM7 channel 
expression in CNS cells is also confirmed. In the CNS, SK1-4 channel activation rescues neurons from 
oxidative stress, whereas, TRPM7 channel inhibition protects CNS cells from a hydrogen peroxide (H2O2) 
harmful effect, as well as hypoxia and apoptosis, so improving cell survival. Excitingly, SK1- 4 channels 
differentially exist in wild-type and Huntington’s affected mouse striatal cells, where diseased cells lack SK1-3 
channels, key players in action potential activity. Interestingly, SK2 or SK3 channel subtypes are also 
functionally expressed in breast cancer cells with various phenotypes. This study established that these ion 
channels are powerful agents in a survival role, in fact controlling growth through cross-talk with an apoptotic 
avenue “intrinsic pathway”. SK2 or SK3 channel activation enhances cell viability, while its inhibition dampens 
cell growth. It is very noteworthy that SK2 and SK3 channels are not expressed in non-tumorigenic breast 
cells.  
 
In brief, SK1-4 and TRPM7 molecules are clearly implicated in the survival of diverse cell types through an 
apoptotic route, indicating that these ionic regulators are promising targets in channelopathies related to 
cellular degeneration and growth. 
 
 
The exploration of CD44 as a mediator of a drug resistant phenotype in ER+ breast 
cancer 
Rebecca Bellerby, JMW Gee, P Barrett-Lee and SE Hiscox 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
The majority of breast cancers express the oestrogen receptor and are potentially amenable to endocrine 
therapy, however the clinical effectiveness of these agents is limited by the phenomenon of acquired resistance 
which is associated with disease relapse and poor prognosis. It has been previously demonstrated that the 
CD44 receptor is overexpressed in acquired tamoxifen resistance where it associates with an enhanced 
migratory phenotype, however little is known regarding the effects of CD44 splice variants in this context. This 
thesis aimed to explore the role of CD44 variant isoforms in a model of ER+ breast cancer derived tamoxifen-
resistance (TamR cells) and expand these explorations into an additional model of acquired fulvestrant-
resistance (Fas-R cells).  
 
Multiple CD44 isoforms were found to be upregulated in resistance although a differential expression profile 
was observed between Tam-R and Fas-R cells. Inhibition of global CD44 expression in both endocrine 
resistant models led to a loss in their migratory, proliferative and invasive capacity and attenuated their 
responses to the CD44 ligand, hyaluronan. Overexpression of CD44v6 in endocrine sensitive MCF-7 cells 
induced EGFR pathway activation leading to enhanced cellular invasion, and attenuated response to 
fulvestrant. Accordingly, CD44v6 suppression in Tam-R cells resulted in a loss of EGFR pathway signalling 
and reduced invasion. Preliminary clinical analysis revealed that co-expression of CD44v6 and EGFR 
associated with a trend for worsened outcome in ER+ breast cancer patients treated with tamoxifen.  
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These data suggest that upregulation of CD44v6 may contribute to an aggressive phenotype in tamoxifen 
resistant cells through a mechanism involving the EGFR. Future use of CD44v6 and EGFR as biomarkers may 
have potential therapeutic value to predict a cohort of ER+ breast cancer patients which relapse earlier on 
tamoxifen and may thus require more aggressive treatment strategies. 
 
 
The antibacterial activity of Humulus lupulus against mycobacteria 
James Arthur Blaxland, AW White and L Baillie 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, 
Cardiff CF10 3NB, Wales, UK 
One third of the world’s population is estimated to be infected with M. tuberculosis, a pathogen which causes 
more human death and misery than any other bacterial disease. Whilst treatment is available, resistance to 
commonly used antimicrobials is a growing problem. Thus there is an urgent need to identify new compounds 
that can kill drug resistant isolates and are able to potentiate the activity of currently available antibiotics.  
 
The plant kingdom is a rich source of antibacterial compounds and a plant which has attracted particular 
interest is Humulus lupulus, more commonly known as the hop, which has been used as an antibacterial in 
beer for hundreds of years. Its antibacterial properties are thought to be due to the combined action of alpha 
and beta acids and polyphenols such as xanthohumol although the precise nature of their interactions and 
relative importance has yet to be determined.  
 
An optimized agar antimicrobial assay was developed and employed based on Mycobacterium smegmatis, to 
characterize the antibacterial activity of fifty commercially available hop varieties with a view to identifying novel 
antibacterial compounds. Surprisingly, no correlation was found between alpha and beta acid content and 
antibacterial activity. Chemical analysis of the most (Citra) and least (Galena) active hop variants using a 
combination of bioactivity based thin layer chromatography, mass spectrometry and HPLC revealed 
differences in the relative amounts of antimicrobial compounds such as humulone (alpha acid), lupulone (beta 
acid) and xanthohumol but failed to identify the presence of novel antibacterial compounds.  
 
Whilst no new antimicrobial compounds were identified, the Citra hop extract was able to potentiate the activity 
of the antibiotics imipenem and ciprofloxacin against clinical isolates of M. abscessus, a fast growing member 
of the mycobacterium family which infects individuals suffering from cystic fibrosis. The Citra hop extract also 
inhibited the growth drug resistant isolates of M. abscessus suggesting that it may have activity against other 
antibiotic resistant mycobacteria such as M. tuberculosis. 
 
With regards to the mode of action, scanning electron microscopy revealed distinct changes to the outer cell 
structure of the bacteria, suggesting that hops contain compounds that interact with the bacterial cell 
membrane and/or cell wall.  
 
These changes were more profound in the presence of sub-inhibitory concentrations of imipenem, a compound 
which also targets the cell wall. Overall hops were shown to contain compounds which inhibited the growth of 
mycobacterium and were able to potentate the activity of antibiotics currently used to treat these pathogens. 
These findings suggest hops may be a fruitful source from which to isolate next generation compounds with 
which to treat increasingly drug resistant strains of mycobacteria. 
 
 
Investigating antibacterial plant-derived compounds from natural honey 
Jennifer Hawkins, AW White and L Baillie 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Honey possesses therapeutic properties which are the result of a range of factors including high sugar content, 
low pH, hydrogen peroxide and bee-derived peptides. Honey also contains antimicrobial phytochemicals which 
represent a rich source of leads for the development of drugs for the treatment of microbial infections.  
 
Honey samples donated by UK beekeepers (217) and Manuka samples (3) were screened for the presence 
of novel antibacterial compounds by determining activity against methicillin resistant Staphylococcus aureus 
(MRSA) using optimized agar well diffusion and broth micro-dilution assays. The majority (92%) of the honeys 
showed inhibitory activity. Identification of unknown factors was performed by neutralizing antibacterial honey 
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components previously described in the literature. Of the samples screened four samples were found to 
contain potentially novel antibacterial compounds.  
 
The pollen present in honey represents a record of the plants which contributed to the making of the honey 
and may be the source of specific antibacterial factors. For this reason pollen was extracted from honey 
samples which demonstrated high levels of antimicrobial activity. Microscopic and DNA meta-barcoding (454 
and Illumina) analysis was performed. Plant species identified with DNA meta-barcoding provided superior 
discrimination and greater repeatability. Key species identified in the antibacterial samples included woodruff 
(Galium odoratum), bluebell (Hyacinthoides non-scripta) and dandelion (Taraxacum officinale).  
 
Extracts from active honeys and characterised plants demonstrated antibacterial activity against MRSA, E. coli 
and P. aeruginosa using broth based methods and thin layer chromatography (TLC) bio-autographic overlay 
methods. Activity-guided characterization using a TLC/mass spectrometry (MS) interface and high 
performance liquid chromatography (HPLC) was performed. Compounds identified using these approaches 
included known pinobanksin derivatives and unknown compounds suggesting that the plants may be the 
original source of active compounds. The demonstration of antibacterial activity may provide new lead 
compounds that could serve as selective agents against MRSA and other antibiotic resistant bacteria. 
 
 
Focal Adhesion Kinase (FAK) as a novel therapeutic target in HER2+ breast cancer 
Glorianne Lazaro and SE Hiscox 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Focal Adhesion Kinase (FAK) is an intracellular kinase known to mediate integrin signalling following cell 
adhesion to the extracellular matrix. It is now emerging as a promising therapeutic target in many tumour types 
due to its overexpression in tumour cells and is associated with various cellular processes involved in cancer 
progression. Given that existing literature demonstrating that FAK plays a key role in the transduction of HER2 
signalling in HER2+ cells and that the levels of FAK expression strongly correlated with HER2 overexpression 
in clinical samples, we explored the potential for improvement of current therapies for HER2+ breast cancer 
by combination treatment strategies with the small molecule FAK inhibitor, PF878.  
 
FAK activity was assessed in a panel of cell lines reflecting HER2- (MCF7, T47D) and HER2+ (BT474, MDA-
361, SKBr3) disease by Western blotting. FAK activity was relatively increased in HER2+ versus HER2- cell 
lines with HER2+ cells demonstrating greatest sensitivity to PF878 with respect to suppression of FAK 
phosphorylation at Y397. The effects of PF878 on cell proliferation as a monotherapy and in combination with 
Herceptin were assessed using MTT and direct coulter cell counting and by Ki67 immuno-staining. Whilst 
PF878 did not affect the proliferation as a monotherapy, treatment of HER2+ cells with PF878 and Herceptin 
combined resulted in synergistic inhibitory action on cell proliferation with an associated suppression in AKT 
pathway activity. This combination treatment strategy produced the greatest effects in MDA-361 cells which 
were intrinsically insensitive to Herceptin-monotherapy.  
 
Inhibition of FAK activity also suppressed HER2+ cell migration in response to the exogenous ligand Heregulin 
and to conditioned-media derived from fibroblasts as assessed in Boyden Chamber migration assays. In this 
latter context, our data suggests that FAK may act through a STAT3-dependent mechanism to regulate 
fibroblast-stimulated migratory and invasive responses. Collectively, these data support a role for FAK in 
HER2+ breast cancer where its targeting has the potential to improve Herceptin response as well as suppress 
stromal-induced signalling that can contribute to disease progression and spread. 
 
 
Interfacial phenomena between bacterial or mammalian cells and orthopaedic 
biomaterials 
Emily Callard Preedy, S Evans, S Perni and P Prokopovich 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Adhesion as a scientific phenomenon has been researched for the past 70 years, as the notion of two entities 
contacting effects a huge expanse of daily activities, from writing to sophisticated cellular and bacterial 
interactions essential for growth and survival.  
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Inherently, a robust and adequate model of adhesion was acquired, one in which biological aspects were 
considered. Initially, the methodology required was optimised using the atomic force microscope (AFM) by 
testing a model bone substrate against ultra-high molecular weight polyethylene (UHMWPE), a material 
commonly found in the articulating acetabular cup. Once a force mapping technique was established 
experimentation continued to bacterial adhesion against model bone samples of various roughness, 
establishing that the adhesion phenomena occurs at a scale dependency due to the alterations in the 
topography of the surface at the micro to nano level.  
 
Aseptic loosening and osteolysis are major causes of failures in implanted biomedical devices at the hip. These 
issues are governed by the deterioration of the moving components, producing particles known as wear debris 
associated with the metals, bone cement, and UHMWPE materials initiating an immune response which is 
detrimental to the surrounding cells and tissues adjacent to the implant. The notion of mechanical aspects 
altering the health of mammalian cells has been ignored throughout the research of implantations and their 
effect on the cells by foreign bodies; the only concept studied to date is the viability and functionality post 
exposure. Therefore, this thesis aims at observing ii mesenchymal and osteoblast (both rodent and human) 
cells associated to wear debris (metal and polymeric particles of various sizes and compositions) exposure 
and the effect this has on cell nanomechanical and adhesive properties using the AFM techniques. The data 
obtained indicated that Cobalt nanoparticles were more damaging on all cell types than Titanium and polymeric 
particles. 
 
 
Investigation into the effects of zinc on the anti-breast cancer properties of 
disulfiram 
Helen L Wiggins, SE Hiscox, AD Westwell and AT Jones 
 Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Breast cancer is the second-leading cause of cancer related death in women and future therapies may involve 
the strategic use of previously developed drugs, which have established toxicity profiles and are often ex-
patent. The alcoholdeterrent disulfiram has been proposed as an anti-cancer agent, based on its capacity to 
interact with copper-dependent processes. However, little has been done to determine the relationship 
between this drug and zinc, despite knowledge that disulfiram binds this metal and zinc levels are dysregulated 
in breast cancer. This thesis investigated whether zinc is an important factor when considering disulfiram 
efficacy as an anti-breast cancer agent.  
 
Disulfiram was toxic to MCF-7 and BT474 breast cancer cell lines and produced a striking time-dependent 
biphasic toxicity response between 5- 20 µM. Co-incubation of the drug with low-level zinc removed this effect, 
suggesting that the availability of extracellular zinc significantly influenced disulfiram efficacy. Structure-activity 
relationship studies with disulfiram analogues revealed the biphasic effect could be influenced by altering the 
size of chemical groups bound to the drug’s nitrogen atom. 
 
Live-cell confocal microscopy using fluorescent endocytic probes and the zinc dye Fluozin-3, coupled with the 
development of a complimentary Fluozin-3 flow cytometry assay found that disulfiram rapidly increased zinc 
levels in breast cancer cells specifically in endo-lysosomes. This indicates that the ii cytotoxic effects of this 
drug may be due to acute zinc overload. Further investigation into disulfiram effects on lysosomes suggested 
that the drug disrupts lysosomal membranes and releases hydrolytic enzymes into the cytosol. Lysosomal 
membrane permeabilisation has been demonstrated to promote apoptosis and may be a mechanism to explain 
disulfiram cytotoxicity in breast cancer. This could have important clinical implications in situations of high 
intracellular zinc as seen in breast tumours, indicating that breast cancer cells may be more susceptible to the 
zinc ionophore action of disulfiram than non-cancer cells.  
 
 
The role of BCA2 in receptor tyrosine kinase endocytosis and breast cancer 
Jennifer M Wymant, SE Hiscox, AD Westwell and AT Jones 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Breast Cancer Associated gene 2 (BCA2), is a little-studied E3 ligase that is overexpressed in 56% of all 
primary breast cancers and has been linked with increased cell proliferation and invasion in vitro. BCA2 has 
been implicated in EGFR degradation however there is conflicting evidence surrounding its function and effect 
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on receptor biology. This project aimed to elucidate the role of BCA2 in EGFR endocytosis and downregulation 
and to determine its link with breast cancer survival.  
 
Data generated with online mRNA analysis tools indicated that high BCA2 levels were often associated with 
improved breast cancer prognosis. In silico studies also demonstrated that many genes coexpressed with 
BCA2 were regulators of membrane trafficking and suggested that BCA2 expression was repressed by 
HER2/EGFR/Ras signalling.  
 
Experimentally, it was shown that siRNA depletion of BCA2 led to increased EGFR protein levels while 
transient BCA2 overexpression reduced levels of the receptor. It was found that BCA2 overexpressing, EGF 
stimulated cells demonstrated reduced lysosomal degradation of both receptor and ligand. Associated with 
this, downstream EGFR signalling in BCA2 overexpressing cells was reduced in magnitude but prolonged in 
duration and ultimately cell viability was impaired.  
 
These findings support a role for BCA2 in the endolysosomal system. In agreement with this it was shown that 
BCA2 overexpression inhibited the vesicle membrane association of Rab7, a regulator of late endocytosis and 
reported BCA2 interactor. Transferrin receptor levels and transferrin uptake were unaffected by BCA2 
overexpression suggesting trafficking effects may be restricted to EGFR, a distinct class of receptor and/or to 
later (degradation) stages of endocytosis.  
 
This thesis provides a detailed exploration of BCA2 biology and presents evidence of a functional role for the 
protein in the endocytic regulation of EGFR. The mechanism/s underlying the complex relationship between 
BCA2 and breast cancer outcome have yet to be fully determined. 
 
 
Peptide-coated microneedles for antigen specific immunotherapy of type 1 diabetes 
Xin Zhao, S Wong1, C Dayan 1, SA Coulman and JC Birchall 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, Cardiff, UK and 1Diabetes Research 
Group, Institute for Molecular and Experimental Medicine, School of Medicine, Cardiff University, Cardiff, Wales, UK. 
Type 1 diabetes is an autoimmune disorder caused by the destruction of insulin secreting ß cells in the 
pancreas. The aim of this project is to explore the potential of using solid-coated microneedles to target skin 
dendritic cells with an auto-antigen to induce tolerance for the treatment of type 1 diabetes.  
 
A novel coating formulation has been developed to accommodate peptides with different lipophilicities. The 
optimised coating formulation and electro-polishing of the microneedle surface were key factors which enhance 
the efficiency of peptide delivery. Optimised coating formulation did not show adverse effects on peptide 
bioactivity or trigger a pro-inflammatory response.  
 
The delivery route (microneedle vs. intradermal injection) was shown to be the main factor that influenced the 
clearance of peptide from murine skin in vivo. Other factors such as temperature, skin hydration state and 
peptide solubility were also shown to have effects on peptide clearance.  
 
Two autoantigens were used to induce tolerance in non-obese diabetic mice – a potent mimotope m31 and 
endogenous antigen WE14. The proliferation profile of transferred carboxyfluorescein succinimidyl ester 
labelled BDC2.5 T cells in pancreatic lymph nodes in non-obese diabetic mice was used as a readout for the 
development of immunological tolerance. The results herein provide the first demonstration that WE14-coated 
microneedles were able to induce tolerance in vivo, showing reduced proliferation of BDC2.5 T cells.  
 
Additionally, this project examined the potential of short-term topical application of betamethasone to enhance 
peptide-induced tolerance. Both human and mouse dendritic cells showed a pro-tolerogenic state after 
treatment with topical application of betamethasone in vitro. However, full dose betamethasone was shown to 
have systemic toxicity in vivo, resulting in depletion of CD11c+ dendritic cells and CD4+ T cells. Diluted topical 
betamethasone facilitated a small effect on BDC2.5 proliferation; however no advantage on enhancing antigen 
specific immunotherapy was observed. 
 
 
 
 
 77 
INDEX OF AUTHORS 
Abdulkareem, Z ...........................................................72 
Aboukoura, A ............................................................... 3 
Acreman, D .................................................................. 7 
Akhbanbetova, A .........................................................10 
Al-Hassani, S ............................................................... 3 
Ali, A.................................................................. 4, 41, 45 
Ali, B............................................................................. 4 
Allender, CJ ................................................................50 
Alsaqati, M ................................................ 12, 35, 45, 48 
Azlam Shah, NA ........................................................... 4 
 
Baczkowski, E .............................................................. 5 
Baillie, L .............................................. 16, 18, 22, 46, 73 
Barrett-Lee, P ..............................................................72 
Basetto, M ...................................................................25 
Baxter, GF ...................................................................72 
Bellerby, R ..................................................................72 
Benson, J ..................................................................... 6 
Bettam, J ...................................................................... 6 
Bevan, K ...................................................................... 7 
Birchall, JC .......................... 5, 37, 39, 52, 62, 67, 68, 76 
Blaxland, JA ................................................................73 
Bojkowski, A ...................................................... 7, 13, 50 
Borade, T ..................................................................... 8 
Bordoni, C ...................................................................22 
Bowen, JL .............................................................13, 47 
Brancale, A ................................................. 9, 17, 22, 25 
Bultynck, G ..................................................................26 
 
Cassidy, C .................................................................... 9 
Castell, O ..............................................................26, 33 
Caulfield, D .................................................................. 9 
Cavaliere, A ................................................................62 
Chan, W ......................................................................10 
Chesterman, B ............................................................10 
Chin, C ........................................................................11 
Chin, CJ ......................................................................11 
Chong, SY ...................................................................11 
Cockbill, S ...................................................................50 
Coles, Z .......................................................................12 
Colyer, R .....................................................................70 
Cosslett, AG .............................................. 14, 20, 47, 56 
Coulman, SA ....................................... 37, 39, 62, 67, 76 
Crowley, E ...................................................................13 
 
Damrel, J .....................................................................70 
Davies, W ....................................................................60 
Dayan, C .....................................................................76 
Des Clayes, LA ................................................. 7, 13, 50 
Deslandes, PN ......................................................28, 64 
Deslandes, RE .......................................... 16, 28, 31, 65 
Dewdney, RS ..............................................................60 
Diez, F...................................................................37, 39 
Din, HA ........................................................................70 
Dooey, S .....................................................................14 
Doyle, L .......................................................................60 
Dunleavy, E .................................................................15 
Dutkowski, C ...............................................................13 
 
Edmunds, N ................................................................15 
Edwardes, DG .............................................................16 
Elabi, O .......................................................................10 
Elhassan, H .................................................................. 5 
Ellis, L ...................................................................16, 31 
Emery, S .....................................................................20 
Emmanuel, B ..............................................................17 
Esmail, D .....................................................................18 
Evans, DG .................................................................. 18 
Evans, J ..................................................................... 19 
Evans, S ..................................................................... 74 
 
Farrow, L .............................................................. 13, 18 
Ferla, S ......................................................................... 9 
Finlay, P ............................................................... 13, 18 
Ford, WR ......................... 6, 8, 15, 25, 29, 35, 44, 53, 63 
Fosu-Mensah, N ......................................................... 59 
Franchi, J ............................................................. 19, 24 
Freeburn, S ................................................................ 20 
 
Gee, JMW ............................................ 7, 13, 18, 50, 72 
Giancotti, G ................................................................ 17 
Goddard, L ........................................................... 13, 18 
Gough, E .................................................................... 21 
Green, A ............................................................... 13, 18 
Green, R ..................................................................... 21 
Griffiths-Mead, C ........................................................ 22 
Gumbleton, M ....................................................... 55, 57 
 
Hallam, A .................................................................... 52 
Hard, C ....................................................................... 22 
Hawkins, J .................................................................. 73 
Heard, CM .......................................... 10, 11, 38, 52, 70 
Hewitt, EM .................................................................. 23 
Hicks, D ...................................................................... 24 
Higgs, N ..................................................................... 24 
Hiscox, SE ...................................... 4, 41, 45, 72, 74, 75 
Hj Md Jappar, S ......................................................... 25 
Hodson, KL ................. 15, 16, 19, 24, 31, 42, 53, 58, 65 
Horas, NW .................................................................. 25 
Hughes, J ................................................................... 26 
Hughes, ML ...............................9, 15, 16, 31, 42, 53, 58 
Hughes, N .................................................................. 27 
 
Ibrahim, A ................................................................... 27 
Islam, ZJ ..................................................................... 28 
 
Jamieson, D ............................................................... 33 
Jenkins, G .................................................................. 29 
John, DN ...................................... 21, 31, 36, 62, 64, 67 
Jones, AT ....................................................... 33, 70, 75 
Jones, B ......................................................... 29, 37, 39 
Jones, BE ................................................................... 65 
Jones, C ............................................................... 34, 44 
Jones, E ............................................................... 30, 60 
Jones, G ..................................................................... 16 
Jones, GP .................................................................. 31 
Jones, S-A .................................................................. 31 
 
Kainth, N .................................................................... 32 
Kaliray, D .................................................................... 32 
Kandil, S ..................................................................... 30 
Kellett, L ..................................................................... 33 
Kidd, EJ .................................................... 12, 35, 45, 48 
Koh, EJ ....................................................................... 33 
Kyme, S ................................................................ 13, 18 
 
Lambert, R ................................................................. 35 
Lane, EL ......................................................... 10, 49, 67 
Langberg, A .......................................................... 35, 48 
Lazaro, G ................................................................... 74 
Lee, C ......................................................................... 36 
Lee, NTT .................................................................... 36 
Leung, N ..................................................................... 37 
Lewis, J ...................................................................... 38 
 78 
Lim, SY .......................................................................38 
Lo, M ...........................................................................39 
 
Machiwana, K .............................................................40 
Mahy, K .......................................................................40 
Maillard, J-Y ..........................................................21, 61 
Malyshev, D ................................................................46 
Mangoche, H ...............................................................41 
Mantzourani, E ......................................................16, 31 
Masento, S ..................................................................41 
McClelland, RA ................................................. 7, 13, 50 
McDonald, E ...............................................................42 
McGahon, S ............................................................6, 43 
McGlinchy, H ...............................................................43 
McLeod, R .................................................................... 5 
Miller, L .......................................................................44 
Mistry, D ......................................................................45 
Mitoko, TA .............................................................34, 44 
Moghal, MJ .................................................................45 
Morthanassi, A ............................................................46 
Mottram, H ..................................................................18 
Moule, RJ ....................................................................47 
Murphy, C ...................................................................47 
 
Newth, B ...............................................................35, 48 
Ngai, JCM ...................................................................49 
Ngu, CWS ...................................................................49 
Noorani, A ......................................................... 7, 13, 50 
Northwood, W .............................................................50 
 
Oakes, KE ...................................................................51 
Ong, JN .......................................................................52 
 
Parker, S .....................................................................52 
Patel, EV .....................................................................53 
Patel, J ........................................................................53 
Perni, S .......................................................................74 
Pook, E .......................................................................54 
Pothecary, K ...............................................................52 
Powell, B .....................................................................54 
Preedy, EC ..................................................................74 
Price-Davies, R ............................................... 27, 40, 43 
Prokopovich, P ...................................... 3, 11, 23, 40, 74 
 
Quantock, A ................................................................10 
 
Rabana, R ...................................................................55 
Roberts, D ...................................................................13 
 
Sakota, H ................................................................... 55 
Salmon, D .................................................................. 56 
Sands, K ............................................................... 38, 70 
Saran, K ..................................................................... 57 
Sayers, E .................................................................... 70 
Sewell, RDE ............................................... 3, 41, 64, 71 
Shah, C ...................................................................... 57 
Simons, C ................................................. 19, 49, 58, 68 
Smith, D ..................................................................... 58 
Smith, J ........................................................................ 7 
Smith, MW ...................................................... 24, 33, 38 
Sully, A ....................................................................... 52 
 
Taj, J .......................................................................... 58 
Tan, AW ..................................................................... 70 
Tan, WT ..................................................................... 59 
Taylor, KM .................................................. 6, 43, 54, 66 
Thomas, N .................................................................. 60 
Thomas, RS ............................................. 27, 32, 51, 57 
Todd, E ....................................................................... 60 
Tugbobo, J ................................................................. 61 
 
Ullal, D ........................................................................ 62 
 
Varsani, J ................................................................... 62 
Virdee, HK .................................................................. 71 
 
Waller, S ..................................................................... 11 
Walton, B .................................................................... 63 
Wann, KT ................................................................... 72 
Ward, E ...................................................................... 64 
Way, C ......................................... 15, 16, 31, 42, 53, 58 
Westlake, N ................................................................ 64 
Westwell, AD ........................................ 7, 30, 59, 62, 75 
Whelton, V .................................................................. 65 
White, AW ............................................ 4, 32, 36, 54, 73 
Wiggins, HL ................................................................ 75 
Williams, E ................................................................. 65 
Williams, G ................................................................. 66 
Williams, K ................................................................. 67 
Wong, MY .................................................................. 67 
Wong, S ..................................................................... 76 
Wymant, JM ............................................................... 75 
 
Yemm, R .............................................................. 34, 44 
Yong, FC .................................................................... 68 
Yong, FY .................................................................... 68 
 
Zhao, X ................................................................. 68, 76 
 
 
 
